

COMMONWEALTH OF MASSACHUSETTS

SUFFOLK, ss.

SUPERIOR COURT
CIVIL ACTION NO. _____

TAMAR MASSOYAN-ARTINIAN, on behalf of
her children, and MADISON SCHILTZ,

Plaintiffs,

v.

MONICA BHAREL, in her official capacity as
Commissioner of the Massachusetts
Department of Public Health and the
MASSACHUSETTS DEPARTMENT OF
PUBLIC HEALTH,

Defendants.

**EXPERT AFFIDAVIT OF P. DOSHI, T. JEFFERSON, P. GOTZSCHE, AND C.
HENEGHAN**

We, Peter Doshi, Thomas Jefferson, Peter Götzsche, and Carl Heneghan, state as follows:

1. We submit this affidavit in support of Plaintiffs' Motion for a preliminary injunction. We have personal knowledge of the facts set forth herein and, if called to testify, each of us could competently testify as to the following:

EXPERIENCE & CREDENTIALS

2. I, Peter Doshi, hold a PhD, and I am an Associate Professor with Tenure in the Pharmaceutical Health Services Research Department at the University of Maryland School of Pharmacy.¹ I teach a required course in the PharmD curriculum, "Medical Evidence," which trains

¹ <https://faculty.rx.umaryland.edu/pdoshi/>.

students in skills necessary to critically appraise the scientific literature. I research the drug and vaccine approval process, how the risks and benefits of medical products are communicated, and how to improve the credibility and accuracy of evidence synthesis and biomedical publications. At the University of Maryland, I lead the RIAT Support Center which aims to accelerate the correction of the scientific record of clinical trials by making clinical trial publications more accurate and more complete, addressing the problems of publication bias and reporting bias. I have received national recognition for my work on clinical trial data transparency.² I am also an associate editor of *The BMJ* (formerly, the British Medical Journal), which is roughly equivalent to the *Journal of the American Medical Association* in the United States.³ (Attached as Exhibit A is a copy of my CV.) I have studied influenza policy since around 2004. I have many peer reviewed publications on the topic (see Exhibit A), and my PhD dissertation⁴ is on the topic of CDC and WHO influenza control policies (primarily vaccines). In 2013, I published a peer-reviewed article entitled “Influenza Vaccines: Time for a Rethink” by invitation of the editor-in-chief of *JAMA Internal Medicine*, a professor of medicine at U.C. San Francisco, based on being considered an “expert in the field.”

3. I, Thomas Jefferson, hold an MD degree and am a Fellow of Faculty of Public Health in the United Kingdom and a Member of Royal College of General Practitioners. I am a Senior Clinical Tutor at the University of Oxford. My specialty is analyzing evidence-based medicine and bias in drug and vaccines testing. I am the lead author of Cochrane reviews on influenza vaccines, and have published widely on the topic of influenza vaccines, other vaccines, and public health. (Attached as Exhibit B is a copy of my CV.) I started my health care career as

² <https://www.nytimes.com/2013/06/30/business/breaking-the-seal-on-drug-research.html>.

³ <https://www.bmj.com/about-bmj/editorial-staff/peter-doshi>.

⁴ <http://dspace.mit.edu/handle/1721.1/69811>.

a general practitioner (1980–1985 and 1999-2001), trained in public health in 1986 and obtained a MSc and Fellowship of Faculty of Public Health, as well as a diploma in Health Economics. I have been a contributor to The Cochrane Collaboration for over 20 years and am an author and editor for the Cochrane Acute Respiratory Infections (ARI) Group and a member of other Cochrane Groups. I have experience in synthesizing data from both large pharmaceutical and RWE data sets, both within formal studies and raw data. I have worked in vaccines, antivirals, infectious disease agents, neurodegenerative diseases, diabetic drugs, and different devices in classes IIb and III in a variety of designs (such as trials, economic evaluations, meta-analyses and epidemiological studies) and the use of regulatory evidence in Cochrane reviews. My work is cited in the James Lind Library. I am a member of the Italian MoH NITAG (national independent technical advisory group) on vaccines and a founder of the Brighton Collaboration, an international network of researchers developing standardized reporting of potential vaccines' harms.

4. I, Peter Gøtzsche, am a medical doctor and Doctor of Medical Science. I have been involved in medical research and the evaluation of medical research for 45 years. In 1993, I co-founded the Cochrane Collaboration which is a collaborative effort by patients, scientists, and researchers around the world to evaluate medical research to assist patients, health professionals, and policy makers to make better decisions. During the twenty-five years I worked with the Cochrane Collaboration, for which I was the Director of the Nordic Cochrane Centre, the group has published about 10,000 systematic reviews or protocols for upcoming reviews on the benefits and harms of interventions used in healthcare. In 2010, I became Professor of Clinical Research Design and Analysis at the University of Copenhagen. In 2018, I founded the Institute for Scientific Freedom where I continue with the same kind of work that I performed at the Cochrane Collaboration. (A copy of my CV with a list of books, book chapters and publications are attached

as Exhibit C.) I am the author of seven books since 2007, the first of which is *Rational Diagnosis and Treatment: Evidence-based Clinical Decision-making (4th ed.)*. One of my most recent books, published in 2020, and the one which is most relevant to the issues in this case, is titled *Vaccines: Truths, Lies and Controversy*. The book was published by People's Press in Denmark; will be published by Skyhorse in New York in 2021; and will appear in many languages. The book has a chapter on the influenza vaccines, and specifically reviews the evidence of its benefits and harms.

5. I, Carl Heneghan, am a registered medical doctor in the United Kingdom and am on the specialist register as a general practitioner since 2005. I hold a DPhil and I am Professor of Evidence Based Medicine at the University of Oxford. I have 25 years' experience as a clinical epidemiologist with expertise in evidence-based medicine, research methods, and evidence synthesis. I have over 400 peer-reviewed publications (current H index 70); published 95 systematic reviews and am currently Editor in Chief of BMJ Evidence-Based Medicine, contact editor in the Cochrane Acute Respiratory Infection group, and Editor of the Catalogue of Bias. My work includes investigating drugs and devices, advising governments on regulatory evidence, assessing health claims, and research on common presenting conditions in primary care, including work on acute respiratory infections. I am a clinical advisor to two UK All Parliamentary Party Groups on Surgical Mesh and Hormone Pregnancy Tests, an adviser to the WHO clinical trials registry platform and a founder of the AllTrials campaign; three times I have been voted one of the top 100 NHS clinical leaders by the Health Service Journal. In 2018, I was awarded National Institute for Health Research Senior Investigator status (Senior Investigators are among the most prominent and prestigious researchers funded by the NIHR and the most outstanding leaders of patient and people-based research within the NIHR research community). In 2019, I received a lifetime achievement award from Oxford's Medical Science Division for my sustained

commitment to education and teaching. I am Director of the Centre for Evidence-Based Medicine (CEBM), which builds capacity through teaching and training activities. I teach undergraduates, postgraduates, and teachers of EBM, and I am Director of Programs in Evidence-Based Health Care. (Attached as Exhibit D is a copy of my CV.)

6. We have not received any compensation, either directly or in-kind, for this affidavit.

THE “FLU”

7. The Massachusetts Department of Public Health repeatedly refers to influenza vaccines as an approach for dealing with the “flu.” However, most cases of the “flu,” respiratory infections and illnesses, are not caused by influenza virus but rather by other viruses.⁵ Every year, hundreds of thousands of respiratory specimens are tested across the United States and, on average, only 16% are found to be influenza positive.⁶ Other viruses, *e.g.*, adenoviruses, respiratory syncytial virus, rhinoviruses, and coronaviruses, cause a clinically indistinguishable disease all known colloquially as “flu.” Hence, the influenza vaccine, even if it were a 100% effective product, could only address a small fraction of the “flu” cases in Massachusetts as it does not and cannot address the other viruses.

THE INFLUENZA VACCINE

8. There is no single “influenza vaccine.” There are a wide range of distinct products, produced by different manufacturers, each with different ingredients, manufacturing facilities, and safety and efficacy profiles that regulators need to evaluate prior to initial approval and licensing each year.

⁵ See <https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.12789>; see also <https://academic.oup.com/ajcp/article/147/1/43/2697603>.

⁶ Doshi P. Influenza: marketing vaccine by marketing disease. *BMJ* 2013;346:f3037 <https://www.bmj.com/content/346/bmj.f3037>.

9. Not only is each influenza vaccine a unique product, the process for culturing the influenza virus and creating the vaccines results in variations from year to year, batch to batch, and potentially even from dose to dose. This is because, unlike drugs that are made from a consistent small molecule, these products are biologics produced using biological material. Each brand of influenza vaccine also changes each year to target strains of influenza virus expected to be in circulation in the coming season. The influenza vaccine is therefore not a single, unchanging product over time, but rather differs from year to year, product to product, and batch to batch.

10. One implication of this is that, once a given product is licensed, new formulations of that product (annually produced) are allowed on the market each year without knowing their efficacy or safety profile. Performance in a given season can only be discovered after the fact (*i.e.*, after the season has ended).

NO EVIDENCE THAT INFLUENZA VACCINES PREVENT TRANSMISSION OF INFLUENZA

11. The Cochrane Collaboration, considered an independent scientific body, conducts systematic reviews of all the best available scientific studies to assess the current state of the science on questions of interest. Its partners and funders include the U.S. National Institutes of Health (NIH), the World Health Organization (WHO), national health agencies, and leading medical universities from around the globe.⁷ The process of conducting a systematic review involves a systematic, thorough search, and critical assessment of all relevant articles on a given clinical topic. Systematic reviews are a methodology for reducing bias when appraising the scientific literature and help protect against “cherry picking.” Systematic reviews are widely

⁷ <https://www.cochrane.org/about-us/our-funders-and-partners>.

regarded as the most trustworthy sources of information, sitting atop the Evidence-Based Medicine pyramid.⁸

12. In 2010, Cochrane published a systematic review entitled “Vaccines for preventing influenza in healthy adults” which, after a review of the published randomized clinical trials and comparative studies for the influenza vaccine, “found no evidence that vaccines prevent viral transmission” of influenza.⁹ In 2014, Cochrane updated this systematic review with 41 new trials and in 2018 it updated it again with 52 additional trials comprising over 80,000 additional individuals.¹⁰ These updates did not change the conclusion reached in 2010 that **there is no evidence that influenza vaccines prevent viral transmission of influenza.**

13. In 2018, Cochrane conducted the same systematic review of all published clinical trials and studies with regard to children entitled “Vaccines for preventing influenza in healthy children.”¹¹ It concluded that “**we could find no convincing evidence that vaccines can reduce ... community transmission of influenza.**”¹²

NO RELIABLE EVIDENCE THAT INFLUENZA VACCINES PREVENT HOSPITALIZATIONS AND DEATH

14. Randomized clinical trials have not demonstrated that administration of influenza vaccines reduces the risk of hospitalization or mortality, something demonstrated clearly by the Cochrane review on this topic.¹³ These trials were conducted prospectively and were randomized, hence reducing the potential bias. There have been a number of observational studies (studies that

⁸ <https://guides.lib.uci.edu/ebm/pyramid>.

⁹ <https://pubmed.ncbi.nlm.nih.gov/20614424/>.

¹⁰ <https://pubmed.ncbi.nlm.nih.gov/24623315/>; <https://pubmed.ncbi.nlm.nih.gov/29388196/>.

¹¹ <https://pubmed.ncbi.nlm.nih.gov/29388195/>.

¹² <https://pubmed.ncbi.nlm.nih.gov/29388195/> (emphasis added).

¹³ <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004876.pub4/full>.

looked retrospectively at historical data, generally from medical claims databases) that were not randomized, and hence highly susceptible to bias, which indicated influenza vaccines lowered the rate of hospitalization. These observational studies are unreliable and inconsistent with the well-controlled clinical trials which have not demonstrated any such reduction. Many of them have reported a dramatic and totally implausible efficacy of influenza vaccines (one famous one¹⁴ reported influenza vaccines reduced all deaths by half – not just influenza-associated deaths, but all deaths). Such results have long been criticized as plainly implausible,¹⁵ and a variety of studies have been conducted to understand how these analyses could arrive at such unbelievable results.¹⁶

15. In 2018, the Cochrane review of influenza vaccines in healthy children reached the conclusion that “at present we could find no convincing evidence that vaccines can reduce mortality, hospital admissions, serious complications, or community transmission of influenza.”¹⁷ As for adults, in 2018 Cochrane concluded that “We found low-certainty evidence that hospitalisation rates and time off work may be comparable between vaccinated and unvaccinated adults, although the confidence interval around the effect for hospital admission is wide and there was substantial variation in the direction of effect on time off work.”¹⁸ In other words, there was no compelling evidence of demonstrating benefit in a reduction in hospital admission or time off work, and Cochrane recommended that a sufficiently large, “publicly funded, high-quality, placebo-controlled trial run over several seasons should be undertaken.”¹⁹ Other systematic

¹⁴ <https://www.nejm.org/doi/full/10.1056/NEJMoa070844>.

¹⁵ <https://pubmed.ncbi.nlm.nih.gov/18163274/>.

¹⁶ <https://pubmed.ncbi.nlm.nih.gov/16368725/> ; <https://pubmed.ncbi.nlm.nih.gov/16368724/> ; <https://pubmed.ncbi.nlm.nih.gov/18556629/>.

¹⁷ <https://pubmed.ncbi.nlm.nih.gov/29388195/>.

¹⁸ <https://pubmed.ncbi.nlm.nih.gov/29388196/>.

¹⁹ <https://pubmed.ncbi.nlm.nih.gov/29388196/>.

reviews focusing on randomized controlled trials have reached similar conclusions regarding the lack of a reduction in hospitalization and mortality from influenza vaccines. For example, a non-Cochrane systematic review published in *The Lancet Infectious Diseases* concluded that the “[e]vidence for protection in adults aged 65 years or older is lacking.”²⁰

16. In addition to the lack of credible evidence demonstrating any ability to prevent hospitalization and death, there are randomized trials which report findings that raise questions about the ability of influenza vaccines to **increase** risk of non-influenza flu-like symptoms; in one such study, conducted by the Centers for Disease Control and Prevention, the authors write: “During the 1997-1998 influenza season, vaccine recipients reported significantly more ILI-related [ILI = influenza like illness] sick days, lost workdays, and lost work hours for physician visits than placebo recipients.”²¹ The fact that the vaccine group in a randomized trial fared worse than the placebo group underscores the unpredictability of effects.

INFLUENZA VACCINES CAN CAUSE SERIOUS HARM

17. While influenza vaccines are often portrayed as risk free, no medical intervention is risk free, and serious adverse events linked to influenza vaccine have occurred. In general, the evidence base on harms from influenza vaccines can be characterized as largely inadequate, leaving great uncertainty about the benefit/harms profile, particularly in children.

18. Part of the reason for this lack of certainty is that harms from influenza vaccines are not adequately studied. For example, while Cochrane explained that “influenza vaccines were associated with serious harms such as narcolepsy and febrile convulsions,” it surprisingly found:

...only one safety study of inactivated vaccine in children under 2 years, carried out nearly 30 years ago in 35 children (ab Wright 1976a). The lack of safety data for inactive vaccines in younger

²⁰ <https://pubmed.ncbi.nlm.nih.gov/22032844/>.

²¹ <https://pubmed.ncbi.nlm.nih.gov/11015795/>.

children is particularly surprising given that the inactive vaccine is now recommended for healthy children six months and older in the USA and Canada (AAPCID 2004; Harper 2004; Orr 2004).²²

The Cochrane report also highlights a number of other issues. For many studies, adverse events are not adequately described or reported. Many important adverse events in part lack a more robust evidence base for lack of standardized ways of measuring adverse events, a point raised in other safety reviews.²³ For some influenza vaccines, manufacturers refused to provide all data regarding harms. Adverse events also tend to be actively monitored for only a short period of time, relying on passive data collection methods for detecting adverse events after a brief initial period.

19. Also consider events that occurred during the last pandemic a decade ago, with two “swine flu” H1N1 vaccines in 2009-10, vaccines for which heightened surveillance was put in place. That influenza season would witness the following, as one of us wrote about in *JAMA Internal Medicine*: “Australia suspended its universal vaccination program for children younger than 5 years because of a surge in febrile convulsions following vaccination (1 in 110 children).²⁴

20. In terms of the potential for injury from the influenza vaccine, it is worth noting that in the last ten years, the Vaccine Adverse Events Reporting System (VAERS), administered by the CDC and FDA, has received reports of the following serious events following receipt of an influenza vaccine: 1,527 deaths; 3,327 permanent disabilities; 12,692 hospitalizations; and 40,040 emergency room and/or medical office visits.²⁵ A report from researchers at Harvard Medical School, including the Director of Bioinformatics, funded by the Agency for Health Research and

²² <https://pubmed.ncbi.nlm.nih.gov/29388195/>.

²³ <https://pubmed.ncbi.nlm.nih.gov/26822822/>.

²⁴ Stokes B. Ministerial review into the public health response into the adverse events to the seasonal influenza vaccine. Department of Health, Government of Western Australia; July 2010. https://ww2.health.wa.gov.au/-/media/Files/Corporate/Reports-and-publications/PDF/Stokes_Report.pdf. Accessed December 7, 2020.

²⁵ <https://wonder.cdc.gov/vaers.html> (Query date Nov 25, 2020; covers July 1, 1990 to present.)

Quality, an agency within the United States Department of Health and Human Services, stated that “fewer than 1% of vaccine adverse events are reported” to VAERS.²⁶

21. Influenza vaccines represent 50% (3,852) of the 7,705 compensated claims (10/01/1988 through 09/01/2020),²⁷ for which damages have been paid out by the Vaccine Injury Compensation Program, administered in the United States Court of Federal Claims.²⁸ The injuries for which this compensation has been paid for claims of injury from the influenza vaccine include: Acute Disseminated Encephalomyelitis (ADEM), Anaphylaxis (severe allergic reaction), Axonal Polyneuropathy, Bell’s Palsy, Cellulitis, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Clinically Isolated Syndrome (CIS), Complex Regional Pain Syndrome (CRPS), Cardiac Arrest, Death, Fibromyalgia, Guillain-Barre Syndrome (GBS), Insomnia, Multiple Sclerosis (MS), Motor Neuropathy, Optic Neuritis, Parsonage-Turner Syndrome (brachial neuritis), Postural orthostatic tachycardia syndrome (POTS), Sensory Polyneuropathy, Shoulder Injury Related to Vaccine Administration (SIRVA), Small Fiber Neuropathy, Stevens Johnson Syndrome (SJS), Subcutaneous Abscess, Transverse Myelitis (TM), Vasovagal Syncope.²⁹

22. We are not drawing conclusions regarding the causal role of the vaccine in the VAERS reports or federal court compensation cases, nor do we know the frequency of each type of adverse event in the population as such conclusions cannot be made without further study. Instead, we highlight them to indicate the scale of such reports and the need for more rigorous study of influenza vaccine safety.

²⁶ <https://digital.ahrq.gov/sites/default/files/docs/publication/r18hs017045-lazarus-final-report-2011.pdf>.

²⁷ <https://www.hrsa.gov/sites/default/files/hrsa/vaccine-compensation/data/data-statistics-report.pdf>.

²⁸ <https://www.uscfc.uscourts.gov/vaccine-programoffice-special-masters>.

²⁹ <https://www.uscfc.uscourts.gov/aggregator/sources/7>.

UNINTENDED CONSEQUENCES AND NON-SPECIFIC EFFECTS

23. In addition to potential injuries, the influenza vaccine can have other unintended consequences: so-called “off-target” or “nonspecific effects.” This section outlines a few of these nonspecific effects.

24. An important nonspecific effect of influenza vaccine is that it may increase susceptibility to other influenza like illnesses. For example, a study from researchers at the University of Hong Kong, Queen Mary Hospital, and Centre for Influenza Research compared children receiving the influenza vaccine with those receiving a saline injection in a prospective randomized double-blind study.³⁰ Both groups had a statistically similar rate of influenza, but the group receiving the influenza vaccine had a statistically significant 4.4 times increased risk of non-influenza infections. Thus, the influenza vaccine appears to have increased these children’s susceptibility to other respiratory viral infections.

25. Rigorous observational studies also suggest that influenza vaccination may increase the risk of non-influenza respiratory viruses or novel influenza viruses, not covered in that year’s vaccine.³¹

26. There is also evidence for cohort, or year of birth, effects in influenza mortality, which have in particular been noticed during pandemics.³² The difference in survival rates depends on the experience individuals have in surviving influenza infection, which generates robust and long-lived immune memory. These individuals, upon encountering an influenza viral strain in old age for which they previously developed immunity, enjoy immunological memory to

³⁰ <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404712/>.

³¹ <https://pubmed.ncbi.nlm.nih.gov/29525279/>; <https://pubmed.ncbi.nlm.nih.gov/20386731/>.

³² <https://pubmed.ncbi.nlm.nih.gov/23717567/>; <https://pubmed.ncbi.nlm.nih.gov/31502229/>; <https://pubmed.ncbi.nlm.nih.gov/9652423/>.

these strains. In contrast, it is well established that influenza vaccines do not provide long-lived immunity conferred by natural infection and, moreover, influenza vaccines' very modest efficacy is even poorer for the elderly. The combination of these considerations can make a reasonable case that, given what we currently know about the disease and influenza vaccines, arguably the most effective strategy for an individual is to experience some influenza infection as a healthy adult, when the risk of complications is very low, thus generating a better immunity portfolio against influenza in old age, a time when the risk of complications is much higher.

CONCLUSION

27. While the harms from influenza vaccines are typically understated or not properly studied, the benefits of influenza vaccines are exaggerated, often contrary to the scientific findings, or simply asserted without evidence. It is unfortunate that public health officials justify their policies and statements regarding the influenza vaccine through selective citations of the evidence base rather than conclusions reached after systematic and thorough review of the reliable evidence.³³

28. For the avoidance of doubt, we are not against any individual receiving the influenza vaccine and in this affidavit we have not provided any opinion regarding other vaccines.

29. Rather, it is our collective scientific view that before a product is recommended to a patient, let alone mandated to a patient, there should be clear evidence to support the recommendation. There should be rigorous placebo-controlled, randomized trials that have

³³ As an additional example, the CDC technical document on influenza vaccines expressly states that "Influenza vaccination **might reduce** the frequency of secondary complications and risk for influenza-related hospitalization and death," which reflects the unproven nature of whether influenza vaccines can reduce hospitalization and death. <https://www.cdc.gov/mmwr/volumes/65/rr/rr6505a1.htm> (emphasis added). Nonetheless, the CDC's website pages designed for public and state health department consumption does not include this qualifier but rather inaccurately presents the evidence as clear cut and definitive. <https://www.cdc.gov/flu/about/burden-averted/2019-2020.htm> This is another example of the gap between the science and the policy.

demonstrated that influenza vaccines prevent transmission and reduce hospitalizations, ICU admissions, or mortality. Ideally, there should be at least two such trials, publicly funded, and run over multiple influenza seasons with multiple different influenza vaccines. Unfortunately, the reality is that, despite influenza vaccines being recommended since 1960, not a single placebo-controlled randomized trial was ever set up to study whether the vaccine carries any of these potential benefits. The proven benefits should also be large enough that it can be confidently judged that influenza vaccines will bring public health benefits in excess of any harms. The history of influenza vaccines does not support this premise.³⁴


SIGNED UNDER THE PAINS AND PENALTIES OF PERJURY,




Peter Doshi



Peter Gøtzsche



Thomas Jefferson



Carl Heneghan

This 17 th day of December, 2020.

³⁴ It is also troubling to mandate a product whose safety and efficacy remain untested due to its reformulation every year and hence is effectively a new product every year, in addition to variations between products and lots of each influenza vaccine product.

EXHIBIT A

Curriculum Vitae of Peter Doshi, PhD

1) Biographical Information

A. Undergraduate Education

Brown University 1999 – 2002
Providence, Rhode Island
Bachelor of Arts
Anthropology

B. Graduate Education

Harvard University 2003 – 2006
Cambridge, Massachusetts
Master of Arts
Regional Studies—East Asia

Massachusetts Institute of Technology 2006 – 2011
Cambridge, Massachusetts
Doctor of Philosophy
History, Anthropology, and Science, Technology and Society

C. Postdoctoral Training

Johns Hopkins University School of Medicine 2011 – 2013
Baltimore, Maryland
Postdoctoral fellowship in Comparative Effectiveness Research
Divisions of General Pediatrics and General Internal Medicine

D. Employment Experience

University of Maryland School of Pharmacy
Assistant Professor of Pharmaceutical Health Services Research 2014 – 2019
Associate Professor of Pharmaceutical Health Services Research 2019 – present

BMJ 2013 – present
Associate Editor

Johns Hopkins University November 2012
Krieger School of Arts and Sciences
Part-time lecturer

2) Scholarly Activity

A. Publications in Refereed/Peer Reviewed Journals (Note: **Name of the faculty member in bold** and the corresponding author underlined. Students, residents, fellows, or post-docs supervised by the faculty member are indicated with an asterisk*)

1. **Doshi P**, Spence O*, Kuzucan A*, Powers JH 3rd. Communication of Nonefficacy Benefits of New Drugs Approved on the Basis of Noninferiority Trials Alone: Cohort Study of FDA and Sponsor Communication, 2011-2017. JAMA Intern Med. 2019;179(5):719–721. doi:10.1001/jamainternmed.2018.7040
2. Desai B*, Hong K*, Powers JH 3rd, **Doshi P**. Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling [published online ahead of print, 2019 Oct 28]. J Gen Intern Med. 2019;10.1007/s11606-019-05460-2. doi:10.1007/s11606-019-05460-2
3. Spence O*, Hong K*, Onwuchekwa Uba R*, **Doshi P**. Availability of study protocols for randomized trials published in high-impact medical journals: A cross-sectional analysis [published online ahead of print, 2019 Aug 26]. Clin Trials. 2019;1740774519868310. doi:10.1177/1740774519868310
4. **Doshi P**, Sieluk J*, Hung A*. The possible harms of statins: What do product labels, patient package inserts, and pharmacy leaflets tell us?. J Am Pharm Assoc (2003). 2019;59(2):195–201. doi:10.1016/j.japh.2018.12.003
5. Jefferson T, **Doshi P**, Boutron I, Golder S, Heneghan C, Hodgkinson A, Jones M, Lefebvre C, Stewart LA. When to include clinical study reports and regulatory documents in systematic reviews. BMJ Evid Based Med. 2018 Dec;23(6):210-217. doi: 10.1136/bmjebm-2018-110963. Epub 2018 Oct 11. PubMed PMID: 30309870.
6. Jørgensen L, **Doshi P**, Gøtzsche P, Jefferson T. Challenges of independent assessment of potential harms of HPV vaccines. BMJ. 2018 Sep 24;362:k3694. doi: 10.1136/bmj.k3694. PubMed PMID: 30249615.
7. **Doshi P**. Pandemrix vaccine: why was the public not told of early warning signs? BMJ. 2018 Sep 20;k3948. doi: 10.1136/bmj.k3948.
8. Jørgensen L, **Doshi P**, Gøtzsche P, Jefferson T. Challenges of independent assessment of potential harms of HPV vaccines. BMJ. 2018 Sep 24;k3694. doi: 10.1136/bmj.k3694.
9. Hodgkinson A, Dietz KC, Lefebvre C, Golder S, Jones M, **Doshi P**, et al. The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors. Systematic Reviews. 2018 Dec [cited 2018 Oct 2];7(1). doi: 10.1186/s13643-018-0766-x
10. Spence O*, Onwuchekwa Uba R*, Shin S*, **Doshi P**. Patient consent to publication and data sharing in industry and NIH-funded clinical trials. Trials 2018

May 3;19(1):269. doi: 10.1186/s13063-018-2651-2.

0 citations (Scopus), 55 social media mentions (PlumX Metrics), 4 readers on Mendeley (PlumX Metrics)

11. **Doshi P**, Hur P*, Jones M, Albarmawi H*, Jefferson T, Morgan DJ, et al. Informed consent to study purpose in randomized clinical trials of antibiotics, 1991 through 2011. *JAMA Intern Med* 2017;177(10):1452-1459.
4 citations (Scopus), 53 blog and social media mentions (Altmetric), 13 news outlet mentions (Altmetric), 9 readers on Mendeley (PlumX metrics), 7 full text views in EBSCO databases (PlumX Metrics), 342 PDF downloads from journal website
12. **Mayo-Wilson E**, Li T, Fusco N, Bertizzolo L, Canner JK, Cowley T, **Doshi P**, Ehmsen J, Gresham G, Guo N, Haythornthwaite JA, Heyward J, Hong H, Pham D, Payne JL, Rosman L, Stuart EA, Suarez-Cuervo C, Tolbert E, Twose C, Vedula S, Dickersin K. Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy. *J Clin Epidemiol* 2017 Nov;91:95-110.
3 citations (Scopus), 62 blog and social media mentions (PlumX Metrics), 11 readers on Mendeley (PlumX Metrics)
13. **Doshi P**. The unofficial vaccine educators: are CDC funded non-profits sufficiently independent? *BMJ* 2017 Nov 7;359:j5104.
0 citations (Scopus), 273 social media mentions (Altmetric), 4 readers on Mendeley (Altmetric), 1734 full text views on journal website, 205 PDF downloads from journal website
14. Sieluk J*, Palasik B*, dosReis S, **Doshi P**. ADHD medications and cardiovascular adverse events in children and adolescents: cross-national comparison of risk communication in drug labeling. *Pharmacoepidemiol Drug Saf* 2017 Mar;26(3):274-284.
0 citations (Scopus), 6 social media mentions (Altmetric), 3 readers on Mendeley (Altmetric)
15. **Spelsberg A**, Prugger C, **Doshi P**, Ostrowski K, Witte T, Husgen D, et al. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. *BMJ* 2017 Feb 7;356:j337.
3 citations (Scopus), 263 blog and social media mentions (Altmetric), 7 news outlet mentions (Altmetric), 21 readers on Mendeley (Altmetric), 18,941 full text views on journal website, 1927 PDF downloads from journal website, 9 user-generated Bitly links to article with a total of 200 link clicks (PlumX Metrics)
16. **Doshi P**, Jefferson T. Open data 5 years on: A case series of 12 freedom of information requests for regulatory data to the European Medicines Agency. *Trials* 2016;17(1).
9 citations (Scopus), 59 blog and social media mentions (Altmetric), 15 readers on Mendeley (PlumX Metrics), 10 full text views in EBSCO databases (PlumX Metrics), 8 user-generated Bitly links to article with a total of 99 link clicks (PlumX Metrics)

17. **Doshi P.** Is this trial misreported? Truth seeking in the burgeoning age of trial transparency. *BMJ* 2016 Oct 24;355:i5543.
2 citations (Scopus), 59 blog and social media mentions (Altmetric), 10 readers on Mendeley (Altmetric), 1761 full text views on journal website, 239 PDF downloads from journal website
18. **Heneghan CJ, Onakpoya I, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Mahtani KR, Nunan D, Howick J, Jefferson T.** Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. *Health Technol Assess* 2016 May;20(42):1-242.
10 citations (Scopus), 84 blog and social media mentions (Altmetric), 1 news outlet mention (PlumX Metrics) 1 policy document mention (Altmetric), 46 readers on Mendeley (Altmetric), 1 Wikipedia reference (PlumX Metrics)
19. **Doshi P.** Data too important to share: do those who control the data control the message? *BMJ* 2016 Mar 2;352:i1027.
13 citations (Scopus), 93 blog and social media mentions (Altmetric), 4 news outlet mentions (Altmetric), 20 readers on Mendeley (Altmetric), 9127 full text views on journal website, 1086 PDF downloads from journal website, 3 user-generated Bitly links to article with a total of 5 link clicks (PlumX Metrics)
20. **Persaud N, Doshi P.** North American regulatory agencies can and should make clinical trial data publicly available. *CMAJ* 2016 Feb 2;188(2):96-97.
5 citations (Scopus), 21 blog and social media mentions (Altmetric), 1 reader on Mendeley (Altmetric), 1 full text view in EBSCO databases (PlumX Metrics)
21. **Hung A*, Sieluk J*, Doshi P.** The Untapped Potential of Pharmacy Leaflets for Informing Patients About Drug Benefits and Risks. *JAMA Intern Med* 2016 Jan;176(1):11-12.
1 citation (Scopus), 87 blog and social media mentions (Altmetric), 9 readers on Mendeley (Altmetric), 1 full text view in EBSCO databases (PlumX Metrics), 517 PDF downloads from journal website
22. **Doshi P.** Defining antibiotic effectiveness and resistance: how a private party may soon rule judgments over susceptibility testing. *BMJ* 2016 Jan 6;352:h6849.
0 citations (Scopus), 19 social media mentions (Altmetric), 3 readers on Mendeley (Altmetric), 733 full text views on journal website, 168 PDF downloads from journal website
23. **Mayo-Wilson E, Hutfless S, Li T, Gresham G, Fusco N, Ehmsen J, Heyward J, Vedula S, Lock D, Haythornthwaite J, Payne JL, Cowley T, Tolbert E, Rosman L, Twose C, Stuart EA, Hong H, Doshi P, Suarez-Cuervo C, Singh S, Dickersin K.** Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: A protocol for a systematic review. *Syst Rev* 2015;4(1).
2 citations (Scopus), 13 social media mentions (Altmetric), 22 readers on Mendeley (Altmetric)

24. Mayo-Wilson E, Doshi P, Dickersin K. Are manufacturers sharing data as promised? *BMJ* 2015 Sep 25;351:h4169.
6 citations (Scopus), 57 blog and social media mentions (Altmetric), 4 readers on Mendeley (Altmetric), 974 full text views on journal website, 211 PDF downloads from journal website
25. Doshi P. Speeding new antibiotics to market: a fake fix? *BMJ* 2015 Mar 25;350:h1453.
14 citations (Scopus), 150 blog and social media mentions (Altmetric), 2 news outlet mentions (Altmetric), 25 readers on Mendeley (Altmetric), 6165 full text views on journal website, 811 PDF downloads from journal website, 2 full text views in EBSCO databases (PlumX Metrics), 6 user-generated Bitly links to article with a total of 286 link clicks (PlumX Metrics)
26. Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. *Cochrane Database Syst Rev* 2014;2014(4).
128 citations (Scopus), 398 blog and social media mentions (Altmetric), 37 news outlet mentions (Altmetric), 188 readers on Mendeley (Altmetric), 1 policy document reference (Altmetric), 5 Wikipedia references (Altmetric), 4 YouTube video mentions (Altmetric), 9 user-generated Bitly links to article with a total of 32 link clicks (PlumX Metrics)
27. Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports. *BMJ Open* 2014 Sep 30;4(9):e005253-2014-005253.
8 citations (Scopus), 88 blog and social media mentions (Altmetric), 1 news outlet mention (Altmetric), 23 readers on Mendeley (Altmetric), 1 policy document reference (Altmetric), 4490 full text views on journal website, 567 PDF downloads from journal website, 9 user-generated Bitly links to article with a total of 18 link clicks (PlumX Metrics)
28. Jefferson T, Doshi P. Multisystem failure: the story of anti-influenza drugs. *BMJ* 2014 Apr 10;348:g2263.
31 citations (Scopus), 26 blog and social media mentions (Altmetric), 33 readers on Mendeley (Altmetric), 1 Wikipedia reference (PlumX Metrics) 5952 full text views on journal website, 1344 PDF downloads from journal website, 5 user-generated Bitly links to article with a total of 3 link clicks (PlumX Metrics)
29. Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. *BMJ* 2014 Apr 9;348:g2545.
106 citations (Scopus), 776 blog and social media mentions (Altmetric), 32 news outlet mentions (Altmetric), 156 readers on Mendeley (Altmetric), 2 Wikipedia references (PlumX Metrics), 105,987 full text views on journal website, 18,869 PDF downloads from journal website, 1 full text view in EBSCO databases

- (PlumX Metrics), 26 user-generated Bitly links to article with a total of 139 link clicks (PlumX Metrics)*
30. **Doshi P**, Dickersin K, Healy D, Vedula SS, Jefferson T. Restoring invisible and abandoned trials: A call for people to publish the findings. *BMJ* 2013;346(7913). *78 citations (Scopus), 336 blog and social media mentions (Altmetric), 47 news outlet mentions (Altmetric), 1 Wikipedia reference (PlumX Metrics), 89 readers on Mendeley (Altmetric), 56,338 full text views on journal website, 5169 PDF downloads from journal website, 19 user-generated Bitly links to article with a total of 134 link clicks (PlumX Metrics)*
 31. **Doshi P**. Influenza vaccines: time for a rethink. *JAMA Intern Med* 2013 Jun 10;173(11):1014-1016. *10 citations (Scopus), 95 social media mentions (Altmetric), 1 news outlet mention (PlumX Metrics), 19 readers on Mendeley (Altmetric), 1 full text view in EBSCO databases (PlumX Metrics), 972 PDF downloads from journal website, 4 user-generated Bitly links to article with a total of 2 link clicks (PlumX Metrics)*
 32. **Doshi P**, Jefferson T. The first 2 years of the European Medicines Agency's policy on access to documents: secret no longer. *JAMA Intern Med* 2013 Mar 11;173(5):380-382. *19 citations (Scopus), 3 blog mentions (Altmetric), 10 readers on Mendeley (Altmetric), 4 full text views in EBSCO databases, 1079 PDF downloads from journal website, 2 user-generated Bitly links to article with a total of 1 link click (PlumX Metrics)*
 33. **Doshi P**, Jefferson T. Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. *BMJ Open* 2013 Feb 26;3(2):10.1136/bmjopen-2012-002496. Print 2013. *38 citations (Scopus), 57 blog and social media mentions (Altmetric), 1 policy document reference (Altmetric), 18 readers on Mendeley (Altmetric), 10,343 full text views on journal website, 1558 PDF downloads from journal website*
 34. **Doshi P**, Jefferson T, Del Mar C. The imperative to share clinical study reports: recommendations from the Tamiflu experience. *PLoS Med* 2012;9(4):e1001201. *95 citations (Scopus), 117 blog and social media mentions (journal website), 141 readers on Mendeley (Mendeley.com), 1 Wikipedia reference (PlumX Metrics), 62,915 full text views on journal website, 5459 PDF downloads from journal website and PubMed Central, 1 user-generated Bitly link to article with a total of 3 link clicks (PlumX Metrics)*
 35. Jefferson T, Jones MA, **Doshi P**, Del Mar CB, Heneghan CJ, Hama R, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. *Cochrane Database Syst Rev* 2012 Jan 18;1:CD008965. *89 citations (Scopus), 66 blog and social media mentions (Altmetric), 7 news outlet mentions (Altmetric), 99 readers on Mendeley (Altmetric), 3 Wikipedia references (PlumX Metrics), 1 YouTube video mentions (Altmetric)*

36. **Doshi P**, Jones M, Jefferson T. Rethinking credible evidence synthesis. *BMJ* 2012 Jan 17;344:d7898.
39 citations (Scopus), 26 blog and social media mentions (Altmetric), 58 readers on Mendeley (Altmetric), 1 policy document reference (Altmetric), 11,133 full text views on journal website, 1832 PDF downloads from journal website
37. **Doshi P**. The elusive definition of pandemic influenza. *Bull World Health Organ* 2011 Jul 1;89(7):532-538.
40 citations (Scopus), 41 readers on Mendeley (PlumX Metrics), 515 full text views in EBSCO databases (PlumX Metrics)
38. Jefferson T, **Doshi P**, Thompson M, Heneghan C, Cochrane Acute Respiratory Infections Group. Ensuring safe and effective drugs: who can do what it takes? *BMJ* 2011 Jan 11;342:c7258.
37 citations (Scopus), 12 blog and social media mentions (Altmetric), 2 news outlet mentions (Altmetric), 38 readers on Mendeley (Altmetric), 7022 full text views on journal website, 11 PDF downloads from journal website, 3 user-generated Bitly links to article with a total of 109 link clicks (PlumX Metrics)
39. Jefferson T, Jones M, **Doshi P**, Del Mar C, Dooley L, Foxlee R. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. *Cochrane Database Syst Rev* 2010 Feb 17;(2):CD001265. doi(2):CD001265.
60 citations (Scopus), 2 blog and social media mentions (Altmetric), 14 readers on Mendeley (Altmetric)
40. **Doshi P**. Neuraminidase inhibitors--the story behind the Cochrane review. *BMJ* 2009 Dec 8;339:b5164.
58 citations (Scopus), 47 blog and social media mentions (Altmetric), 4 news outlet mentions (Altmetric), 52 readers on Mendeley (Altmetric), 14,332 full text views on journal website, 7 PDF downloads from journal website
41. Jefferson T, Jones M, **Doshi P**, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. *BMJ* 2009 Dec 8;339:b5106.
209 citations (Scopus), 45 blog and social media mentions (Altmetric), 5 news outlet mentions (Altmetric), 2 Wikipedia references (Altmetric), 101 readers on Mendeley (Altmetric), 79,183 full text views on journal website, 13,916 PDF downloads from journal website, 7 full text views in EBSCO databases (PlumX Metrics), 2 user-generated Bitly links to article with a total of 1 link click (PlumX Metrics)
42. **Doshi P**. Calibrated response to emerging infections. *BMJ* 2009 Sep 3;339:b3471.
63 citations (Scopus), 2 blog mentions (Altmetric), 1 Wikipedia reference (PlumX Metrics), 8 readers on Mendeley (Altmetric), 9667 full text views on journal website, 30 PDF downloads from journal website
43. **Doshi P**. Trends in recorded influenza mortality: United States, 1900-2004. *Am J*

Public Health 2008 May;98(5):939-945.

48 citations (Scopus), 11 social media mentions (Altmetric), 3 news outlet mentions (Altmetric), 37 readers on Mendeley (Altmetric), 3466 full text views in EBSCO databases (PlumX Metrics)

B. Presentations at Scientific or Professional Meetings

(Note: **Name of the faculty member in bold**. Students, residents, fellows, or post-docs supervised by the faculty member are indicated with an asterisk*)

1. **Doshi P.** The BMJ Investigative Journalism Conference. "Standards for drug approval: too stringent, too lax, or just right?" Berlin, Germany. November 18, 2019
Presentation; International; Podium
2. **Doshi P.** Friends of the National Library of Medicine conference. "Better clinical trials for new product development" Bethesda, MD. June 14, 2017
Invited presentation; National; Podium
3. **Doshi P.** "The gain to be realized by research transparency." 2016 Consumers United for Evidence-based Health Care annual meeting July 29, 2016, Washington DC
Invited presentation; National; Podium
4. **Doshi P**, Sieluk J*, Hung A*. "The Possible Harms of Statins: What do Product Labels and Pharmacy Leaflets Tell Us?" AACP Annual Meeting, Anaheim, CA. July 2016;
Invited presentation; National; Poster
5. **Doshi P.** Johns Hopkins School of Public Health. "The Hopkins mandatory flu vaccination policy, the search for truth, and freedom of speech in an academic institution" Baltimore, MD. June 10, 2016
Invited presentation; Local; Podium
6. **Doshi P.** "Adaptive Licensing & Access to Data" webcast presentation to European Public Health Alliance, Brussels, Belgium. April 18, 2016
Invited presentation; International; Webcast
7. **Doshi P.** "Speeding new antibiotics to market: a fake fix?", National Physicians Alliance annual meeting. Washington, DC.; October 17, 2015
Invited presentation; National; Podium
8. **Doshi P.** "How CUE can engage lay journalists", 2015 Consumers United for Evidence-based Health Care annual meeting, July 24, 2015. Washington, DC
Invited presentation; National; Podium
9. **Doshi P.** "Good and Bad Reanalysis", Society for Clinical Trials. May 19, 2015. Washington, DC
Invited presentation; National; Podium

10. **Doshi P.** “How Open Data Can Reduce Reporting Biases and Help Patients Choose Wisely,” Global Health & Innovation Conference. March 29, 2015, New Haven, CT
Invited presentation; National; Podium
11. **Doshi P.** “Who wants my data and what are they going to do with it?”, Consumers United for Evidence-based Healthcare (CUE) annual meeting, Washington D.C., July 25, 2014
Invited presentation; Non-reviewed; National; Podium
12. **Doshi P.** “Searching for evidence under the waterline”, Health Technology Assessment International (HTAi) annual meeting, Washington, DC, June 18, 2014
Invited presentation; International; Podium
13. **Doshi P.** “‘Open’ access to clinical trials: rhetoric and fine print”, Society for Clinical Trials annual meeting, Philadelphia, May 19, 2014
Invited presentation; National; Podium
14. **Doshi P.** “Thoughts on misleading analyses”, Presentation at Institute of Medicine consensus study meeting, February 4, 2014
Invited presentation; National; Podium
15. **Doshi P.** “Restoring Invisible and Abandoned Trials: the RIAT concept”, presentation at CBI conference on Clinical Data Disclosure and Transparency, January 30, 2014
Invited presentation; National; Podium
16. **Doshi P.** “Restoring Invisible and Abandoned Trials: the RIAT concept”, presentation at “The state of contemporary biomedical literature” conference sponsored by age.na.s, Rome, Italy, December 12, 2013
Invited presentation; International; Podium
17. **Doshi P.** “Restoring Invisible and Abandoned Trials: the RIAT concept”, presentation at oPen conference, Naples, Italy, December 13, 2013
Invited presentation; International; Podium
18. **Doshi P.** “Credible evaluation of trials: what kind of data do we need?”, Presentation at Institute of Medicine workshop on sharing clinical research data, October 5, 2012
Invited presentation; National; Podium
19. **Doshi P, Bass E.** “Do media understand that systematic reviews are not just another ‘new study’?” 18th Annual National Research Services Award (NRSA) Conference; June 23, 2012
Presentation; National; Poster

C. Special Lectures (Invited)

1. "Working with regulatory data – a non-regulatory, non-industry perspective" Presentation to closed FDA-Health Canada meeting, Silver Spring, November 13, 2018; Invited lecture.
2. "Better evidence for better health" Presentation to WHO Uppsala Monitoring Centre 40th Anniversary, Uppsala, Sweden; May 17, 2018; Invited lecture
3. "The RIAT Initiative for Tackling Bias in Biomedical Literature" Presentation to National Library of Medicine ClinicalTrials.gov team, March 5, 2018; Invited lecture.
4. "Interim guidance on how to decide whether to include clinical study reports and other regulatory documents into Cochrane reviews" Presentation to Cochrane Scientific Committee, by web, February 28, 2018; Invited lecture
5. "Ensuring Accuracy in Clinical Trial Publications: Weighing Options" Continuing medical education lecture, Food and Drug Administration. Silver Spring, MD. October 25, 2017; Invited lecture
6. Office of Research Integrity conference "Quest for Research Excellence". Washington, DC. August 9, 2017; Panel Participation
7. "Why we need clinical trial data, and how FDA can help reduce abuse of the medical literature" Food and Drug Administration, Silver Spring, MD. June 6, 2017; Invited lecture
8. "Ensuring accuracy in clinical trial publications: weighing options" online webcast through University of Maryland M-CERSI program. April 20, 2017; Invited lecture
9. "Ensuring accuracy in clinical trial publications: weighing options" Food and Drug Administration, Silver Spring, MD. March 14, 2017; Invited lecture
10. "Finding "Big Data" (OK, big detail) under the waterline" Johns Hopkins University, Baltimore, MD. January 27, 2017; Invited lecture
11. "How We Fooled Ourselves into Thinking the Revolution on Data Transparency Was Won," Johns Hopkins Center for Clinical Trials seminar series January 6, 2016; Invited lecture
12. "The NYAG's contribution to evidence-based medicine," New York State Attorney General's Office. New York, NY; November 9, 2015; Invited lecture
13. "Breaking the Seal on Drug Company Research", presentation at Des Moines University "Leadership series" seminar, Des Moines, Iowa; September 18, 2014; Invited lecture
14. Dean's Convocation panel on "Big Data." University of Maryland School of Law; September 22, 2014; Panel participation

D. Other Publications and Related Activities

1. Publications not peer reviewed

1. Lexchin J, Herder M, **Doshi P**. Canada finally opens up data on new drugs and devices. *BMJ*. 2019;365:l1825. Published 2019 Apr 17. doi:10.1136/bmj.l1825
2. **Doshi P**. EMA scales back transparency initiatives because of workload. *BMJ* 2018;362:k3513. doi: 10.1136/bmj.k3513.
3. **Doshi P**, Shamseer L*, Jones M, Jefferson T. Restoring biomedical literature with RIAT. *BMJ* 2018 Apr 26;361:k1742. doi: 10.1136/bmj.k1742.
0 citations (Scopus), 60 social media mentions (Altmetric), 1 reader on Mendeley (Altmetric), 118 PDF downloads from journal website
4. **Doshi P**. EMA recommendation on hydroxyethyl starch solutions obscured controversy. *BMJ* 2018 Mar 20;360:k1287. doi: 10.1136/bmj.k1287.
1 citation (Scopus), 22 blog and social media mentions (Altmetric), 1 reader on Mendeley (Altmetric), 161 PDF downloads from journal website
5. **Doshi P**. CDC tightens controls on scientists' communication with news media. *BMJ* 2018 Feb 14;360:k675.
0 citations (Scopus), 5 social media mentions (Altmetric), 3 news outlet mentions (Altmetric), 4 readers on Mendeley (Altmetric), 403 full text views on journal website, 63 PDF downloads from journal website
6. **Doshi P**. FDA to begin releasing clinical study reports in pilot programme. *BMJ* 2018 Jan 23;360:k294.
0 citations (Scopus), 47 blog and social media mentions (Altmetric), 294 full text views on journal website, 61 PDF downloads from journal website
7. **Doshi P**. "Independent" reanalysis of landmark starch solutions trial was published by original authors. *BMJ* 2017 Jul 21;358:j3552.
0 citations (Scopus), 96 blog and social media mentions (Altmetric), 2 news outlet mentions (Altmetric), 2 readers on Mendeley (Altmetric), 2536 full text views on journal website, 274 PDF downloads from journal website
8. **Doshi P**. The problem with US website for collecting adverse events after vaccination is resolved. *BMJ* 2017 Sep 8;358:j4164.
0 citations (Scopus), 133 social media mentions (Altmetric), 131 full text views on journal website, 46 PDF downloads from journal website
9. **Doshi P**. US government website for collecting adverse events after vaccination is inaccessible to most users. *BMJ* 2017;357.
0 citations (Scopus), 325 social media mentions and interactions (PlumX Metrics), 2 news outlet mentions (PlumX Metrics), 550 full text views on journal website, 67 PDF downloads from journal website
10. **Doshi P**, Godlee F. The wider role of regulatory scientists. *BMJ* 2017 Apr

27;357;j1991.

4 citations (Scopus), 45 blog and social media mentions (Altmetric), 3 readers on Mendeley (Altmetric), 1224 full text views on journal website, 216 PDF downloads from journal website

11. **Doshi P.** FDA unease about faster drug approval. *BMJ* 2017;357.
2 citations (Scopus), 124 blog and social media mentions (Altmetric), 1 news outlet mention (Altmetric), 3 readers on Mendeley (Altmetric), 908 full text views on journal website, 169 PDF downloads from journal website
12. **Doshi P.** Medical response to Trump requires truth seeking and respect for patients. *BMJ* 2017 Feb 7;356:j661.
0 citations (Scopus), 188 blog and social media mentions (Altmetric), 2 news outlet mentions (Altmetric), 3 readers on Mendeley (Altmetric), 8710 full text views on journal website, 147 PDF downloads from journal website
13. **Doshi P.** Update: New England journal of medicine publishes correction to 2012 chest trial of hydroxyethyl starch versus colloids. *BMJ* 2016;352.
3 citations (Scopus), 4 social media mentions (Altmetric), 2 readers on Mendeley (Altmetric), 653 full text views on journal website, 233 PDF downloads from journal website
14. **Zito JM, Doshi P.** For-profit Uses of Real-World Data: What Would Frances Kelsey Do? *Med Care* 2016 Dec;54(12):1045-1047.
3 citations (Scopus), 1 social media mention (Altmetric), 2 readers on Mendeley (Altmetric)
15. **Doshi P.** FDA drug summaries: a simplification too far? *BMJ* 2015 Jun 12;350:h3135.
0 citations (Scopus), 14 social media mentions (Altmetric), 1 news outlet mention (Altmetric), 4 readers on Mendeley (Altmetric), 665 full text views on journal website, 181 PDF downloads from journal website, 3 user-generated Bitly links to article with a total of 4 link clicks (PlumX Metrics)
16. **Doshi P.** Convicting Zika. *BMJ* 2016 Apr 7;353:i1847.
4 citations (Scopus), 79 social media mentions (Altmetric), 52 readers on Mendeley (Altmetric), 17,401 full text views on journal website, 1085 PDF downloads from journal website, 4 user-generated Bitly links to article with a total of 39 link clicks (PlumX Metrics)
17. **Doshi P, Jefferson T.** The evidence base for new drugs: New legislation in germany provides another piece of a complex puzzle. *BMJ* 2015;350.
0 citations (Scopus), 61 blog and social media mentions (Altmetric), 1 news outlet mention (Altmetric), 1 reader on Mendeley (Altmetric), 1 Wikipedia reference (PlumX Metrics), 1118 full text views on journal website, 474 PDF downloads from journal website, 3 user-generated Bitly links to article with a total of 1 link click (PlumX Metrics)
18. **Doshi P, Stahl-Timmins W, Merino JG, Simpkins C.** Visualising childhood

vaccination schedules across G8 countries. *BMJ* 2015;351.
2 citations (Scopus), 17 social media mentions (Altmetric), 6 readers on Mendeley (Altmetric), 1331 full text views on journal website, 272 PDF downloads from journal website, 1 user-generated Bitly link to article with a total of 1 link click (PlumX Metrics)

19. Jones M, Jefferson T, **Doshi P**, Del Mar C, Heneghan C, Onakpoya I. Commentary on Cochrane review of neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. *Clin Microbiol Infect* 2015;21(3):217-221.
5 citations (Scopus), 2 social media mentions (PlumX Metrics)
20. **Doshi P**. No correction, no retraction, no apology, no comment: paroxetine trial reanalysis raises questions about institutional responsibility. *BMJ* 2015 Sep 16;351:h4629.
16 citations (Scopus), 535 blog and social media mentions (Altmetric), 52 news outlet mentions (Altmetric), 46 readers on Mendeley (Altmetric), 21,165 full text views on journal website, 2473 PDF downloads from journal website, 18 user-generated Bitly links to article with a total of 266 link clicks (PlumX Metrics)
21. **Doshi P**. 21st century cures: is US medicines bill a colossal mistake? *BMJ* 2015 Jul 23;351:h4013.
3 citations (Scopus), 66 blog and social media mentions (Altmetric), 1 news outlet mention (Altmetric), 6 readers on Mendeley (Altmetric), 1563 full text views on journal website, 127 PDF downloads from journal website, 1 user-generated Bitly link to article with a total of 2 link clicks (PlumX Metrics)
22. **Doshi P**. No vote in US Congress on proposal to create new pathway for approving antibiotics. *BMJ* 2015 Mar 31;350:h1767.
0 citations (Scopus), 3 social media mentions (Altmetric), 1 news outlet mention (Altmetric), 152 full text views on journal website, 60 PDF downloads from journal website
23. **Doshi P**, Zito J, DosReis S. Digging for data on harms in duloxetine trials: It's time for policy makers to get serious about drug related harms. *BMJ* 2014;348.
2 citations (Scopus), 6 blog and social media mentions (Altmetric), 16 readers on Mendeley (Altmetric), 1092 full text views on journal website, 363 PDF downloads from journal website
24. Jefferson T, Jones MA, **Doshi P**, Del Mar CB, Hama R, Thompson M, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. *Sao Paulo Med J* 2014;132(4):256-257.
2 citations (Scopus), 2 readers on Mendeley (PlumX Metrics)
25. **Doshi P**. US incentive scheme for neglected diseases: a good idea gone wrong? *BMJ* 2014 Jul 21;349:g4665.
4 citations (Scopus), 2 blog and social media mentions (Altmetric), 1 policy document reference (Altmetric), 19 readers on Mendeley (PlumX Metrics), 3158

- full text views on journal website, 350 PDF downloads from journal website, 6 user-generated Bitly links to article with a total of 2 link clicks (PlumX Metrics)*
26. **Doshi P.** EMA policy on transparency is "strikingly" similar to deal struck with drug company, say experts. *BMJ* 2014 Jun 12;348:g3852.
1 citation (Scopus), 16 blog and social media mentions (Altmetric), 3 readers on Mendeley (PlumX Metrics), 606 full text views on journal website, 98 PDF downloads from journal website, 2 user-generated Bitly links to article with a total of 13 link clicks (PlumX Metrics)
 27. **Jefferson T, Doshi P.** Multisystem failure: the story of antinfluenza drugs. *Recent Prog Med* 2014 May;105(5):187-190.
2 citations (Scopus), 11 social media mentions and interactions (PlumX Metrics)
 28. **Doshi P.** From promises to policies: is big pharma delivering on transparency? *BMJ* 2014 Feb 26;348:g1615.
6 citations (Scopus), 60 blog and social media mentions (Altmetric), 1 reader on Mendeley (PlumX Metrics), 1510 full text views on journal website, 345 PDF downloads from journal website, 6 user-generated Bitly links to article with a total of 17 link clicks (PlumX Metrics)
 29. **Doshi P, Groves T, Loder E.** Clinical trial data: get them while you can. *BMJ: British Medical Journal* 2014 01/11;348(7940):8-8.
4 citations (Scopus), 19 social media mentions (Altmetric), 4 readers on Mendeley (PlumX Metrics), 1270 full text views on journal website, 262 PDF downloads from journal website
 30. **Doshi P, Vedula SS, Li T.** Yoda and truth seeking in medicine: Making sense of the curious case of rhBMP-2. *BMJ* 2013;347(7915).
2 citations (Scopus), 12 blog and social media mentions (Altmetric), 4 readers on Mendeley (Altmetric), 967 full text views on journal website, 246 PDF downloads from journal website
 31. **Doshi P, Goodman SN, Ioannidis JP.** Raw data from clinical trials: within reach? *Trends Pharmacol Sci* 2013 Dec;34(12):645-647.
29 citations (Scopus), 1 social media mention (PlumX Metrics), 34 readers on Mendeley (Mendeley.com)
 32. **Doshi P.** Transparency interrupted: the curtailment of the European Medicines Agency's Policy on access to documents. *JAMA Intern Med* 2013 Nov 25;173(21):2009-2011.
7 citations (Scopus), 10 blog and social media mentions (Altmetric), 10 readers on Mendeley (PlumX Metrics), 655 PDF downloads from journal website, 3 user-generated Bitly links to article with a total of 89 link clicks (PlumX Metrics)
 33. **Doshi P.** Putting GlaxoSmithKline to the test over paroxetine. *BMJ* 2013 Nov 12;347:f6754.
6 citations (Scopus), 67 blog and social media mentions (Altmetric), 23 readers on Mendeley (Altmetric), 1 Wikipedia reference (PlumX Metrics), 3012 full text views

on journal website, 466 PDF downloads from journal website, 1 full text view in EBSCO databases (PlumX Metrics), 2 user-generated Bitly links to article with a total of 11 link clicks (PlumX Metrics)

34. **Doshi P.** Influenza: marketing vaccine by marketing disease. *BMJ* 2013 May 16;346:f3037.
17 citations (Scopus), 952 social media mentions (Altmetric), 9 news outlet mentions (PlumX Metrics), 72 readers on Mendeley (Altmetric), 36,002 full text views on journal website, 4488 PDF downloads from journal website, 29 user-generated Bitly links to article with a total of 1535 link clicks (PlumX Metrics)
35. **Doshi P,** Jefferson T. Drug Data Shouldn't Be Secret. *New York Times* 2012 04/11;161(55738):1.
0 citations (Scopus)
36. **Doshi P, Akabayashi A.** Japanese Childhood Vaccination Policy. *Camb Q Healthc Ethics* 2010 Jul;19(3):283-289.
5 citations (Scopus), 2 social media mentions (Altmetric), 5 readers on Mendeley (Altmetric), 22 full text views on journal website, 51 PDF downloads from journal website
37. Jefferson T, Jones M, **Doshi P,** Del Mar C. Possible harms of oseltamivir--a call for urgent action. *Lancet* 2009 Oct 17;374(9698):1312-1313.
30 citations (Scopus), 26 readers on Mendeley (Mendeley.com)
38. **Doshi P.** Science in the Private Interest: Has the Lure of Profits Corrupted Biomedical Research? *IEEE Technology & Society Magazine* Spring 2006;25(1):10-11.
0 citations (Scopus), 491 full text views on journal website
39. **Doshi P.** Selling 'pandemic flu' through a language of fear. *Christian Science Monitor* 2006 03/21;98(79):9.
0 citations (Scopus)
40. **Doshi P.** Viral Marketing. *Harper's Magazine* 2006 03;312(1870):54.
0 citations (Scopus)
41. **Doshi P.** Are US flu death figures more PR than science? *BMJ* 2005;331(7529):1412.
13 citations (Scopus), 63 blog and social media mentions (Altmetric), 3 news outlet mentions (Altmetric), 11 readers on Mendeley (Altmetric), 1 YouTube video mention (Altmetric), 12,755 full text views on journal website, 1345 PDF downloads from journal website

2. [Letters to the editor in refereed journals](#)

1. **Doshi P,** Spence O*, Powers JH. Noninferiority Trials. *N Engl J Med* 2018 Jan 18;378(3):304. 0 citations (Scopus)

2. Jones M, Del Mar C, **Doshi P**. Findings of an Observational Study of Neuraminidase Inhibitors Highly Sensitive to Decision to Exclude 1652 Treated Patients. *Clin Infect Dis* 2017 Sep 15;65(6):1050. 1 citation (Scopus), 2 readers on Mendeley (PlumX Metrics), 104 PDF downloads from journal website
3. Kuzucan A*, **Doshi P**, Zito JM. Pharmacists can help to end direct-to-consumer advertising. *Am J Health Syst Pharm* 2017 May 15;74(10):640-642. 0 citations (Scopus), 58 social media mentions and interactions (PlumX Metrics), 1 reader on Mendeley (Altmetric), 81 full text views in EBSCO databases (PlumX Metrics)
4. **Doshi P**, Jefferson T. Neuraminidase Inhibitors and Influenza Infection. *JAMA Intern Med* 2016 Mar;176(3):415-416. 0 citations (Scopus), 237 PDF downloads from journal website, 22 readers on Mendeley (PlumX metrics)
5. **Doshi P**, Heneghan C, Jefferson T. Oseltamivir for influenza. *Lancet* 2015 Sep 19;386(9999):1134-1135. 0 citations (Scopus), 1 social media mention (PlumX Metrics)
6. Collignon P, **Doshi P**, Del Mar C, Jefferson T. Safety and efficacy of inactivated influenza vaccines in children. *Clin Infect Dis* 2015 Feb 1;60(3):489. 1 citation (Scopus), 2 social media mentions (Altmetric), 10 readers on Mendeley (PlumX Metrics), 2 Wikipedia references (PlumX Metrics), 61 PDF downloads from journal website
7. Del Mar C, **Doshi P**, Hama R, Jones M, Jefferson T, Heneghan C, et al. Neuraminidase inhibitors for influenza complications. *Lancet* 2014;384(9950):1260-1261. 0 citations (Scopus), 1 social media mention (PlumX Metrics), 20 readers on Mendeley (Mendeley.com)
8. **Doshi P**, Jefferson T. Clinical trials: Tamiflu reviewers respond to critics. *Nature* 2014 May 15;509(7500):288. 1 citation (Scopus), 2 social media mentions (Altmetric), 10 readers on Mendeley (Altmetric), 107 full text views in EBSCO databases (PlumX Metrics), 1 user-generated Bitly link to article with a total of 2 link clicks (PlumX Metrics)
9. **Doshi P**, Jefferson T. Authors' reply to Dunning. *BMJ* 2014 Apr 30;348:g3018. 0 citations (Scopus), 1 reader on Mendeley (PlumX Metrics), 295 full text views on journal website, 87 PDF downloads from journal website
10. **Doshi P**. The importance of influenza vaccination-reply. *JAMA Intern Med* 2014 Apr;174(4):645-646. 0 citations (Scopus), 208 PDF downloads from journal website
11. **Doshi P**, Abi-Jaoude E, Lexchin J, Jefferson T, Thomas RE. Influenza vaccination of health care workers. *CMAJ* 2013;185(2):150. 2 citations (Scopus), 3 readers on Mendeley (Mendeley.com)
12. **Doshi P**. EFPIA-PhRMA's principles for clinical trial data sharing have been misunderstood. *BMJ* 2013;347(7922). 2 citations (Scopus), 5 social media mentions (Altmetric), 1 news outlet mention (Altmetric), 2 readers on Mendeley

(Altmetric), 832 full text views on journal website, 170 PDF downloads from journal website

13. **Doshi P.** The 2009 influenza pandemic. *Lancet Infect Dis* 2013;13(3):193. 1 citation (Scopus), 2 readers on Mendeley (Mendeley.com)
14. **Jones M**, Hama R, Jefferson T, **Doshi P.** Neuropsychiatric adverse events and oseltamivir for prophylaxis. *Drug Saf* 2012 Dec 1;35(12):1187-8; author reply 1188-90. 8 citations (Scopus), 2 readers on Mendeley (PlumX Metrics), 47 full text views in EBSCO databases, 122 PDF downloads from journal website
15. **Heneghan C**, Jefferson T, **Doshi P.** Antivirals for treatment of influenza. *Ann Intern Med* 2012 Sep 4;157(5):385-6; author reply 386-7. 0 citations (Scopus)
16. Cochrane Neuraminidase Inhibitors Review Team. Does oseltamivir really reduce complications of influenza? *Clin Infect Dis* 2011 Dec;53(12):1302-3; author reply 1303-4. 0 citations (Scopus), 33 PDF downloads from journal website
17. **Doshi P**, Jefferson T. WHO and pandemic flu. Another question for GSK. *BMJ* 2010 Jun 29;340:c3455. 2 citations (Scopus), 1 social media mention (PlumX Metrics), 4 readers on Mendeley (PlumX Metrics), 1168 full text views on journal website, 4 PDF downloads from journal website
18. **Jefferson T**, **Doshi P.** WHO and pandemic flu. Time for change, WHO. *BMJ* 2010 Jun 29;340:c3461. 5 citations (Scopus), 1 social media mention (PlumX Metrics), 2 readers on Mendeley (PlumX Metrics), 1343 full text views on journal website, 7 PDF downloads from journal website
19. **Collignon P**, **Doshi P**, Jefferson T. Ramifications of adverse events in children in Australia. *BMJ* 2010 Jun 9;340:c2994. 7 citations (Scopus), 132 social media mentions (Altmetric), 6 readers on Mendeley (PlumX Metrics), 2885 full text views on journal website, 11 PDF downloads from journal website
20. **Doshi P.** Pandemic influenza: severity must be taken into account. *J Infect Dis* 2010 May 1;201(9):1444-1445. 4 citations (Scopus), 5 readers on Mendeley (PlumX Metrics), 19 full text views in EBSCO databases (PlumX Metrics), 13 PDF downloads from journal website
21. **Doshi P.** Doshi responds. *Am J Public Health* 2008;98(11):1928-1930. 0 citations (Scopus), 5 social media mentions (Altmetric)
22. **Doshi P.** Reason for optimism. *BMJ* 2008;336(7637):172. 0 citations (Scopus), 4 readers on Mendeley (PlumX Metrics), 457 full text views on journal website, 95 PDF downloads from journal website
23. **Doshi P.** Popular and scientific attitudes regarding pandemic influenza. *Emerg Infect Dis* 2008 Sep;14(9):1501-2; author reply 1502. 1 citation (Scopus), 4 readers on Mendeley (PlumX Metrics), 176 full text views in EBSCO database (PlumX Metrics)

24. **Doshi P.** Estimation of death rates from pandemic influenza. *Lancet* 2007 Mar 3;369(9563):739; author reply 739-40. 1 citation (Scopus), 12 readers on Mendeley (Mendeley.com)
25. **Doshi P.** Influenza vaccination: policy versus evidence: Policy is in the lead. *Br Med J* 2006;333(7576):1020-1021. 2 citations (Scopus), 5 readers on Mendeley (PlumX Metrics), 982 full text views on journal website, 298 PDF downloads from journal website

3. Referee for professional or scientific journal

1. AHRQ Effective Health Care Program
2. American Journal of Respiratory and Critical Care Medicine
3. American Journal of Public Health
4. Annals of Internal Medicine
5. BMC Medical Research Methodology
6. BMC Public Health
7. BMJ
8. Canadian Medical Association Journal (CMAJ)
9. CNS Drugs
10. Drug and Therapeutics Bulletin
11. European Journal of Pediatrics
12. European Journal of Public Health
13. Expert Review of Vaccines
14. Health Affairs
15. Health Policy
16. Health Technology Assessment (Italian government)
17. Healthcare Policy
18. Influenza and Other Respiratory Viruses
19. JAMA Internal Medicine
20. Journal of Biomedical Research
21. Journal of Clinical Epidemiology
22. Journal of Medical Ethics
23. New England Journal of Medicine
24. PLOS Medicine
25. PLOS ONE
26. Trials
27. World Medical and Health Policy

4. Editorial positions on professional or scientific journals

Associate Editor
The BMJ (www.bmj.com)

2013 – ongoing

Guest editorial board member 2017 – 2018
Scientific Data (www.nature.com/sdata/)

E. Honors and Awards

New Investigator Award 2015
American Association of Colleges of Pharmacy

The Wired Smart List 2013 (UK) 2013
<http://www.wired.co.uk/magazine/archive/2013/12/features/the-smart-list-2013>

Nathan Wolfe/CNN Prize 2013
Johns Hopkins Bloomberg School of Public Health

Siegel Teaching Prize 2011
Massachusetts Institute of Technology

MIT-Japan Program intern 2009
Massachusetts Institute of Technology

Presidential Fellowship 2006 – 2007
Massachusetts Institute of Technology

Noma-Reischauer Prize in Japanese Studies 2006
Graduate Student Essay Prize for “The Lost Lessons of SMON [subacute myelo-optico neuropathy]”
Kodansha Ltd., Publishers and the Reischauer Institute, Harvard University

Joseph Fletcher Memorial Prize for excellence in an A.M. thesis 2006
Harvard University

Summer Foreign Language Assistance Scholarship (FLAS) for Japanese 2004
Harvard University

Best Socio-Cultural Anthropologist 2002
Brown University

Perry Gatson Scholarship Award for Outstanding Achievement in Anthropology 2002
Brown University

3) Service

A. Scientific, Professional and Scholarly Organizations

The BMJ **2013 – indefinite**

The BMJ (formerly the *British Medical Journal*) is an international peer reviewed medical journal. I serve as an associate editor, a paid position, in which capacity I write articles, commission articles, handle manuscripts, and contribute to journal decision making.
International organization; Staff position

Health Canada **2017 – ongoing**

Selected to be on “roster of experts” for Health Canada’s Health Products and Food Branch (HPFB) activated related to the implementation of public release of clinical information
International organization; Volunteer position

European Medicines Agency **Jan - Apr 2013**

Participated in two advisory groups (rules of engagement & good analysis practice) regarding EMA’s draft Policy 0070, Publication of Clinical Trial Data
International organization; Volunteer position

Committee on Publication Ethics **2015 – ongoing**

International organization; Member; 3 years

American College of Cardiology **2013**

Writing committee member on Data Transparency Health Policy Statement
National organization; Volunteer position

AACP **2014 – 2016**

National organization; Member; 2 years

Rho Chi **2017 – ongoing**

Inducted in 2017
National organization; Member; 1 years

Cochrane **2018 – ongoing**

International organization; Member; 5 years

B. Additional professional service

Reagan-Udall Foundation for the FDA **2016 – ongoing**

Unpaid member of IMEDS Steering Committee

EXHIBIT B

CURRICULUM VITAE Thomas Oliver JEFFERSON
(1 August 2020)

Brief biographies appear in the series "Lifeline" on [The Lancet 2003](#); 361:188. (11 January)
and in the Feature [Pioneers of Transparency](#) BMJ 2014;350:g7717

H-Index 58

Two most cited papers:

[Guidelines for authors and peer reviewers of economic submissions to the BMJ](#)

MF Drummond, TO Jefferson. BMJ 313 (7052), 275-283 (1720 citations)

[Vaccines for preventing influenza in healthy adults](#)

V Demicheli, T Jefferson, E Ferroni, A Rivetti, C Di Pietrantonj. Cochrane database of systematic reviews (1558 citations)

Key words: Evidence synthesis, Epidemiology, Health Economics, Regulatory data, Market access

ADDRESS (Home)

Via Adige 28a
 00061 Anguillara Sabazia
 (Roma)
 Italy
 Mobile ++39 32 92025051
 Email jefferson.tom@gmail.com

MEDALS & DECORATIONS

UNPROFOR Medal (1992)
 OFFICER (BROTHER) Order of St John of Jerusalem (1994).
 NATO Medal (Former Yugoslavia Clasp) 1996

RELEVANT ACADEMIC & PROFESSIONAL QUALIFICATIONS

Degree in Medicine and Surgery, Pisa University (1979).
 Diploma of the Royal College of Obstetrician & Gynaecologists UK (DRCOG, 1982).
 Certificate of Vocational Training in General Practice UK (1984).
 Membership of the Royal College of General Practitioners UK (MRCGP 1985).
 Membership of the Chartered Institute of Linguists UK (1985).
 Diploma in Tropical Medicine & Hygiene UK (London School of Hygiene & Tropical Medicine 1987).
 MSc Community Medicine UK (London School of Hygiene & Tropical Medicine 1988).
 Membership of the Faculty of Public Health Medicine UK (MFPHM 1990).
 Accreditation in Public Health Medicine UK (1990).
 Accreditation in General Practice UK (1990).
 Titolo di Scuola di Guerra (1991)
 Certificate in Health Economics, University of Aberdeen UK (1996).
 Fellowship of the Faculty of Public Health Medicine UK (FFPHM 1999).

RECENT and PRESENT ACTIVITIES

Until November 2019 I provided scientific supervision for the Agenas (Agenzia per i Servizi Sanitari Regionali) HTA programme for non-pharmaceuticals. Agenas is an agency of the Italian MoH. Part of my work entailed supervising a group of 10 researchers and taking responsibility for designing, devising and carrying out HTA and Horizon Scanning assessments. I was scientific lead for the European EUNeHTA Joint Action 2 (Workpackage 4 – devices and diagnostics) project (2012-2015, see below). The EUNeHTA Collaboration is a network of European public agencies producing structured HTA information for national use. In 2021 the Collaboration should become a permanent network funded by the

Commission. I was also scientific coordinator for Workpackage 4 which assessed non pharmaceutical interventions, such as in vitro tests. This involved coordinating some 70 researchers from 28 agencies from 23 countries (from Estonia to Bulgaria, to Greece and Sweden). The project started in 2012 and was completed in 2015. I carried out the same role for the previous EUNeHTA project (Joint Action 1 or JA1 with the European Commission). Until November 2019 I was a member of two different workpackages and a reviewer for two projects in these workpackages as part of the EUNeHTA JA3.

I co-developed a methodology for synthesising evidence of effectiveness, efficiency, safety and resource utilisation using regulatory information and data from different sources, both regulatory and open source. This activity was initially funded by NIHR UK until mid-2015, then the Cochrane Methods Innovations Fund (MIF), NIHR again and since 2016 the Cochrane Nordic Centre. The MIF project was a collaboration to draft advice of when and how to include regulatory material in Cochrane reviews. I am developing this work further by streamlining the use of regulatory data and its incorporation into user friendly, timely reviews.

As part of a team in the Nordic Cochrane Centre we carried out a [systematic review of HPV vaccines](#) based on regulatory documents. The evidence set for the review was assembled by us from a variety of sources into an Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies, shortly to be published. At present we are developing the same reviews further with the complete regulatory dataset released by Health Canada after a court case.

Since 2015 I am a Fellow of the Centre for Evidence Based Medicine of the **University of Oxford**, in the UK. I am now Senior Clinical Tutor on the Complex Reviews Module of the MSc in Evidence Based Health course.

I am visiting Professor Visiting Professor Institute of Health & Society at the Faculty of Medicine of Newcastle University (2019-2021).

With the 3 other Cochrane colleagues I am a co-investigator in a John and Laura Arnold Foundation grant for development of a RIAT support centre (2017-2020).

RIAT stands for Restoring Invisible and Abandoned Trials. In short, RIAT is a mechanism that enables researchers to address two long-standing problems in the medical literature: non-publication of trials and misreporting. Our concept was first outlined here: <http://www.bmj.com/content/346/bmj.f2865>

The RIAT Support Center will help accelerate the correction of the scientific record of clinical trials by making it more accurate and more complete.

Finally, with the help of the Cochrane Central Editorial Unit we stabilised of our three long-standing influenza vaccine reviews. These were released in January 2018.

My activity line of regulatory data started with updating of Cochrane review A159 (Neuraminidase Inhibitors for influenza). A159 is currently based exclusively on regulatory information (essentially clinical study reports - CSRs from EMA and comments by FDA and PMDA - about 150K pages in all).

The story is told in:

David Payne. Tamiflu: the battle for secret drug data. *BMJ* 2012;345:e7303 doi: 10.1136/bmj.e7303 (Published 29 October 2012).

<http://www.bmj.com/content/345/bmj.e7303>

<http://www.nytimes.com/2013/06/30/business/breaking-the-seal-on-drug-research.html?pagewanted=1&r=3&smid=tw-share>

<http://www.newsweek.com/2014/11/21/medical-science-has-data-problem-284066.html>
[The pioneers of transparency](#). *BMJ* 2015;350:g7717 (Published 02 Jan 2015)

I was a member of EMA's Clinical Trials Advisory Group 2 (CTAG2).

I am on the editorial board of [BMJ Evidence Based Medicine](#) (BMJ EBM).

I am an unpaid collaborator to the project *Beyond Transparency in Pharmaceutical Research and Regulation* led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022).

I currently teach on the Complex Reviews module of the MSc in Evidence Based Health Care at Oxford University and currently supervising to MSc students. This involves reviews of regulatory data, economic studies, diagnostic studies, qualitative studies and IPI meta-analyses.

I am a member of the WHO Infection Prevention and Control Research and Development Expert Group for COVID-19.

PAST CONSULTANCIES AND OTHER ACTIVITIES

In the past I have carried out research for the **Ministry of Defence UK** (suite of Cochrane reviews on viral and arthropod borne fevers prevention), **NICE** (HTA of zanamivir for influenza), **Roche** (the economics of antivirals neuraminidase inhibitors), **EU** (systematic review of evidence of safety of MMR vaccines and of the economics of pneumococcal vaccines), **WHO** (systematic review of evidence of safety of Hepatitis B vaccines), **Glaxo SmithKline** (systematic review of evidence of safety and effectiveness of DPT vaccines), **Sanofi- Synhtelabo** (Development of Pleconaril), **Istituto Superiore di Sanita'** and **ASSR** (now Agenas), (coordinator of the national clinical guidelines project) (see below), **Netherlands Health Council** (safety of Hepatitis B vaccine update review), **IMS Health**

(Antidiabetic drugs) the **Piemonte Region** of Northern Italy (suite of Cochrane reviews on influenza vaccines), **Agenzia di Sanita' Pubblica Lazio** - Public Health Agency of Lazio Region (guidelines implementation trial project and coordination of a two cluster randomised trials of guidelines implementation, on behalf of the UK's Technology Assessment Programme I updated two reviews on the effects of editorial peer review. I have been involved in a 5 year update and rewrite of his Cochrane review on Neuraminidase Inhibitors exclusively based on regulatory information. (HTA – 10/80/01 Update and amalgamation of two Cochrane Reviews: neuraminidase inhibitors for preventing and treating influenza in healthy adults and children—<http://www.nets.nihr.ac.uk/projects/hta/108001>).

I am a member of the editorial base of the Cochrane Acute Respiratory Infections Group. Reviewer, Cochrane Infectious Diseases, Acute Respiratory Infections, Hepato-biliary, Airways and Colorectal Cancer Groups.

Director, Health Reviews Ltd, my own company.

Member, editorial, board of *Recenti Progressi in Medicina* and *BMC Health Services Research*.

Peer reviewer for BMJ, Lancet, JAMA, JAMA Internal Medicine, CMAJ, New England Journal of Medicine, Vaccine and Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Emerging Technology bulletins.

I am an Academic Editor, PLOS ONE (2013-17) and have been a contributor to Last's Dictionary of Epidemiology (4th edition).

I do anonymous market access consultancy interviews for various pharmaceutical companies.

Between 1996 and 2009 I was the Co-ordinator of the Cochrane Vaccines Field and 1999 and 2012 I was honorary Research Fellow at the UK Cochrane Centre.

In 2011-13, I acted as an expert witness in a litigation case related to the antiviral oseltamivir, in two litigation cases on potential vaccine-related damage and in a labour case on influenza vaccines in healthcare workers in Canada. In 2016-17 I was a member of an independent data monitoring committee for a **Sanofi Pasteur** clinical trial on an influenza vaccine and a member of three advisory boards for **Boehringer Ingelheim** (on bronchodilator drug), Takeda (cardiovascular drug) and Bayer (blood replacement).

As part of my [HTA activity](#) I have interviewed, collaborated and interacted with scores of clinicians in both primary and hospital care both in Italy and the rest of Europe. Over the past thirty years, I have worked in most therapeutic and prevention areas. Also as part of my Italian HTA and scientific activity I have interacted with patient organisations and have considerable knowledge of the regional Italian structure and its workings thanks to my role as consultant to Agenas.

The HTA report output is accessible at: <https://www.agenas.gov.it/aree-tematiche/hta-health-technology-assessment/attivita-hta/report-hta>

The Horizon scanning output is accessible at: <https://www.agenas.gov.it/aree-tematiche/hta-health-technology-assessment/hs-horizon-scanning/report-hs>

Since 2017 I am a member of the Italian MoH National Immunisation Technical Advisory Group (NITAG).

GENERAL PERSONAL & PROFESSIONAL BACKGROUND

I was born on 31 March 1954 in Viareggio (near Pisa), Italy. I was educated in Italy and went to UK in 1980 to do my hospital jobs prior to joining the Army. My professional career has spanned two specialties, General Practice (1980-1985) and Public Health (since 1986). I served in the British Army between 1981 and 1999.

My Army service took place in three continents and two conflicts (South Atlantic and Yugoslavia). I held the rank of Lieutenant Colonel. I am married with five children.

GENERAL PRACTICE CAREER

SHO Medicine, Arbroath Infirmary (1980 - 1981).

SHO Casualty, Croydon (1981).

Post Graduate Medical Officers' Course held Royal Military Academy, Sandhurst and the Royal Army Medical College, London (1981).

SHO O&G, British Military Hospital Hong Kong (1982).

Trainee GP and Regimental Medical Officer in several Gurkha units in Hong Kong and Nepal (1982 - 1984).

GP principal at Royal Military Academy Sandhurst, Armoured Regiment in Germany and Gurkha Battalion in UK and South Atlantic (1984 -1986).

Staff officer (various roles, 1987-1999)

Partner (part-time), North Lane Practice, Aldershot, Hampshire (1999-2001).

PUBLIC HEALTH CAREER

Registrar at the Department of Preventive Medicine at the Royal Army Medical College London (1987-1990).

Honorary Lecturer to the Department of Public Health at King's College Hospital, London (Professors Jim McEwen Norman Noah, 1989 - 1996).

Honorary Senior Lecturer to the Department of Public Health at King's College Hospital, London (1997 - current).

Detachment to the London School of Hygiene and Tropical Medicine on the Diploma in Tropical Medicine and Hygiene Course first and then on Master of Science in Community Medicine (1987- 1988).

Senior Registrar at the RAMC Training Centre near Aldershot (1988 - 1990). Student on the Higher Command and Staff Course at the Italian Army Staff College, Rome (1990 - 1991).

Second in Command of a Medical Battalion in Germany consisting of 250 personnel (1991 - 1992).

Assistant Force Medical Officer, United Nations Protection Force in Yugoslavia (UNPROFOR). I set up all medical facilities for the initial deployment in March 1992 and Director of Public Health for UNPROFOR. I was stationed in Sarajevo (Bosnia- Hercegovina), Belgrade (Serbia) and Zagreb (Croatia) for the duration of six months. Deputy Commander Medical (Preventive Medicine) British Army of the Rhine. I was responsible for all Preventive Medicine services for a population of 120.000 souls (1992-93).

Senior Technical Officer on the Health Services Market Test for British Forces Germany (1993-94). Responsible for developing the Statement of Requirement in preparation for the issuing of the Invitation To Tender and the developing of the purchasing function. Staff Officer, Ministry of Defence, Army Medical Directorate (1994-99). Responsible for health surveillance and health policy formulation for the British Army. My department carried out morbidity surveillance for the British Army and for the NATO SFOR mission in the Former Republic of Yugoslavia (FRY).

In February 1994 I was appointed Visiting Professor in Health Services Research at the University of Pavia, Northern Italy.

In June 1997 I was appointed Edmund Parkes Professor of Preventive Medicine at the Royal Defence Medical College. The chair is recognised by the Faculty of Public Health Medicine of the Royal College of Physicians of the United Kingdom. Additional responsibilities included the strategic management of the Army's 90-strong Environmental Health cadre. This lapsed when I left the Army.

Principal in family medicine, Aldershot, UK, 1999-2001.

British Medical Association HC Roscoe Fellow for the study of the prevention and treatment of the common cold (2000-2002).

Adviser the Lazio Region Public Health Agency (IT) and the Istituto Superiore di Sanità (on the development of evidence-based clinical guidelines) 2001-2005

PRIZES

1982 Army Syntex Award for research into obstetric performance in different ethnic groups (see publication 5).

1984 University of Surrey Research Prize for work on haematological indices of pregnant Gurkha women (see publication 6).

1990 Parkes Memorial Prize for work on the selection and training of Army recruits (see publications 17 e 22).

2009 BMJ prize for best use of BMJ archival material (publication 232)

Past grants:

MOD(UK) - systematic reviews of interventions to prevent influenza in healthy adults

Roche UK Ltd - cost of illness study of the burden of influenza.

BMA Roscoe Fellowship - systematic review of the effects of antivirals for the common cold.

UK HTA programme - systematic review of the effects of zanamavir.

EU - systematic review of safety of MMR vaccines.

EU - systematic review of the economics of pneumococcal vaccines.

WHO - systematic review of evidence of safety of Hepatitis B vaccines.

WHO - systematic review of evidence of safety of aluminium in DTP vaccines.

Glaxo SmithKline Ltd - systematic review of evidence of safety and effectiveness of DPT vaccines.

NHS R&D programme - systematic review of the effects of peer review. An update was commissioned in May 2004.

Regione Piemonte, Italy – systematic reviews of the effects of influenza vaccines in children and elderly and quality studies and their publication on high impact factor journals.

Netherlands Health Council (safety of Hepatitis B vaccine update review)

DH (UK)/NIHR Cochrane review update incentive scheme (several awards)

Lazio Public Health Agency – systematic review of the epidemiology of *S.Pneumoniae*

DH (UK) National coordinating Centre for Methodology

WHO - Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review .

UK NIHR – Developing, updating and rewriting the Cochrane review on Neuraminidase Inhibitors exclusively based on regulatory information.

Cochrane - Methods Innovation Fund (MIF) 2014-17 to develop a methodology for summing up evidence of effectiveness, efficiency and safety using regulatory information and data from different sources, both regulatory and open source.

Arnold Foundation – RIAT centre

RECREATIONAL ACTIVITIES

Weight training, skiing.

MEMBERSHIP OF OTHER ORGANISATIONS (past and present)

Health Economics Study Group (HESG)

International Association of Health Economists (listed in the world directory of Health Economists).

Cochrane Airways Collaborative Review Group

LOCKNET (JAMA/BMJ peer-review network).

World Association of Medical Editors (WAME)

Health Technology Assessment International (international society for HTA)

PUBLICATIONS & REPORTS

1. CAROLI G, JEFFERSON T O. Wedding Party with S.Haifa. Annali Sclavo. 1978; 20: 959-962.
2. CAROLI G, JEFFERSON T O. Finding of E.Coli Phage in Urinary Tract Infections. Annali Sclavo. 1980; 22: 857-860.
3. JEFFERSON T O. Personal View. BMJ. 1982; 284: 1328.
4. JEFFERSON T O, COHEN C. Familial Siringomyelia with Mental Impairment. J R Army Med Corps. 1982; 128: 41-42.
5. JEFFERSON T O, REIDY A J. Incidence of Instrumental Deliveries in Primigravidae of 3 Different Ethnic Groups. J R Army Med Corps. 1983; 129: 46-47.
6. REIDY A J, JEFFERSON T O, KENNEDY P M D. Some Haematological Data on Pregnant Gurkha Women. J R Army Med Corps. 1984; 130: 20-21.

7. JEFFERSON T O. Physical Fitness and Smoking Patterns in a Gurkha Battalion. J R. Army Med Corps. 1986; 132: 168-172.
8. JEFFERSON T O, RASOR P A. Non Simulated Casualty Workload in 2 Field Hospital During Exercise "Bold Gannett". Giornale di Medicina Militare. 1985; 135: 265-268.
9. JEFFERSON T O, TAYLOR V M. Perinatal mortality in infants of two different ethnic groups. Family Practice 1985; 2:175-176.
10. JEFFERSON T O. (Anonymous) Mea culpa. Update. 1985; 31: 932.
11. JEFFERSON T O. Patterns of smoking in 2 infantry battalions. British Army Review. 1986; 82: 84.
12. JEFFERSON T O. A Camera in general practice (Ota's Naevus). Update. 1987; 35: 237.
13. KENNEDY P M D, JEFFERSON T O, REIDY A J. Growth in Gurkha Infants. Family Practice. 1986; 3: 54.
14. JEFFERSON T O. Buon Natale (Letter to the Editor). J Royal Coll Gen Pract.1986: 291.
15. OLLIER W, FENSTENSTEIN, JEFFERSON T O. HLA Antigens in Nepalese. Proceedings of the 3rd Asian Oceania Histocompatibility Conference, Sapporo 1986.
16. JEFFERSON T O. The Prevention of AIDS: Some Principles for the Inception and Assessment of a Health Education Campaign. Rivista Italiana d'Igiene 1988; 48: 3-11.
17. JEFFERSON T O. An Investigation of Medical Discharges from the British Army 1979-1986. J R Army Med Corps. 1989; 135: 115-123.
18. JEFFERSON T O, BRAND H, LEVRE` E, CAROLI G. The Personal Prevention of Malaria. Rivista Italiana d'Igiene 1989; 430: 443-450.
19. JEFFERSON T O, CAROLI G, MOLINARI G, PEIRONE A P. Public Health and Community Medicine in England. Rivista Italiana d'Igiene 1989; 49: 226-238.
20. BASNET I, HADYAPANIOTOU C, JEFFERSON T O, MILLS A. Abortion Services in Wandsworth (MSc Field Service Attachment). London School of Hygiene & Tropical Medicine, 1988.
21. TAYLOR L E, JEFFERSON T O, CAROLI G . Water Supply Engineering and Public Health in the United Kingdom. Rivista Italiana d'Igiene 1990; 50: 81-93.

22. JEFFERSON T O. An Investigation into Regular Recruit Wastage from the British Army, 1988. J R Army Med Corps 1990; 136: 138-145.
23. TAYLOR L E, JEFFERSON T O, CAROLI G. The Water Supply of London. Rivista Italiana d'Igiene. 1990; 3-4: 169-177.
24. DEMICHELI V, JEFFERSON T O, AMPOLA M, CAROLI G, PEIRONE A P. Il Lay Belief System. Nota 1: Lo Studio del Comportamento Sanitario. Rivista Italiana d'Igiene 1990; 3-4: 134-150.
25. JEFFERSON T O, DEMICHELI V, CAROLI G. Nesso tra Casi di Leucemia Infantile e Centrale Nucleare di Sellafield (U K): un Puzzle Epidemiologico. Rivista Italiana d'Igiene 1990 3-4: 178-191.
26. DEMICHELI V, JEFFERSON T O. Le Conseguenze Economiche della Salmonellosi. Antibioticoterapia per la pratica. 1991; 2: 73-81.
27. JEFFERSON T O. First Aid Training. An Appraisal. The Soldier's Longest Journey. J R Army Med Corps. 1991; 137: 27-30.
28. JEFFERSON T O. Procedures for the collection and bottling of mineral waters - Guidelines for handlers. Rivista Italiana d'Igiene 1990; 5-6: 496-8.
29. BISOGNI L, JEFFERSON T O, DEMICHELI V, LOMOLINO G, PACELLI G. Studio della prevalenza delle infezioni ospedaliere in un ospedale generale di zona. Rivista Italian di Antibioticoterapia per la pratica 1991; 4: 159-63.
30. DEMICHELI V, LOMOLINO G, JEFFERSON T O. Audit nei servizi di Igiene Pubblica: l'opinione dei cittadini sugli interventi per inconvenienti igienici. Atti del IV Congresso Nazionale della Societa` Italiana di VRQ, Pavia 22-25 Settembre 1991, pagina 66. Editrice Periodici 1991.
31. DEMICHELI V, LOMOLINO G, JEFFERSON T O. La qualita` delle iniziative di formazione: l'aggiornamento del personale sul problema delle infezioni ospedaliere. Atti del IV Congresso Nazionale della Societa` Italiana di VRQ, Pavia 22-25 Settembre 1991, pagina 81. Editrice Periodici 1991.
32. DEMICHELI V, LOMOLINO G, JEFFERSON T O. L'apporto della Economia Sanitaria alla qualita` delle decisioni. La determinazione del costo della sofferenza. Atti del IV Congresso Nazionale della Societa` Italiana di VRQ, Pavia 22-25 Settembre 1991, pagina 106. Editrice Periodici 1991.
33. DEMICHELI V, LOMOLINO G, JEFFERSON T O. Affermazioni di consenso e verifica della qualita`. Atti del IV Congresso Nazionale della Societa` Italiana di VRQ, Pavia 22-25 Settembre 1991, pagina 107. Editrice Periodici 1991.

34. DEMICHELI V, JEFFERSON T O. Cost-benefit analysis of the introduction of mass vaccination against Hepatitis B in Italy. *Journal of Public Health Medicine* 1992; 4: 367-375. (Paper presented to the third European Health Services Research Meeting - University College London, 13 - 14 December 1991).
35. DEMICHELI V, JEFFERSON T O. Manuale di Programmazione e organizzazione Sanitaria. Quaderni di Epidemiologia 17. La Goliardica Pavese, Pavia 1992.
36. DEMICHELI V, JEFFERSON T O. Criteri di valutazione del nesso causale e loro applicazione alla questione delle relazioni fra le radiazioni ionizzanti e la leucemia infantile. *Tecnica Sanitaria* 1993 (in press).
37. JEFFERSON T O, DEMICHELI V, LOMOLINO G. Problemi di Valutazione epidemiologica nelle piccole catastrofi ambientali. Il caso di Camelford in Cornovaglia. *Tecnica Sanitaria* 1993 (in press).
38. JEFFERSON T O. Public Health Aspects of the war in Yugoslavia. *Public Health* 1993; 107: 75-8.
39. JEFFERSON T O, DEMICHELI V, WRIGHT D A. An economic evaluation of the introduction of vaccination against Hepatitis A in a peace-keeping operation. The case of the United Nations Protection Force in Yugoslavia (UNPROFOR). *International Journal of Technology Assessment in Health Care* 1994; 10:490-97. Poster presented at the Fifth European Health Services Research Conference at Maastricht, (December 1993).
40. DEMICHELI V, LOMOLINO G, JEFFERSON T O. Audit of an environmental service in Italy. *Proceedings of the Summer Conference of the Faculty of Public Health Medicine, 1992, Eastbourne, Sussex, Inghilterra.*
41. JEFFERSON T O, DEMICHELI V. The costs of disease - a look at world literature. Presented at the "Meeting Internazionale sui costi delle malattie e della Salmonellosi", Pavia University (5-6 April 1993) (in press).
42. JEFFERSON T O, DEMICHELI V. Is vaccination against Hepatitis A and B cost-effective? A preliminary look at world literature. Presented at the "Meeting Internazionale sui costi delle malattie e della Salmonellosi", Pavia University (5-6 April 1993) (in press).
43. JEFFERSON T O, DEMICHELI V. Is vaccination against Hepatitis B efficient? A review of world literature. *Health Economics* 1994; 3:25-37. Paper presented at the Fifth European Health Services Research Conference at Maastricht, (December 1993).
44. JEFFERSON T O. Public Health and the war in Yugoslavia. In McKee M (ed): *Health for all in a changing Europe*. HFA 2000 News 1993; 25:4-5.

45. DEMICHELI V, JEFFERSON T O. Cost-benefit analysis of the introduction of mass vaccination against Hepatitis B in Italy (letter to the Editor). *Journal of Public Health Medicine* 1993; 14: 289-290.
46. JEFFERSON T O, MUGFORD M, GRAY A, DEMICHELI V. Purchasers and cost-effectiveness of interventions. Are secondary economic evaluations possible? Abstract presented at the Second Cochrane Colloquium, Hamilton, Ontario, October 1994.
47. JEFFERSON T O, BEHRENS R, DEMICHELI V. Should British soldiers be vaccinated against Hepatitis A? An economic analysis. *Vaccine* 1994; 12:1379-83.
48. JEFFERSON T O, PIERCE B, DEMICHELI V. Economic burden of an outbreak of a communicable disease of unknown aetiology in a military unit. *Journal of Epidemiology and Community Health* 1994; 48:423. (letter to the Editor).
49. AKEHURST R, GRAY A, BUXTON M, CHALMERS I, DONALDSON C, CHURNSIDE R, FENN P, FORBES J, GRIFFIN J, HOWARD S, JEFFERSON T, MC GUIRE A, MUGFORD M, O'BRIEN B, OXMAN A, TOWSE A. Assembling information in reviews of randomised controlled trials for subsequent cost-effectiveness analysis. Oxford: UK Cochrane Centre, Workshop Report, November 1993.
50. JEFFERSON T O, MACMILLAN A H M. Whither diplomatosis? Whither APHOM? *J Royal Army Med Corps* 1994 (letter to the editor).
51. JEFFERSON T O, MUGFORD M, DEMICHELI V. QALY league tables. *Health Economics* 1994; 3:205. (letter to the editor).
52. MUGFORD M, JEFFERSON T O, SOLL R. A Secondary Systematic Review to Assess whether and how results of randomised controlled trials of surfactant treatment for neonatal RDS can be used to inform questions of cost-effectiveness. Abstract presented at the Second Cochrane Colloquium, Hamilton, Ontario, October 1994.
53. MUGFORD M, McGUIRE A, JEFFERSON T O. Results of a survey of health economists on generalising from economic evaluations.
54. JEFFERSON T O, MUGFORD M, GRAY A, DEMICHELI V. An exercise on the feasibility of carrying out secondary economic analyses. Abstract presented at the Second Cochrane Colloquium, Hamilton, Ontario, October 1994.
55. JEFFERSON T O. Environmental problems for workers abroad. In: Behrens R H, Riley W (editors). *Caring for expatriates and workers abroad. Health issues and ethical dilemmas. Proceedings of an international meeting organised by the British Postgraduate Medical Federation the Hospital for Tropical Diseases and the London School of Hygiene and Tropical Medicine.* British Postgraduate Medical Federation, London 1994.

56. JEFFERSON T O, DEMICHELI V. A panel priority rating exercise for the British Forces Germany Health Services Market Test. *J Royal Army Med Corps* 1995; 141:29-34.
57. DEMICHELI V, CASADIO G P, LANCIOTTI G, NOVACO F, JEFFERSON T O. The Emilia costing study: valutazione dell'impatto economico della salmonellosi umana. *Mecosan* 1995; 11:8-15.
58. WILLIAMS C, COYLE D, GRAY A, HUTTON J, JEFFERSON T O, KARLSSON G, KESTELOOT K, UYL-DE-GROOT, WAIT S. European School of Oncology advisory report to the Commission of the European Communities for "Europe Against Cancer Programme" - cost-effectiveness in cancer care. *European Journal of Cancer* 1995; 31:1410-24.
59. JEFFERSON T O. Book Review - A Literature Review of the Cost-Effectiveness of Nuclear Medicine by Jan Carter. King's Fund Centre. London: 1995. *BMJ* 1995.
60. JEFFERSON T O. Book Review - The Measures of Medicine: Benefits, Harms and Costs by Richard K Riegelman. Blackwell Science. London: 1995. *BMJ* 1995.
61. JEFFERSON T O. The Army and the Cochrane Collaboration (editorial). *J Royal Army Med Corps* 1995; 141:57-58.
62. JEFFERSON T O. Book Review - Outcomes into Clinical Practice by T Delamothe (editor). BMJ Publishing Group. London: 1994. *J Royal Army Med Corps* 1995; 141:57-58.
63. JEFFERSON T O, DEMICHELI V. Studi economici sulle riviste mediche: e' tempo di pensare a linee guida. *Mecosan* 1995; 13: 8-12.
64. JEFFERSON T O, DEMICHELI V, ENTWISTLE V. Assessing quality of economic submissions to the BMJ. *BMJ* 1995; 311:393-94 (letter to the editor).
65. JEFFERSON T O, DEMICHELI V. Are guidelines for peer-reviewing economic evaluations necessary? A survey of current editorial practice. *Health Economics* 1995; 4:383-88.
66. SASSI F, DEMICHELI V, JEFFERSON T O. Systematic Review and synthesis of economic studies. Paper presented at the Scientific Basis of Health Services conference. London 2-4 October 1995.
67. JEFFERSON T O, DEMICHELI V, MACMILLAN A H M. Epidemiological needs assessment in the British Army. Poster presented at the Scientific Basis of Health Services conference. London 2-4 October 1995.
68. DEMICHELI V, JEFFERSON T O. Le salmonellosi e lo studio dei costi delle

malattie. In De Palma A, Novaco F, Orlandi L (editors). Le salmonellosi: epidemiologia, costo economico e strategie di intervento. Regione Emilia-Romagna, Assessorato alla Sanita', Bologna 1995; 6-12.

69. JEFFERSON T O, DEMICHELI V. The costs of disease - a look at world literature. In De Palma A, Novaco F, Orlandi L (editors). Le salmonellosi: epidemiologia, costo economico e strategie di intervento. Regione Emilia-Romagna, Assessorato alla Sanita', Bologna 1995; pages 70-74.
70. DEMICHELI V, JEFFERSON T O. Presentazione dello studio sulla valutazione delle conseguenze economiche della salmonellosi umana in Emilia-Romagna. In De Palma A, Novaco F, Orlandi L (editors). Le salmonellosi: epidemiologia, costo economico e strategie di intervento. Regione Emilia-Romagna, Assessorato alla Sanita', Bologna 1995; 90-93.
71. SASSI F, DEMICHELI V, JEFFERSON T O. Pooling cost data from systematic reviews of economic studies. Poster presented at the Third Cochrane Colloquium, Oslo, Norway, 4-8 October 1995.
72. JEFFERSON T O. The quest for trials on the efficacy of human vaccines: results of the handsearch of the *Vaccine* journal. Poster presented at the Third Cochrane Colloquium, Oslo, Norway, 4-8 October 1995.
73. JEFFERSON T O. Book Review - Chalmers I, Altman DG. Systematic reviews BMJ Publishing Group. London: 1995. *J Royal Army Med Corps* 1995; 141:179
74. JEFFERSON T O, DEMICHELI V. Economic evaluation of Influenza vaccination and economic modelling. Can results be pooled? *Pharmacoconomics* 1996; 9 Suppl 3: 67-72.
75. JEFFERSON T O, DEMICHELI V, MACMILLAN A H M. Pilot study of the introduction of the J95 health data collection system. *J Royal Army Med Corps* 1996; **142**:25-29.
76. JEFFERSON T O, JEFFERSON V M. The quest for trials on the efficacy of human vaccines. Results of the handsearch of "*Vaccine*". *Vaccine* 1996; 14: 461-64.
77. DRUMMOND M F, JEFFERSON T O for the BMJ Working Party on guidelines for authors and peer-reviewers of economic submissions to the British Medical Journal. Buxton M Demicheli V, Donaldson C, Jönsson B, Mugford M, Rennie D, Rovira J, Rutten F, Schulman K, Smith R, Tonks A, Torrance G, Towse A). Guidelines for authors and peer-reviewers of economic submissions to the British Medical Journal. *BMJ* 1996; 313:275-83 (3 August).
78. JEFFERSON T O, MUGFORD M, GRAY A, DEMICHELI V. An exercise on the

feasibility of carrying out secondary economic analyses. *Health Economics* 1996;5:155-165.

79. JEFFERSON T O, DEMICHELI V, MUGFORD M. *Elementary Economic Evaluation in Health Care*. London: BMJ Books 1996.

80. DEMICHELI V, JEFFERSON T O. Economic aspects of vaccination (Editorial). *Vaccine* 1996;

81. JEFFERSON T O. Economic evaluations as an aid to decisions on whether to carry out trials - Commentary. *Lancet* 1996; 348: 141 (20 July).

82. JEFFERSON TO, ROMANO G, DEMICHELI V. La valutazione dell'impatto economico di incidenti tossinfettivi alimentari: problemi metodologici e prospettive italiane. *L'Igiene Moderna* 1996; 105:993-1003.

83. DEMICHELI V, RIVETTI D, JEFFERSON TO. Economic aspects of a small epidemic of Hepatitis A in a religious community in Northern Italy. *Journal of Infection* 1996; 33:87-90

84. JEFFERSON TO (Book Review). *Medical Informatics.....the essentials*. By F T de Dombal. Butterworth Heinemann. Oxford: 1996. *J Royal Med Corps* 1997;143:64.

85. JEFFERSON T O. New and not so new vaccines- Editorial. *BMJ* 1996;313:768 (28 September 1996).

86. JEFFERSON TO, DEMICHELI V, PRATT M, DEEKS J, SASSI F, MACMILLAN A. The effectiveness of vaccines against Hepatitis B in healthcare workers. In Gluud C, Jørgensen T, Morabito A, Pagliaro L, Poynard T, Sutton R (eds). *Cochrane Database of Systematic Reviews*; Issue 4. Update Software 2001.

87. DEMICHELI V, JEFFERSON TO, PRATT M, BEHRENS R, GRAVES P, BOTTASSO F, RIVETTI D, MACMILLAN A, MORRIS C. The effects of Anthrax vaccines. In Garner P, Gelband H, Oliaro P, Salinas R (eds). *Cochrane Database of Systematic Reviews*; Update Software 2001, Issue 4.

88. MILLER SASTJ, JEFFERSON TO. *Military Health Surveillance*. *J Royal Med Corps* 1997; 143:3 (editorial)

89. DEMICHELI V, JEFFERSON TO, PRATT M, BEHRENS R, GRAVES P, BOTTASSO F, RIVETTI D, MACMILLAN A, MORRIS C. The effects of Plague vaccines. In Garner P, Gelband H, Oliaro P, Salinas R (eds). *Cochrane Database of Systematic Reviews*; Issue 4. Update Software 2001.

90. DEMICHELI V, JEFFERSON TO, PRATT M, BEHRENS R, GRAVES P, BOTTASSO F, RIVETTI D, MACMILLAN A, MORRIS C. The effects of vaccines

against Tick-Borne Encephalitis (TBE). In Garner P, Gelband H, Olliaro P, Salinas R (eds). Cochrane Database of Systematic Reviews; Update Software 2000, issue 4.

91. JEFFERSON TO, DEMICHELI V, PRATT M. Evidence-based vaccinology. The work of the Cochrane Vaccines Field. *Journal of Epidemiology and Community Health* 1998;52:207-208.

92. JEFFERSON TO, SMITH R, DRUMMOND MF, KALE R, YI Y, PRATT M. Evaluating the BMJ guidelines on economic submissions: prospective audit of economic submissions to the *BMJ* and *Lancet*. Paper presented at the Third International Congress on Peer Review in Biomedical Publication, Prague 18-20 September 1997.

93. JEFFERSON TO, DEMICHELI V, HUTTON J. The use of systematic reviews for peer reviewing. Poster presented at the Third International Congress on Peer Review in Biomedical Publication, Prague 18-20 September 1997.

94. JEFFERSON TO, DEMICHELI V. A systematic review of world literature on the economics of influenza. *Information and News on Influenza. European Scientific Working Group on Influenza.* 1997; 7:6.

95. JEFFERSON TO Redundant publication in biomedical sciences. Scientific misconduct or necessity? *Science and Engineering Ethics* 1998; 4:135-40. (See Corrigenda in *Science and Engineering Ethics* 1998; 4:392).

96. RIVETTI D, DEMICHELI V, DEEKS J, JEFFERSON TO, PRATT M. The effectiveness and safety of vaccines against human anthrax: a systematic review. *Vaccine* 1998; 16:880-84.

97. GRAVES PM, DEMICHELI V, JEFFERSON TO, DEEKS JJ, PRATT M. The effects of cholera vaccines. In Garner P, Gelband H, Olliaro P, Salinas R (eds). Cochrane Database of Systematic Reviews; Update Software 2000, Issue 4.

98. JEFFERSON TO. Vaccine trial data systematically assembled, pooled and disseminated by the Cochrane Collaboration. *Vaccine* 1998; 16:1487-95.

99. JEFFERSON TO, DEMICHELI V. No evidence that vaccines cause insulin dependent diabetes mellitus. *Journal of Epidemiology and Community Health* 1998; 52: 674-675.

100. DEMICHELI V, JEFFERSON T O. An exploratory review of the economics of recombinant vaccines against Hepatitis B (HB). In: Ronchi E (Editor) *Biotechnology and Medical innovation: Socio-economic assessment of the technology, the potential and the products.* OECD, Paris 1997 pages 105-123.

101. HUTTON J, JEFFERSON TO. Assessing the potential cost-effectiveness of pneumococcal vaccines: methodological issues and current evidence. Abstract 1998.
102. WRIGHT LA, DEMICHELI V, GILLESPIE WJ, JEFFERSON TO. Morbidity surveillance in the British Army - the first 12 months. *J R Army Med Corps* 1998; 144:11-17.
103. JEFFERSON TO. An introduction to Health Economics. Epidemiology Supercourse on the Web (editor R LaPorte, University of Pittsburgh) 1998. <http://www.pitt.edu/~super1/hec02/>.
104. JEFFERSON TO, DRUMMOND MF, SMITH R, YI Y, PRATT M, KALE R. Evaluating the *BMJ* guidelines on economic submissions - Prospective audit of economic submissions to the *BMJ* and *Lancet*. *JAMA* 1998; 280:275-77.
105. JEFFERSON TO. Vaccines and their adverse effects - real or perceived (editorial). *BMJ* 1998; 317:159-60.
106. JEFFERSON TO. Economic evaluation alongside the UK collaborative ECMO trial (commentary). *BMJ* 1998; 317:915-6.
107. JEFFERSON TO, DEMICHELI V. The socioeconomics of influenza. In Nicholson, Hay and Webster (editors): *Textbook of Influenza*. London: Blackwell 1998 pages 541-47.
108. JEFFERSON TO, DEMICHELI V. Relation between experimental and non-experimental study designs. HB vaccines: a case study. *Journal of Epidemiology and Community Health* 1999; 53:51-54.
109. DEMICHELI V, RIVETTI D, DEEKS JJ, JEFFERSON TO. Vaccines for preventing influenza in healthy adults (Cochrane Review). In: *The Cochrane Library, Issue 1, 2003*. Oxford: Update Software.
110. JEFFERSON TO, DEMICHELI V, DEEKS JJ, RIVETTI D. Neuraminidase inhibitors for influenza. *Cochrane Database of Systematic Reviews (Acute Respiratory Infections Module)*; Oxford: Update Software 2003, Issue 1.
111. JEFFERSON TO, DEMICHELI V, DEEKS JJ, RIVETTI D. Amantadine & rimantadine for influenza. *Cochrane Database of Systematic Reviews (Acute Respiratory Infections Module)*; Oxford: Update Software 2003, Issue 1.
112. JEFFERSON TO, DEMICHELI V. Methodological quality of economic modelling studies: a case study with hepatitis B vaccines. *Pharmacoeconomics* 1998; 14:251-7.
113. JEFFERSON TO, DEMICHELI V, DEEKS JJ, RIVETTI D. Cochrane reviews and systematic reviews of economic evaluations: the case of amantadine and rimantadine in

the prevention and treatment of influenza. In: Snacken R, Szucs TD (editors). The socioeconomics of influenza and its control measures. *Pharmacoeconomics* 1999; 16: S85-S98.

114. JEFFERSON TO, DEMICHELI V. J95-EPINATO based planning parameters for medical support to operations other than war (OOTW). *J R Army Med Corps* 1998; 144:72-78.

115. HUTTON J, IGLESIAS C, JEFFERSON TO. Assessing the potential cost-effectiveness of pneumococcal vaccines: methodological issues and current evidence. *Drugs and Aging* 1999 15 Suppl 1:31-36.

116. JEFFERSON TO. What are the costs and benefits of editorials and non-systematic reviews? *BMJ* 1999; 318:135. (Personal View) (9 January).

117. JEFFERSON TO, DEMICHELI V, DEEKS JJ, RIVETTI D. Prevention and early treatment of influenza in healthy adults. *Vaccine* 2000; 18:957-1030.

118. JEFFERSON TO, MEIER CR, WEGMÜLLER Y. The impact of influenza on adults. Poster presented at the 21st International Congress of Chemotherapy, Birmingham, UK, 4-7 July 1999. *Journal of Antimicrobial Chemotherapy* 1999 4(Suppl): 43. Abstract P10. (Winner of the 21st International Congress of Chemotherapy Young Investigators Award)

119. JEFFERSON TO, WEGMÜLLER Y, BARKER C, WARD P. Influenza in the workplace: effect of Oseltamivir on ability to perform usual activities and attendance at work. Poster presented at the 21st International Congress of Chemotherapy, Birmingham, UK, 4-7 July 1999. *Journal of Antimicrobial Chemotherapy* 1999 4(Suppl): 46. Abstract P23.

120. JEFFERSON TO, RABINOVICH R, TUOMILEHTO J. Vaccines and their real or perceived adverse effects – authors' conclusions are at odds with investigators'. *BMJ* 1999; 318:1487 (letter to the editor).

121. JEFFERSON TO. Should the topics of Cochrane Reviews be Prioritised? Abstract presented at the seventh Cochrane Colloquium, Rome 4-7 October 1999.

122. JEFFERSON TO, DEMICHELI V. Should we Review Single Interventions or All Comparators in a Decision-Making Context? Abstract presented at the seventh Cochrane Colloquium, Rome 4-7 October 1999.

123. JEFFERSON TO, MILAN S. How are the topics of Cochrane Reviews decided? Abstract presented at the seventh Cochrane Colloquium, Rome 4-7 October 1999.

124. JEFFERSON TO. Do vaccines make best use of available resources? (In other words are they cost-effective?). In: Furminger I (editor): 4th European Conference on Vaccinology: the societal value of vaccination. *Vaccine* 1999; 17:S69-73.

125. GODLEE F, JEFFERSON TO (Editors). Peer Review in Health Sciences. London: BMJ Books 1999.
126. JEFFERSON TO. Real or perceived adverse effects of vaccines and the media – a tale of our times (Editorial). *Journal of Epidemiology and Community Health* 2000; 54:402-3.
127. JEFFERSON TO. Economic and non-economic factors in evaluating prevention versus treatment. Abstract of talk given at the AAAS Annual Meeting and Science Innovation Symposium (Abstract A 51). Washington DC 17-22 February 2000.
128. JEFFERSON TO, DEEKS JJ. The use of systematic reviews for peer reviewing. In: GODLEE F, JEFFERSON TO (Editors). *Peer Review in Health Sciences*. London: BMJ Books 1999.
129. COLORECTAL CANCER COLLABORATIVE GROUP. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. *BMJ* 2000; 321:531-5.
130. JEFFERSON TO, DEMICHELI V, DEEKS JJ, RIVETTI D. Prevention and early treatment of influenza in healthy adults. *Vaccine* 2000; 18:957-1030.
131. JEFFERSON T O, DEMICHELI V, MUGFORD M. *Elementary Economic Evaluation in Health Care*. Second Edition. London: BMJ Books 2000.
132. HEIJBEL H, JEFFERSON TO. Vaccine Safety – Improving monitoring. *Vaccine* 2001; 19:2457-60.
132. JEFFERSON TO. Comment: Efficacy and safety of the oral neuraminidase inhibitor Oseltamivir in treating acute influenza. A randomised controlled trial. *Evidence-based healthcare* 2000; 4:94.
133. MEIER CR, NAPAL KOV PN, WEGMUELLER Y, JEFFERSON T, JICK H. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. *European Journal of Clinical Microbiology and Infectious Diseases* 2000;19(11):834-842.
133. JEFFERSON TO, HEIJBEL H. Demyelinating disease and Hepatitis B vaccination - Is there a link? *Drug Safety* 2001; 24(4):249-54.
134. JEFFERSON TO. Monitoring the safety of vaccines: methodological challenges. Paper presented at the 8th Annual meeting of the European Society of Pharmacovigilance. Verona, Italy 21-23 September 2000. Abstract number 45.

135. JEFFERSON TO, DEMICHELI V. The quality of methods of economic evaluations in healthcare: time for action (editorial). *BMJ* 2002; 324:313-4. (9 February).
136. WAGER E, JEFFERSON TO. Shortcomings of peer review in biomedical journals. *Learned Publishing* 2001; 14:257-63.
137. JEFFERSON TO, DEMICHELI V, VALE L. The quality of systematic reviews of economic evaluations in healthcare and what they are telling us: it is time for action. *JAMA* 2002; 287:2809-2812.
138. BURLS A, CLARK W, STEWART T, PRESTON C, BRYAN S, JEFFERSON T, FRY-SMITH A. Zanamivir for the treatment of influenza in adults. NHS HTA Programme, London: 2002; Vol 6: No 9.
139. JEFFERSON TO, TYRRELL D. Antivirals for the Common Cold (Cochrane Review). In: *The Cochrane Library*, Issue 1, 2003. Oxford: Update Software.
140. JEFFERSON TO, ALDERSON P, DAVIDOFF F, WAGER E. Editorial peer review for improving the quality of reports of biomedical studies (Cochrane Methodology Review). In: *The Cochrane Library*, Issue 1, 2003. Oxford: Update Software.
141. JEFFERSON TO, TYRRELL D. Vaccines for the Common Cold (Protocol for a Cochrane Review). In: *The Cochrane Library*, Issue 1, 2003. Oxford: Update Software.
142. SPIER R, JEFFERSON TO, DEMICHELI V. An editorial policy statement. Submission of economic evaluations of vaccines. *Vaccine* 2002; 20:1693-1695.
143. JEFFERSON TO, ALDERSON P, DAVIDOFF F, WAGER E. Effects of editorial peer review: a systematic review. *JAMA* 2002; 287:2784-2786.
144. JEFFERSON TO, WAGER E, DAVIDOFF F. Measuring the quality of editorial peer review. *JAMA* 2002; 287:2786-2790.
145. WAGER E, GODLEE F, JEFFERSON TO. How to survive peer review. London, BMJ Books 2002.
146. JEFFERSON TO. Advances in the diagnosis and management of influenza. *Current Infectious Diseases Reports* 2002; 4: 206-10.
147. JEFFERSON TO, BIANCO E, DEMICHELI V. Influenza vaccines in adults. *Occupational Medicine* 2002; 52(5):255-58.
148. JEFFERSON TO, DEMICHELI V, VALE L. Methodological quality of economic evaluations of health care interventions – evidence from systematic reviews. In:

- Donalson C, Mugford M, Vale L (editors). Evidence-based Health economics: from effectiveness to efficiency in health care. London BMJ Books 2002. Pages 67-88.
149. DEMICHELI V, JEFFERSON TO, VALE L. Effectiveness estimates in economic evaluation. In: Donalson C, Mugford M, Vale L (editors). Evidence-based Health economics: from effectiveness to efficiency in health care. London BMJ Books 2002. Pages 89-98.
150. JEFFERSON TO, BIANCO E. Quanto protetti? Aretre' Roche 2002; 35:24-5.
151. JEFFERSON T, RUDIN M. 1st International Symposium on the Evaluation of Safety of Human Vaccines. Expert Opin Drug Saf 2002; 1(2):195-98.
152. JEFFERSON TO, TRAVERSA G. Hepatitis B vaccination: risk-benefit profile and role of systematic reviews in the assessment of causality of adverse events following immunisation. Journal of Medical Virology 2002; 67:451-53.
153. JEFFERSON TO, DEMICHELI V. Polysaccharide Pneumococcal Vaccines. Editorial . BMJ 2002 (in press).
154. JEFFERSON T, DEMICHELI V, VALE L. Educating authors and reviewers of economic evaluations of health care. JAMA 2002 Aug 28;288(8):959 (Letter to the Editor).
155. JEFFERSON TO, PRICE D, DEMICHELI V. Unintended Events following immunisation with MMR: a systematic review. Pharmacoepidemiology and Drug Safety 2002; 11:S286 (abstract).
156. JEFFERSON TO, RUDIN M, DIPIETRANTONJ C. systematic review of the effects of DTP vaccines in children with or without inactivated polio vaccine (IPV). Pharmacoepidemiology and Drug Safety 2002; 11:S285 (abstract).
157. MELE A, JEFFERSON T, FRANCO E, SALMASO S. Change from oral poliovirus vaccine to inactivated poliovirus vaccine. The Lancet 2002; 360:1178 (12 October).
156. BONHOEFFER J, KOHL K, CHEN R, DUCLOS P, HEIJBEL H, HEININGER U, JEFFERSON T, LOUPI E and The Brighton Collaboration. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 2002; 21:298-302.
157. JEFFERSON TO, SHASHOK K. Journals: how to decide what's worth publishing. Nature 2003; 421:209-10.
158. DEMICHELI V, RIVETTI A, DI PIETRANTONJ C, CLEMENTS CJ, JEFFERSON T. Hepatitis B vaccination and multiple sclerosis - Evidence from a systematic review. Journal of Viral Hepatitis 2003; 5:343-4.

159. JEFFERSON TO, RUDIN M, DIPIETRANTONJ C. Systematic review of the effects of pertussis vaccines in children. *Vaccine* 2003; 21(17-18):2012-2023.
160. JEFFERSON TO, DEMICHELI V. Economic Analysis on influenza vaccination and treatment. *Annals of Internal Medicine* 2003; 138(7):607 (letter to the Editor).
161. MELE A, JEFFERSON TO. The use of Hepatitis A vaccine in Italy - evidence-based recommendations from an expert panel. *Vaccine* 2003; 21:2223 (editorial).
162. JEFFERSON TO, DEMICHELI V. Observational data on harm are already included in systematic reviews. *BMJ* 2003; 327:750.
163. JEFFERSON TO, PRICE D, DEMICHELI V, BIANCO E. Unintended Events following immunisation with MMR: a systematic review. *Vaccine* 2003; 21(25-26):3954-60.
164. JEFFERSON TO, SHASHOK K, WAGER E. Get Peered! *BMJ* 2003. (Christmas issue).
165. GODLEE F, JEFFERSON TO (Editors). *Peer Review in Health Sciences*. Second edition. London: BMJ Books 2003.
166. MATERIA E, BAGLIO G, CANONACO D, JEFFERSON T, MELE A, MARCHISIO P, DI DOMENICANTONIO R, GUASTICCHI G. Promoting clinical and organizational appropriateness of tonsillectomy in Italy. *European J Public Health* 2003; 13: 86 (Supplement. Abstracts of the 11th Annual EUPHA Meeting Globalisation and health in Europe: harmonising public health practices, Roma 20-22 November 2003.)
167. JEFFERSON TO, RUDIN M, DIPIETRANTONJ C. Adverse events following immunization with aluminium-containing DTP vaccines - systematic review of the evidence. *Lancet Infect Dis* 2004; 4: 84–90.
168. JEFFERSON T. Informed choice and balance are victims of the MMR-autism saga. *Lancet Infect Dis* 2004; 4: 135-36.
169. JEFFERSON T, PRICE D, DEMICHELI V, BIANCO E. Selective quotation of evidence in vaccines research. *Lancet* 2004; 363: 1738 (letter to the Editor).
170. JEFFERSON TO. The role of editorial peer review in the evaluation of vaccine safety. *Vaccine* 2004; 22: 2073-75.
171. JEFFERSON TO, Demicheli V. The first international symposium on vaccine safety. *Vaccine* 2004; 22: 2042-43.
172. PERRIA C. For the IMPEMEG Study Group (Pierluigi Bartoletti, Paolo Billi, Virgilio Calzini, Maurizio D'Amato, Alfonso Fiorillo, Gabriella Guasticchi, Carmelina Guerriera,

Giuseppe Grasso, Tom Jefferson, Sergio Leotta, Donatella Mandolini, Walter Marrocco, Mazzieri Scheggi, Amina Pasquarella, Carla Perria, Concetta Suraci). **Strategies for the introduction and implementation of a guideline for the treatment of type 2 diabetics by general practitioners (GPs) of the Lazio region of Italy (IMPLEMEG study): Protocol for a cluster randomised controlled trial [ISRCTN80116232].** BMC Health Services Research 2004, 4:13 (14 Jun 2004)
<http://www.biomedcentral.com/1472-6963/4/13>

173. JEFFERSON TO, RUDIN M, DIPIETRANTONJ C. Reply to the letter to the Editor Vaccine 2004; 22(21-22):2685.

174. JEFFERSON TO. Bioterrorism and compulsory vaccination. Better vaccines are needed if vaccination is to be made compulsory. (Editorial). BMJ 2004; 329: 524-25. (4 September)

174. JEFFERSON TO. What are we to do about influenza? (Editorial). BMJ 2004; 329: 633-4.

175. SMITH S, DEMICHELI V, JEFFERSON T, HARNDEN A, MATHESON N, DI PIETRANTONJ C. Vaccines for preventing influenza in healthy children (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd.

176. RIVETTI D, DEMICHELI V, DI PIETRANTONJ C, JEFFERSON TO, THOMAS R. Vaccines for preventing influenza in the elderly (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd.

177. JEFFERSON TO. How to deal with influenza: Author's reply. BMJ 2004;329:1238, doi:10.1136/bmj.329.7476.1238-b

178. BIANCO E, DE MASI S, MELE A, JEFFERSON T. Effectiveness of immune globulina in preventing infectious hepatitis and hepatitis A: a systematic review. Digestive and Liver Disease 2004; 36: 834-42

179. JEFFERSON TO, Demicheli V, Price D. Informed choice, balance and the MMR-autism saga (authors' reply). The Lancet Infectious Diseases 2005; 5(1):3-4..

180. JEFFERSON TO. Glossary of peer review. Journal of Epidemiology and Community Health 2004; 58:272.

181. JEFFERSON T, SMITH S, DEMICHELI V, HARNDEN A, RIVETTI A, DI PIETRANTONJ C. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review. Lancet 2005; 365:773-80 (26th of February).

182. JEFFERSON T. L'applicazione della medicina basata sulle prove alla tomoscintigrafia a emissione di positroni (PET). Decidere in Medicina 2005; 2:34-40.

183. JEFFERSON T, SMITH S, DEMICHELI V, HARNDEN A, RIVETTI A. Influenza vaccines in healthy children – authors' reply. *The Lancet* 2005; 385:2087.
184. JEFFERSON T. Peer review and publishing: it's time to move the agenda on. *The Lancet* 2005; 366:283-284. DOI:10.1016/S0140-6736(05)66968-1.
185. JEFFERSON T. Microbial challenge studies of volunteers—a challenge worth accepting. *Lancet* 2005 (in press) commentary.
186. JEFFERSON T, SMITH S, DEMICHELI V, HARNDEN A, RIVETTI A. Safety of influenza vaccines in children. *Lancet* 2005; 366:803-04.
187. JEFFERSON T, RIVETTI D, RIVETTI A, RUDIN M, DI PIETRANTONJ C, DEMICHELI V. Efficacy and effectiveness of influenza vaccines in the elderly: systematic review. *Lancet* 2005 ; 366:1165 -1174.
188. JEFFERSON T. *Attenti alle bufale*. Roma: Pensiero Scientifico Editore 2005.
189. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A. Antivirals for influenza in healthy adults: systematic review. *The Lancet* 2006; 367: 303-13. Published Online January 19 2006; DOI: 10.1016/S0140-6736(06) 67970-1.
190. THOMAS RE, JEFFERSON TO, DEMICHELI V, RIVETTI D. Influenza vaccination for health care workers who work with the elderly: A systematic review. *The Lancet Infectious Diseases* 2006; 6:273-79.
191. JEFFERSON T. Alternative models of quality control for scientific research. *Nature* 2006 (<http://www.nature.com/nature/peerreview/debate/index.html>).
192. JEFFERSON T. *Attenti alle bufale*. Roma, Pensiero Scientifico Editore 2005
193. JEFFERSON T, FERRONI E, CURTALE F, GIORGI ROSSI P, BORGIA P. S. *pneumoniae* in Western Europe: serotype distribution and incidence in children less than 2 years old. *The Lancet Infectious Diseases* 2006; 6:405-10.
194. JEFFERSON T, FRATI D, GRASSO E. *Aviaria: influenza dei polli?* Roma: Pensiero Scientifico Editore 2006
195. JEFFERSON T, RUDIN M, BRODNEY FOLSE S, DAVIDOFF F. Editorial peer review for improving the quality of reports of biomedical studies. *The Cochrane Database of Methodology Reviews* 2006, Issue 1. Art. No.: MR000016.pub2. DOI: 10.1002/14651858.MR000016.pub2.
196. JEFFERSON T. The prevention of seasonal influenza – policy versus evidence. *BMJ* 2006; 333:912-15.

197. JEFFERSON T. Influenza. *Clinical Evidence* 2006.
196. D RIVETTI, T JEFFERSON, R THOMAS, M RUDIN, A RIVETTI, C DI PIETRANTONJ, V DEMICHELI. Vaccines for preventing influenza in the elderly. *Cochrane Database of Systematic Reviews* 2006, Issue 3. Art. No.: CD004876. DOI: 10.1002/14651858.CD004876.pub2.
197. Jefferson T. Look at all the evidence before stockpiling Amantadine. *BMJ* 2007; 334:439 (letter to the editor).
198. TO Jefferson, D Rivetti, C Di Pietrantonj, A Rivetti, V Demicheli. Vaccines for preventing influenza in healthy adults. *Cochrane Database of Systematic Reviews* 2007, Issue 2. Art. No.: CD001269. DOI: 10.1002/14651858.CD001269.pub3.
199. TOM JEFFERSON, LUCIA ZARRA, AND LIVIU STOICA. Attenti Alle Bufale ('Beware of Red Herrings'), or, How to Make Evidence-Based Medicine Work for You *J. R. Soc. Med.* 2006 99: 625-627.
200. TOM JEFFERSON AND LUCIA ZARRA. Bufala spotting, part one: assessing research papers *J. R. Soc. Med.* 2007 100: 38-39.
201. TOM JEFFERSON AND LUCIA ZARRA. Bufale spotting, part two: assessing systematic reviews *J. R. Soc. Med.* 2007 100: 180-181.
202. TOM JEFFERSON AND LUCIA ZARRA. Bufale spotting, part three: assessing editorials. *J. R. Soc. Med.* 2007; 100(6): p. 267
203. CARLA PERRIA, DONATELLA MANDOLINI, CARMELINA GUERRERA, THOMAS JEFFERSON, PAOLO BILLI, VIRGILIO CALZINI, ALFONSO FIORILLO, GIUSEPPE GRASSO, SERGIO LEOTTA, WALTER MARROCCO, CONCETTA SURACI AND AMINA PASQUARELLA. Implementing a guideline for the treatment of type 2 diabetics: results of a Cluster- Randomized Controlled Trial (C-RCT) **[ISRCTN80116232]**. *BMC Health Services Research* 2007, 7:79 (04 Jun 2007). <http://www.biomedcentral.com/1472-6963/7/79>
204. TOM JEFFERSON AND LUCIA ZARRA. Bufale Spotting, part 5: Assessing a website. *J. R. Soc. Med.* 2007; 100(8): p. 367 <http://www.jrsm.org/cgi/content/full/100/8/367?ct=ct>
205. TO JEFFERSON, D RIVETTI, C DI PIETRANTONJ. Inactivated influenza vaccines in the elderly—are you sure? (Comment). *The Lancet* (Published Online September 25, 2007, DOI:10.1016/S0140-6736(07)61389-0).
206. TOM JEFFERSON, RUTH FOXLEE, CHRIS DEL MAR, LIZ DOOLEY, ELIANA FERRONI, BILL HEWAK, ADI PRABHALA, SREE NAIR, AND ALEX RIVETTI.

Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review. *BMJ*. 2008; 336(7635): p. 77-80

207. TOM JEFFERSON AND LUCIA ZARRA. *Bufale Spotting, part 7: Assessing an advert*. *J. R. Soc. Med.* 2007; 100(11): p. 502
208. T JEFFERSON. *Cattive Acque*. Il Pensiero Scientifico Editore. 2007
209. TOM JEFFERSON AND LUCIA ZARRA. *Bufale Spotting, part 9: assessing an economic evaluation*. *J R Soc Med.* 2008; 101(4): p. 175-176.
210. T JEFFERSON, A RIVETTI, A HARNDEN, C DI PIETRANTONJ, AND V DEMICHELI. *Vaccines for preventing influenza in healthy children*. *Cochrane Database Syst Rev* 1 Jan 2008: p. CD004879
211. C CATES, T JEFFERSON, AND B ROWE. *Vaccines for preventing influenza in people with asthma*. *Cochrane Database Syst Rev* 1 Jan 2008: p. CD000364.
<http://highwire.stanford.edu/cgi/medline/pmid;18425863>
212. TOM JEFFERSON. *More cases, doctor? Yes please!* *Cases J* 16 Jul 2008 1(1): p. 38. <http://highwire.stanford.edu/cgi/medline/pmid;18631383>
213. TOM JEFFERSON. *Darkness falls*. *BMJ*. 2008; 337(nov12_1): p. a2501
214. FABIO BERNARDINI, MARINA CERBO, TOM JEFFERSON, ALESSANDRA LO SCALZO, MARCO RATTI - *Wireless Capsule Endoscopy in the diagnosis of small bowel disease*. *Age.na.s. HTA Report*. Rome, September 2008.
<http://www.ministerosalute.it/dispositivi/paginainternaf.jsp?id=1202&menu=hta>
215. ANTONELLA CAVALLO, MARINA CERBO, DARIO FELLA, TOM JEFFERSON, ANTONIO MIGLIORE, MARIA ROSARIA PERRINI. - *Prostheses for primary total hip replacement in Italy*. *Age.na.s. HTA Report*, Rome, September 2008.
<http://www.ministerosalute.it/dispositivi/paginainternaf.jsp?id=1202&menu=hta>
216. ANNA MARIA VINCENZA AMICOSANTE, MARINA CERBO, TOM JEFFERSON, SIMONA PAONE, LAURA VELARDI. *Rapid (bed-side) tests for influenza*. *Age.na.s. HTA Report* - Rome, September 2008.
217. T JEFFERSON, C DI PIETRANTONJ, M G DEBALINI, A RIVETTI, AND V DEMICHELI. *Inactivated influenza vaccines: Methods, policies, and politics*. *J Clin Epidemiol* 2008; 1-10. <http://highwire.stanford.edu/cgi/medline/pmid;19124222>
doi: 10.1016/j.jclinepi.2008.07.001.
218. T JEFFERSON, C DI PIETRANTONJ, MG DEBALINI, A RIVETTI, V DEMICHELI. *Study quality, concordance, take home message, funding and impact. Their relationship in influenza vaccines studies*. *BMJ* 2009 338(feb12_2): p. b354

http://www.bmj.com/cgi/content/abstract/338/feb12_2/b354?ct=ct.

221. T JEFFERSON. Ranking antidepressants. *Lancet* 23 May 2009 373(9677): p. 1759;

219. JEFFERSON T. Influenza. *BMJ Clinical Evidence* 2009.

223 A LO SCALZO, M RATTI, T JEFFERSON, F BERNARDINI, AND M CERBO. Wireless capsule for endoscopy in Italy: adding context-specific data to the review of the evidence from literature. *Int J Technol Assess Health Care* 1 Jul 2009 25(3): p. 297. <http://highwire.stanford.edu/cgi/medline/pmid;19619348>

224 JEFFERSON T. Pneumococcal vaccines: confronting the confounders. *The Lancet* 2009; [373](#): 2008-09.

225 TOM JEFFERSON. A brief history of shroud waving through the centuries. *BMJ*. 2009; 338(jun30_3): p. b2610
http://www.bmj.com/cgi/content/extract/338/jun30_3/b2610?ct=ct

226. JEFFERSON T, DEL MAR C, DOOLEY L, FERRONI E, AL-ANSARY LA, BAWAZEER GA, VAN DRIEL ML, FOXLEE R, RIVETTI A. [Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review](#). *BMJ*. 2009 Sep 21;339:b3675. doi: 10.1136/bmj.b3675. Review.

227. HERXHEIMER A, CLARKE M, EDWARDS R, JEFFERSON T, LOKE Y. A/H1N1 flu. Time for case-control studies of NSAIDs and oseltamivir. *BMJ*. 2009 Jul 28;339:b3048. doi: 10.1136/bmj.b3048. No abstract available.

228. MIGLIORE A, RATTI M, CERBO M, JEFFERSON T. Health Technology Assessment: managing the introduction and use of medical devices in clinical practice in Italy. *Expert Rev Med Devices*. 2009 May;6(3):251-7. Review. PMID: 19419283 [PubMed - indexed for MEDLINE]

229. T JEFFERSON, M JONES, P DOSHI, AND C DEL MAR. Possible harms of oseltamivir--a call for urgent action. *Lancet* 17 Oct 2009 374(9698): p. 1312.

230. JEFFERSON, T. Guest Editorial: Mistaken identity: seasonal influenza versus influenza-like illness. *Clinical Evidence* 5 October, 2009.

231. TOM JEFFERSON, MARK JONES, PETER DOSHI, AND CHRIS DEL MAR. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. *BMJ*. 2009; 339(dec07_2): p. b5106.
http://www.bmj.com/cgi/content/abstract/339/dec07_2/b5106?ct=ct

232. TOM JEFFERSON AND ELIANA FERRONI. The Spanish influenza pandemic seen through the BMJ's eyes: observations and unanswered questions. *BMJ*. 2009; 339(dec16_3): p. b5313
http://www.bmj.com/cgi/content/extract/339/dec16_3/b5313?ct=ct

233. A MIGLIORE, MR PERRINI, E ROMANINI, D FELLA, A CAVALLO, M CERBO, AND T JEFFERSON. Comparison of the performance of hip implants with data from different arthroplasty registers. *J Bone Joint Surg Br* 1 Dec 2009 91(12): p. 1545.
<http://highwire.stanford.edu/cgi/medline/pmid;19949114>

234. TOM JEFFERSON. Neuraminidase inhibitors produce a small reduction in duration of seasonal influenza in children and reduce transmission in affected households, but effects on serious complications unclear. *Evid. Based Med*. 2010; 15(1): p. 20-21
<http://ebm.bmj.com/cgi/content/extract/15/1/20?ct=ct>

235. FERRONI E, JEFFERSON T (2011). Angelo Celli and research on the prevention of malaria at the turn of the 20th century. *JLL Bulletin: Commentaries on the history of treatment evaluation* (www.jameslindlibrary.org)

236 THOMAS RE, JEFFERSON T, LASSERSON TJ. Influenza vaccination for health care workers who work with the elderly: a Cochrane review. *Health Technology Assessment, H1N1 and pandemic flu A special themed issue of HTA*, 2010;14(55):493-588.

237. MIGLIORE A, CORIO M, PAONE S, CERBO M AND JEFFERSON T. Accommodating intraocular lenses for patients with cataract: A review. *Expert Review of Ophthalmology* 2011 6:4 (431-436).

238. Cochrane Neuraminidase Inhibitors Review Team. Does Oseltamivir Really Reduce Complications of Influenza? *Clinical Infectious Diseases*. 2011 Dec 15;53(12):1302–3.

239. JEFFERSON T. Should journals sell reprints? *BMJ* 2011;343:d6448 doi: 10.1136/bmj.d6448

240. JEFFERSON T, JONES MA, DOSHI P, DEL MAR CB, HENEGHAN CJ, HAMA R, THOMPSON MJ. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. *Cochrane Database of Systematic Reviews* 2012, Issue 1. Art. No.: CD008965. DOI: 10.1002/14651858.CD008965.pub3.

241. DOSHI P, JONES MA, JEFFERSON T. Rethinking credible evidence synthesis. *BMJ* 2012; 344:d7898 doi: 10.1136/bmj.d7898

242. Drug Data Shouldn't Be Secret. By PETER DOSHI AND TOM JEFFERSON. *The New York Times*, April 10, 2012
URL: <http://www.nytimes.com/2012/04/11/opinion/drug-data-shouldnt-be-secret.html>

Shortened URL: <http://nyti.ms/lvgh9c>

243. DOSHI P, JEFFERSON T, DEL MAR C (2012) The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience. *PLoS Med* 9(4): e1001201. doi:10.1371/journal.pmed.1001201

Short URL: <http://bit.ly/HlBwqO> PDF for printing: <http://bit.ly/HFBYTV>

244. JONES M, HAMA R, JEFFERSON T, DOSHI P. Neuropsychiatric Adverse Events and Oseltamivir for Prophylaxis *Drug Saf* 2012; 35 (12): 1187-1190.

245. DOSHI P, JEFFERSON T. The first 2 years of the European Medicines Agency's policy on access to documents: Secret no Longer. *Arch Intern Med*. Published online December 19, 2012. doi:

<http://dx.doi.org/10.1001/jamainternmed.2013.3838>

<http://archinte.jamanetwork.com/article.aspx?articleid=1486542>

246. DOSHI P, JEFFERSON T. Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. *BMJ Open*. 2013 Feb 26;3(2):e002496.

<http://bmjopen.bmj.com/content/3/2/e002496.full> and

<http://dx.doi.org/10.1136/bmjopen-2012-002496>

247. DOSHI P, DICKERSIN K, HEALY D, VEDULA SS, JEFFERSON T. Restoring invisible and abandoned trials: a call for people to publish the findings *BMJ* 2013; 346 doi: <http://dx.doi.org/10.1136/bmj.f2865> (Published 13 June 2013).

248. CHAN A-W, SONG F, VICKERS A, JEFFERSON T, DICKERSIN K, GØTZSCHE PC et al. Increasing value and reducing waste: addressing inaccessible research. *The Lancet*, [Volume 383, Issue 9913](#), Pages 257 - 266, 18 January 2014.

doi:10.1016/S0140-6736(13)62296-5.

<http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2962296-5/fulltext>.

249. JEFFERSON T, JONES MA, DOSHI P, DEL MAR CB, HAMA R, THOMPSON MJ, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. *Cochrane Database of Systematic Reviews* 2014, Issue 4. Art. No.: CD008965 DOI: 10.1002/14651858.CD008965.pub4

250. HENEGHAN CJ, ONAKPOYA I, THOMPSON M, SPENCER EA, JONES M, JEFFERSON T. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. *BMJ* 2014; 348. DO 10.1136/bmj.g2547. UL <http://www.bmj.com/content/348/bmj.g2547>

251. JEFFERSON T, DOSHI P. Multisystem failure: the story of anti-influenza drugs. *BMJ* 2014;348. DOI 10.1136/bmj.g2263

UL <http://www.bmj.com/content/348/bmj.g2263>

252. JEFFERSON T, DOSHI P. [EMA's double U-turn on its Peeping Tom policy for data release](#). BMJ Blog 2014.
253. JEFFERSON T, DOSHI P, LEMMENS T. EMA's data sharing policy—towards peeping tom based medicine? BMJ Blog 2014.
<http://blogs.bmj.com/bmj/2014/05/22/tom-jefferson-et-al-emas-data-sharing-policy-towards-peeping-tom-based-medicine/>
254. JEFFERSON T, JONES MA, DOSHI P, DEL MAR CB, HAMA R, THOMPSON MJ, ONAKPOYA I, HENEGHAN CJ. Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports. BMJ Open 2014;4:e005253-e005253
<http://bmjopen.bmj.com/cgi/content/full/bmjopen-2014-005253?ijkey=AHfmbBvUum2MicR&keytype=ref>
255. Jefferson T. [EMA's release of regulatory data—trust but verify](#)
BMJ Blogs
256. JEFFERSON T. [EMA's Release of Regulatory Data: Possible Fall out for Journals and Research Synthesis](#).
257. TOM JEFFERSON AND PETER DOSHI: Thanksgiving special—menus needed at the EMA's restaurant
258. PETER DOSHI and TOM JEFFERSON. The Evidence Base for New Drugs (editorial). Published: 2 March 2015; BMJ 2015;350:h952.
<http://www.bmj.com/content/350/bmj.h952>
259. TOM JEFFERSON. The EMA revolution gathers pace
<http://blogs.bmj.com/bmj/2015/06/30/tom-jefferson-the-ema-revolution-gathers-pace/>
260. Are we ready for the EMA revolution?
<http://blogs.bmj.com/bmj/2015/06/30/tom-jefferson-are-we-ready-for-the-ema-revolution/>
261. [EMA confidential—the EMA continues consultation on its 0070 policy and concerns appear](#) <http://blogs.bmj.com/bmj/2015/07/09/tom-jefferson-ema-confidential/>
262. KHALED EL EMAM, TOM JEFFERSON, PETER DOSHI
<http://blogs.bmj.com/bmj/2015/08/27/maximizing-the-value-of-clinical-study-reports/>
263. KHALED EL EMAM, TOM JEFFERSON, PETER DOSHI. [The release of regulatory documents under EMA policy 0070: Now you see them, now you don't.](#)

264. DOSHI P, JEFFERSON T. Open data 5 years on: a case series of 12 freedom of information requests for regulatory data to the European Medicines Agency. *Trials* (2016) 17:78 DOI 10.1186/s13063-016-1194-7.
<http://trialsjournal.biomedcentral.com/articles/10.1186/s13063-016-1194-7>
265. PETER DOSHI & TOM JEFFERSON. [Access to clinical trial data from the European Medicines Agency](#).
266. JEFFERSON T, DEMICHELI V. Is the timing of recommended childhood vaccines evidence based? *BMJ* 2016; 352 doi: <http://dx.doi.org/10.1136/bmj.i867> (Published 23 February 2016) Cite this as: *BMJ* 2016;352:i867.
<http://www.bmj.com/content/352/bmj.i867>
267. CARL J HENEGHAN, IGHO ONAKPOYA, MARK A JONES, PETER DOSHI, CHRIS B DEL MAR, ROKURO HAMA, MATTHEW J THOMPSON, ELIZABETH A SPENCER, KAMAL R MAHTANI, DAVID NUNAN, JEREMY HOWICK, TOM JEFFERSON. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. *Health Technology Assessment* . 2016 (in press) <http://www.journalslibrary.nihr.ac.uk/hta>
268. JEFFERSON T. Facing the unreliability of clinical trials literature. *Drug and Therapeutics Bulletin of Navarre, Spain*. 2015;23(2).
http://www.navarra.es/home_en/Temas/Portal+de+la+Salud/Profesionales/Documentacion+y+publicaciones/Publicaciones+tematicas/Medicamento/BIT/
269. DAVIS C, LEXCHIN J, JEFFERSON T, GÖTZSCHE P, MCKEE M. “Adaptive pathways” to drug authorisation: adapting to industry? *BMJ* 2016;354:i4437 doi: 10.1136/bmj.i4437 (Published 16 August 2016). [Download free here](#)
270. [Tom Jefferson: The EMA’s policy 0070 is live](#) *BMJ blogs*
271. DOSHI P, HUR P, JONES M, ALBARMAWI H, JEFFERSON T, MORGAN DJ, SPEARS PA, POWERS JH. Informed consent to study purpose in randomized controlled trials of antibiotics, 1991-2011. *JAMA Intern Med*. Published online August 21, 2017. doi:10.1001/jamainternmed.2017.3820
272. TOM JEFFERSON. Sticking to principles and anticipating outcomes. *Recenti Prog Med* 2017; 108: 347-49. <https://goo.gl/64jFkp>
- 273 TOM JEFFERSON. [The UK turns to Witty, Vallance, and Van Tam for leadership: revolving doors?](#) *BMJ blogs*.
274. MAHTANI KR, JEFFERSON T, HENEGHAN C. [What makes a systematic review “complex”?](#) *BMJ blogs*.

275. DOSHI P, JEFFERSON T. Disclose Data Publicly, without Restriction. In Davis L, Miller JD, Sharfstein JM, Kesselheim AS. Blueprint for transparency at the US Food and Drug Administration. Winter 2017. Pages 42-45. DOI: 10.1177/1073110517750611.
276. JØRGENSEN L, GØTZSCHE PC, JEFFERSON T. Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies: a necessary basis to address reporting bias in a systematic review. *Systematic Reviews* 2018 7:8. <https://doi.org/10.1186/s13643-018-0675-z>.
277. DEMICHELI V, JEFFERSON T, FERRONI E, RIVETTI A, DI PIETRANTONJ C. Vaccines for preventing influenza in healthy adults. *Cochrane Database of Systematic Reviews* 2018, Issue 2. Art. No.: CD001269. DOI: 10.1002/14651858.CD001269.pub6.
278. JEFFERSON T, RIVETTI A, DI PIETRANTONJ C, DEMICHELI V. Vaccines for preventing influenza in healthy children. *Cochrane Database of Systematic Reviews* 2018, Issue 2. Art. No.: CD004879. DOI: 10.1002/14651858.CD004879.pub5.
279. DEMICHELI V, JEFFERSON T, DI PIETRANTONJ C, FERRONI E, THORNING S, THOMAS RE, RIVETTI A. Vaccines for preventing influenza in the elderly. *Cochrane Database of Systematic Reviews* 2018, Issue 2. Art. No.: CD004876. DOI: 10.1002/14651858.CD004876.pub4.
280. JEFFERSON T, RIVETTI A, DEMICHELI V. Why have three long-running Cochrane Reviews on influenza vaccines been stabilised?
<http://community.cochrane.org/news/why-have-three-long-running-cochrane-reviews-influenza-vaccines-been-stabilised>
281. Tom Jefferson and Peter Doshi: RIP PubMed commons
[BMJ Blogs](#)
282. Jefferson T, Jørgensen L. Redefining the “E” in EBM. *BMJ Evidence Based Medicine*. 10.1136/bmjebm-2018-110918.
283. Mahtani K, Jefferson T, Heneghan C, Nunan D, Aaronson J. What is a 'complex systematic review'? Criteria, definition, and examples. 10.1136/bmjebm-2018-110965
<http://dx.doi.org/10.1136/bmjebm-2018-110965>.
284. Jørgensen L, Gøtzsche PC, Jefferson T. The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias. *BMJ Evidence Based Medicine*. Published Online First: 27 July 2018. doi: 10.1136/bmjebm-2018-111012.
285. Jefferson T, Jørgensen L. Human papillomavirus vaccines, complex regional pain syndrome, postural orthostatic tachycardia syndrome, and autonomic dysfunction - a review of the regulatory evidence from the European Medicines Agency. *Indian J Med Ethics*. Published online on October 17, 2016.

286. Hodkinson A, Dietz KC, Lefebvre C, Golder S, Jones M, Doshi P, Heneghan C, Jefferson T, Boutron I, Stewart L. The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors. *Systematic Reviews* 2018. 7:117. <https://doi.org/10.1186/s13643-018-0766-x>

287. Jefferson T, Demicheli V, Di Pietrantonj C, Rivetti D. Amantadine and rimantadine for influenza A in adults. *Cochrane Database of Systematic Reviews* 2006 , Issue 2 . Art. No.: CD001169. DOI: 10.1002/14651858.CD001169.pub3.

288. Jørgensen L, Doshi P, Gøtzsche P, Jefferson T. Challenges of independent assessment of potential harms of HPV vaccines *BMJ* 2018; 362 doi: <https://doi.org/10.1136/bmj.k3694>

289. Peter Doshi, Tom Jefferson, Mark Jones, John H. Powers III. Baloxavir: Roche's new oseltamivir? <https://www.bmj.com/content/363/bmj.k4531/rr>

290. Tom Jefferson. How Cochrane is doing pharma a good turn. <https://blogs.bmj.com/bmj/2018/11/12/tom-jefferson-cochrane-pharma-good-turn/>

291. Doshi P, Jefferson T, Jones M et al. Call to action: RIAT restoration of a previously unpublished methodology in Gardasil vaccine trials. <https://www.bmj.com/content/346/bmj.f2865/rr-7>
Protocol available at: <https://osf.io/234kw/>. DOI 10.17605/OSF.IO/234KW

292. Tom Jefferson, Florence Bourgeois, Kyungwan Hong, Mark Jones, Haeyoung Lee, Vinay Prasad, O'Mareen Spence, Peter Doshi. Re-analysis of mortality in HPV vaccine trials: systematic review. PROSPERO 2019 CRD42019122348 Available from: http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42019122348

293. Doshi P, Jefferson T, Jones M et al. Additional trials within scope: a follow-up to our "Call to action: RIAT restoration of a previously unpublished methodology in Gardasil vaccine trials". <https://www.bmj.com/content/346/bmj.f2865/rr-9>

294. Carl Heneghan, Tom Jefferson. Gender-affirming hormone in children and adolescents. <https://blogs.bmj.com/bmjebmspotlight/> (Posted on [25th February 2019](#))

295. Jefferson T (2019). Sponsorship bias in clinical trials – growing menace or dawning realisation? *JLL Bulletin: Commentaries on the history of treatment evaluation*. (<https://www.jameslindlibrary.org/articles/sponsorship-bias-in-clinical-trials-growing-menace-or-dawning-realisation/>)

296. Jefferson T, Formoso G, Venturelli F, Vicentini M, Chiarolla E, Ballini L. Hadrontherapy for cancer. An overview of HTA reports and ongoing studies. *Recenti Prog Med* 2019; 110:566.
297. Doshi et al. Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: restoration of previously unpublished methodology. *BMJ Evidence-Based Medicine* 2020. <https://doi.org/10.1136/bmjebm-2019-111331>
298. Jørgensen, L., Gøtzsche, P.C. & Jefferson, T. Benefits and harms of the human papillomavirus (HPV) vaccines: systematic review with meta-analyses of trial data from clinical study reports. *Syst Rev* 9, 43 (2020). <https://doi.org/10.1186/s13643-019-0983-y>
299. Jørgensen, L., Gøtzsche, P.C. & Jefferson, T. Benefits and harms of the human papillomavirus (HPV) vaccines: comparison of trial data from clinical study reports with corresponding trial register entries and journal publications. *Syst Rev* 9, 42 (2020). <https://doi.org/10.1186/s13643-020-01300-1>.
300. Jefferson T, Demasi M, Doshi P. Statins for primary prevention: what is the regulators role? *Evid. Based Med.* 2020 0: p. [bmjebm-2019-111321v1-bmjebm-2019-111321](http://ebm.bmj.com/cgi/content/full/bmjebm-2019-111321). <http://ebm.bmj.com/cgi/content/full/bmjebm-2019-111321>.
301. Jefferson T. Covid 19—many questions, no clear answers. <https://blogs.bmj.com/bmj/2020/03/02/tom-jefferson-covid-19-many-questions-no-clear-answers/>
302. Jefferson T. Refining the “E” in EBM. *BMJ Evidence Based Medicine*.
- Tom Jefferson: Covid 19—we live in surreal times
<https://blogs.bmj.com/bmj/2020/03/05/tom-jefferson-covid-19-we-live-in-surreal-times/>
- Tom Jefferson: Covidair flight 19 from Rome to Oxford and back again.
<https://blogs.bmj.com/bmj/2020/03/10/tom-jefferson-covidair-flight-19-from-rome-to-oxford-and-back-again/>
303. Doshi P, Bourgeois F, Hong K, et al. Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: restoration of previously unpublished methodology. *BMJ Evidence-Based Medicine* Published Online First: 17 March 2020. doi: 10.1136/bmjebm-2019-111331
<https://doi.org/10.1136/bmjebm-2019-111331>
- Tom Jefferson: Covid-19—supermarket wisdom
<https://blogs.bmj.com/bmj/2020/03/20/tom-jefferson-covid-19-supermarket-wisdom/>
- COVID-19. Can Historical Antivirals Be of Use?

<https://www.cebm.net/covid-19/covid-19-can-historical-antivirals-be-of-use/>

COVID-19 – The Tipping Point

<https://www.cebm.net/covid-19/covid-19-the-tipping-point/>

COVID-19: What proportion are asymptomatic?

<https://www.cebm.net/covid-19/covid-19-what-proportion-are-asymptomatic/>

Problems in identifying the origins of an outbreak

<https://www.cebm.net/covid-19/problems-in-identifying-the-origins-of-an-outbreak/>

Covid 19 - Modelling the models

<https://www.cebm.net/covid-19/modelling-the-models/>

<https://www.cebm.net/covid-19/sars-cov-2-viral-load-and-the-severity-of-covid-19/>

Are COVID-19 patients in hospital or admitted to hospital?

<https://www.cebm.net/covid-19/are-covid-19-patients-in-hospital-or-admitted-to-hospital/>

303. Jefferson, T. (2020). Sponsorship bias in clinical trials: growing menace or dawning realisation? *Journal of the Royal Society of Medicine*, 113(4), 148–157.

<https://doi.org/10.1177/0141076820914242>

<http://journals.sagepub.com/share/2F3RYZGUQTJTADJT3AJW?target=10.1177/0141076820914242>

COVID-19 – The great plague of Lombardy – a not so distant resonance chamber

<https://www.cebm.net/covid-19/covid-19-the-great-plague-of-lombardy-a-not-so-distant-resonance-chamber/>

Is Lombardy the widow of Hampstead?

<https://www.cebm.net/covid-19/covid-19-is-lombardy-the-widow-of-hampstead/>

What does RCGP surveillance tell us about COVID-19 in the community

<https://www.cebm.net/covid-19/what-does-rcgp-surveillance-tell-us-about-covid-19-in-the-community/>

COVID-19 – Tracking European Mortality

<https://www.cebm.net/covid-19/covid-19-tracking-european-mortality/>

COVID 19 – The Widow of Hampstead Revisited

Effect of Latitude on COVID-19

Six Countries: Three-quarters of the COVID Deaths

COVID-19 Global Charts of Deaths

Covid 19 Epidemic “Waves”

<https://www.cebm.net/covid-19/covid-19-epidemic-waves/>

COVID 19 – Nova et Vetera: Lazarettos of Venice

<https://www.cebm.net/covid-19/covid-19-nova-et-vetera-lazarettos-of-venice/>

COVID-19: Unravelling the Uncertainties

<https://www.cebm.net/covid-19/covid-19-unravelling-the-uncertainties/>

COVID-19: Re-establishing ‘Fever Hospitals’

<https://www.cebm.net/covid-19/covid-19-reestablishing-fever-hospitals/>

COVID 19 - Understanding the Unknown in Acute Respiratory Infections

<https://www.cebm.net/covid-19/covid-19-understanding-the-unknown-in-acute-respiratory-infections/>

COVID-19: Have we forgotten our children in all this?

<https://www.cebm.net/covid-19/covid-19-have-we-forgotten-our-children-in-all-this/>

Let’s bring back Britain’s fever hospitals

<https://www.spectator.co.uk/article/Lets-bring-back-Britains-fever-hospitals>

Don’t place too much faith in models predicting another coronavirus wave

<https://www.telegraph.co.uk/politics/2020/05/16/dont-place-much-faith-models-predicting-another-coronavirus/>

Jefferson, T. Refining the E in EBM. Evid. Based Med. 2020 0: p. bmjebm-2020-111348v1-bmjebm-2020-111348

<http://ebm.bmjournals.com/cgi/content/full/bmjebm-2020-111348v1?ct>

Could mass testing for Covid-19 do more harm than good?

<https://www.spectator.co.uk/article/could-mass-testing-for-covid-19-do-more-harm-than-good->

Rome, 1 August 2020

Thomas Jefferson

EXHIBIT C

Curriculum vitae

for

Peter C. Gøtzsche

Updated October 2020

Contents

Personal data	3
Education	3
Appointments	3
Pregraduate	3
Postgraduate	3
Funding support	4
Awards and other academic honours	5
Some recent appearances in documentary films and satires	6
Publications	6
DrMedSci thesis	6
Academic books	6
Travel book	7
Articles in international journals with peer review	7
Articles without peer review	18
Book chapters	22
Correspondence, book reviews and similar	23
Secondary publications in Danish	34
Teaching	35
Pregraduate courses	35
Postgraduate courses	35
Lectures	39
Research mentorships	51
Scientific assignments	52
General	52
Editorial work	53
Chairman at congresses and meetings	54
Advisory Board member at international congresses	55
Expert witness in court cases	55
Management experience	55

Personal data

Peter Christian Gøtzsche, Kløvervang 39, 2970 Hørsholm, Denmark
 MD, DrMedSci, MSc (biology and chemistry), fil. mag.
 Director, Institute for Scientific Freedom, Copenhagen
 Visiting Professor, Institute of Health & Society, University of Newcastle, England

Email: pcg@scientificfreedom.dk
 Mobile: +45 53 64 20 66
 Websites: scientificfreedom.dk and deadlymedicines.dk
 Twitter: [@PGtzsche1](https://twitter.com/PGtzsche1)

Date of birth: 26 November 1949
 Family relation: Married, 2 children
 Citizenship: Danish

Education

1968 Student exam, Næstved Gymnasium. Marks: 9.0.
 1970 First part of biology, University of Copenhagen. Marks: ug-
 1970-73 Studies at the universities of Uppsala and Lund.
 1973 MSc in biology and chemistry, University of Lund.
 1974 MSc in biology and chemistry, University of Copenhagen.
 Special subject in entomology. Marks: 10.
 1984 MD, University of Copenhagen. Marks: 10.0.
 1987 Diploma Course in Tropical Medicine, Copenhagen (2 months; passed).
 1990 Thesis, University of Copenhagen.
 1995 Specialist in internal medicine.

Appointments

Pregraduate

01.02.72 - 31.05.72 Teacher, Norrmalmsskolan, Piteå, Sweden (2 months).
 01.09.74 - 31.01.75 Teacher, Falkonergårdens Gymnasium.
 01.04.75 - 31.03.77 Drug representative and product manager, Astra Group A/S.
 01.04.77 - 31.08.83 Head of medical department, Astra-Syntex A/S.

Postgraduate

01.06.84 - 30.09.84 Registrar, Bispebjerg Hospital, Med Dept C
 01.10.84 - 31.12.85 Registrar, Herlev Hospital, Surgical Dept
 01.06.85 - 31.08.85 Registrar, Herlev Hospital, Med Dept F
 01.01.86 - 31.08.86 Registrar, Rigshospitalet, Dept of Infect Dis
 01.09.86 - 30.09.87 Registrar, Hvidovre Hospital, Dept of Hepatology
 01.09.87 - 31.05.95 Chief, Nordic coordination office for AIDS trials, Rigshospitalet
 01.09.88 - 31.01.90 Junior Lecturer, Theory of Medicine, University of Copenhagen
 01.02.89 - 28.02.90 Registrar, Herlev Hospital, Med Dept C
 01.03.90 - 28.02.91 Registrar, Rigshospitalet, Med Dept A
 01.03.91 - 31.08.91 Registrar, Rigshospitalet, Med Dept L
 01.09.91 - 29.02.92 Registrar, Rigshospitalet, Dept of Infect Dis
 01.03.92 - 30.06.93 Senior registrar, Hvidovre Hospital, Dept of Rheumatology
 01.09.92 - 30.06.93 Lecturer, internal medicine, Hvidovre Hospital
 01.07.93 - 31.08.95 Senior registrar, Rigshospitalet, Dept of Infect Dis
 01.10.93 - 31.05.97 Senior House Medical Officer, Rigshospitalet

01.03.92 - 31.12.98	Editor, Bibliotek for Læger
01.02.90 - 31.03.10	Lecturer, Theory of Medicine, University of Copenhagen
01.10.93 - 30.04.19	Director, The Nordic Cochrane Centre
01.06.97 - 30.04.19	Chief physician, Rigshospitalet
01.04.10 - 30.04.19	Professor, Clinical Research Design and Analysis, University of Copenhagen

Funding support

1987	Danish Medical Research Council
1988	Danish Medical Research Council
1989	Danish Medical Research Council
1990	Danish Medical Research Council
1990	Danish Arthritis Foundation
1992	Medical Society in Copenhagen
1992	Fund for progress in Medical Science
1992	Danish Arthritis Foundation
1992	Fonden til Lægevidenskabens Fremme
1992	Todelegatet
1993	Rigshospitalet
1993	Research Foundation for Greater Copenhagen, Faroe Islands and Greenland.
1993	Ministry of Health
1994	Rigshospitalet
1994	European Union, BIOMED I
1995	European Union, BIOMED II
1995	Nordic Council of Ministers
1995	Rigshospitalet
1995	Copenhagen Hospital Foundation
1996	Danish Medical Research Council
1996	Nordic Council of Ministers
1996	Apothecary Foundation
1997	Fonden "En god start i livet"
1997	Nordic Council of Ministers
1997	Sygekassernes Helsefond
1997	Research Fund, Leo Pharmaceuticals
1998	State Institute for Medical Health Technology Assessment
1998	European Union, BIOMED 2
1998	Nordic Council of Ministers
1998	Danish Medical Research Council
1999	Nordic Council of Ministers
1999	Danish Ministry of Health
2000	Nordic Council of Ministers
2000	Ministry of Health
2000	Mindelegat (Mrs. Kay Lynæs)
2001	Nordic Council of Ministers
2001	Mindelegat (Mrs. Kay Lynæs)
2002	Mindelegat (Mrs. Kay Lynæs)
2002	Nordic Council of Ministers
2003	Danish Medical Research Council
2003	Danish Ministry of Health
2003	Rigshospitalet
2003	Nordic Council of Ministers
2004	Nordic Council of Ministers
2005	Nordic Council of Ministers
2006	Nordic Council of Ministers
2006	IMK Charitable Fund
2007	Danish Medical Research Council
2007	The Cancer Foundation
2008	Nordic Council of Ministers
2008	Sygekassernes Helsefond

2008	Rigshospitalet
2008	Danish Medical Research Council
2009	Rigshospitalet
2009	Capital Region of Denmark
2009	Agnes and Poul Friis' Foundation
2010	Augustinus Foundation
2010	Oticon Foundation
2010	Rigshospitalet
2010	Lundbeck Foundation
2010	Kontorchef Gerhard Brønsted's Travel Grant
2010	Tryg Foundation
2010	University of Copenhagen
2010	Sygekassernes Helsefond
2010	Julie von Müllen's Foundation
2010	The Free Research Councils
2011	The Cochrane Collaboration
2011	Rigshospitalet
2012	Rigshospitalet
2012	Tryg Foundation
2012	Sygekassernes Helsefond
2012	The Cochrane Collaboration
2014	Laura and John Arnold Foundation, Houston, Texas, PhD stipend
2014	Laura and John Arnold Foundation, Houston, Texas, PhD stipend
2015	University of Copenhagen, PhD stipend
2020	Laura and John Arnold Foundation, Houston, Texas, research

Awards and other academic honours

1992	Farmer from Stenløse, Peder Laurids Pedersen's donation.
1993	Co-founder of the Cochrane Collaboration
1997	Award of the year from the foundation "A good start in life".
1999	Henrik R. Wulff's prize from Danish Society for Theory in Medicine
2001	Skrabanek Foundation Prize, Trinity College, Dublin.
2001	Niels A. Lassen's prize.
2003	Queen Ingrid's Lecture, Åbenrå Hospital.
2004	Harry Boström Lecture, Swedish Society for Internal Medicine, Annual Meeting.
2006	Top-ten peer reviewer for British Medical Journal for the year 2006.
2007	Winner of the 2007 Society of Medical Writers' Academic Writing Award (for: Jørgensen KJ, Gøtzsche PC. Content of invitations to publicly funded screening mammography. <i>BMJ</i> 2006;332:538-41).
2009	Michael Berger Award, Düsseldorf.
2012	Winner of the annual Prescrire Prize for medical and pharmaceutical books (for: Gøtzsche PC. Mammography screening: truth, lies and controversy. London: Radcliffe Publishing; 2012:1-388).
2014	Winner of the Annual LAP Award (psychiatry award), Denmark.
2014	Co-founder and member of the Board of the Council for Evidence-based Psychiatry, London.
2014	Winner of the British Medical Association's Annual Book Award in the category Basis of Medicine for <i>Deadly Medicines and Organised Crime: How big pharma has corrupted health care.</i>
2014	Award from the International Society of Ethical Psychology and Psychiatry for "intellectual honesty and bravery in tackling the biomedical-industrial complex."
2015	Honourable Award, Consul General Ernst Carlsen's Foundation.
2015	Book of the Year, US Tributaries Radio, for <i>Deadly Psychiatry and Organised Denial.</i>
2015	Top ten finalist for the award "Dane of the year," nominated by psychiatric patients.
2016	HealthWatch Award, London
2016	Protector for StemmeHøremetværket (Hearing Voices Network)
2016	Co-founder and member of the Board, International Institute for Psychiatric Drug Withdrawal.
2017	Elected member of the Cochrane Governing Board, with the most votes of the 11 candidates.
2017	Honored Guests Award in Ethical Human Sciences and Services. Breggin: <i>Psychiatric Drug Facts.</i>
2018	Member of the Advisory Council of International Center for the Study of Patient-Oriented Psychiatry.
2018	Member of the Advisory Council of the Center for the Study of Empathic Therapy, Education & Living.

2020 Award from the Danish Patient Association for being the bravest doctor in the last decade.

Some recent appearances in documentary films and satires

1. The Daily Show, New York. 2014; Sept 16.
2. Frank Wittig Frank.Wittig@swr.de Südwestrundfunk
3. Lægemedelindustrien, NRK1, 2014.
4. Danmark på piller. Tre dokumentarer i DR TV 2014.
5. TV fra en anden planet, kanal 1, juni 2015. <http://kanal-1.dk/tv-fra-en-anden-planet/>.
6. Crazywise, 2016.
7. ”Lykkepillen”. [Dokumentarfilm om Silje Marie Strandberg](#). 2017.
8. [Cause of death: unknown](#). Documentary film about filmmaker’s sister, Renate Hoel. 2017.
9. [Diagnosing psychiatry](#). Documentary film about Peter Gøtzsche. 2018.
10. Speed Demons: Dying For Attention. 2018.
11. sera@westernmassrlc.org
12. The drug industry. sejucer@gmail.com. Russia 1
13. Michael Siewierski, New Roots Films. info@foodchoicesmovie.com 2018 launch.
14. [Medicating normal](#). Periscope Moving Pictures. 2019.

Publications

My scientific works have been cited about 50,000 times. My H-index is 67 according to Web of Science, September 2018, which means that 67 papers have been cited at least 67 times.

DrMedSci thesis

Bias in double-blind trials. Dan Med Bull 1990;37:329-36. Defended 10 May 1990 at the University of Copenhagen, Faculty for Health Sciences. Examiners: Professor, DrMedSci Ib Lorenzen and chief physician, DrMedSci Henrik R. Wulff.

Academic books

- Wulff HR, Gøtzsche PC. Rationel klinik. Evidensbaserede diagnostiske og terapeutiske beslutninger, 4. udgave. København: Munksgaard; 1997.
- Wulff HR, Gøtzsche PC. Rational Diagnosis and Treatment. Evidence-Based Clinical Decision-Making, 3rd edition. Oxford: Blackwell Scientific; 2000. Translated into Swedish, Spanish and Polish.
- Wulff HR, Gøtzsche PC. Rationel klinik. Evidensbaserede diagnostiske og terapeutiske beslutninger, 5. udgave. København: Munksgaard Danmark; 2006.
- Gøtzsche PC. Rational Diagnosis and Treatment. Evidence-Based Clinical Decision-Making, 4th edition. Chichester: Wiley; 2007.
- Gøtzsche PC. Mammography screening: truth, lies and controversy. London: Radcliffe Publishing; 2012. Winner of the Prescire Prize 2012.
- Gøtzsche PC. Deadly medicines and organised crime: How big pharma has corrupted health care. London: Radcliffe Publishing; 2013. Winner, British Medical Association’s Annual Book Award, Basis of Medicine in 2014. Translated into 15 languages.
- Gøtzsche PC. Dødelig medicin og organiseret kriminalitet: Hvordan medicinalindustrien har korrumpert sundhedsvæsenet. København: People's Press; 2013.
- Gøtzsche PC. Deadly psychiatry and organised denial. Copenhagen: People’s Press; 2015. Translated into many languages.
- Gøtzsche PC. Dødelig psykiatri og organiseret fornægtelse. København: People’s Press; 2015.
- Gøtzsche PC. Overlevelse i en overmedicineret verden: Find selv evidensen. København: People’s Press; 2018.
- Gøtzsche PC. Survival in an overmedicated world: look up the evidence yourself. Copenhagen: People’s Press; 2019
- Gøtzsche PC. Death of a whistleblower and Cochrane's moral collapse. Copenhagen: People’s Press; 2019.
- Gøtzsche PC. Vaccines: truth, lies and controversy. Copenhagen: People’s Press; 2020.
- Gøtzsche PC. Mental health survival kit and withdrawal from psychiatric drugs. Copenhagen: Institute for Scientific Freedom; 2020.

Gøtzsche PC. *Mentalt overlevelsesskit og udtræning af psykofarmaka*. København: Institute for Scientific Freedom; 2020.

Travel book

Gøtzsche PC. *På safari i Kenya*. København: Samlerens forlag; 1985.

Articles in international journals with peer review

Total number of citations: about 50,000; H-index: 67 (Web of Science, September 2018).

1. Andersen LA, Gøtzsche PC. Naproxen and aspirin in acute musculoskeletal disorders: a double-blind, parallel study in sportsmen. *Pharmatherapeutica* 1984;3:535-41.
2. Sindet-Pedersen S, Petersen JK, Gøtzsche PC. Incidence of pain conditions in dental practice in a Danish county. *Community Dent Oral Epidemiol* 1985;13:244-6.
3. Geisler C, Gøtzsche PC, Hansen SS, Juul K, Plesner AM, Nissen NI. Naproxen has greater antipyretic effect on fever related to Hodgkin's disease than to other tumours or to infection. *Scand J Haematol* 1985;35:325-8.
4. Sindet-Pedersen S, Petersen JK, Gøtzsche PC, Christensen H. A double-blind, randomized study of naproxen and acetylsalicylic acid after surgical removal of impacted lower third molars. *Int J Oral Maxillofac Surg* 1986;15:389-94.
5. Gøtzsche PC, Hvidberg EF, Juul P. Rational choice of dose: insufficient background knowledge? *Ration Drug Ther* 1986;20:1-7.
6. Gøtzsche PC. Reference bias in reports of drug trials. *BMJ* 1987;295:654-6.
7. Fogh S, Schapira A, Bygbjerg IC, Jepsen S, Mordhorst CH, Kuijlen K, Ravn P, Rønn A, Gøtzsche PC. Malaria chemoprophylaxis in travellers to east Africa: a comparative prospective study of chloroquine plus proguanil with chloroquine plus sulfadoxine/pyrimethamine. *BMJ* 1988;296:820-2.
8. Gøtzsche PC, Hørding M. Condoms to prevent HIV transmission do not imply truly safe sex. *Scand J Infect Dis* 1988;20:233-4.
9. Gøtzsche PC, Andreasen F, Egsmose C, Lund B. Steady state pharmacokinetics of naproxen in elderly rheumatics compared with young volunteers. *Scand J Rheumatol* 1988;17:11-6.
10. Gøtzsche PC, Bygbjerg IC, Olesen B, Møller LH, Salim YS, Faber V. Yield of diagnostic tests of opportunistic infections in AIDS: a survey of 33 patients. *Scand J Infect Dis* 1988;20:395-402.
11. Andersson PG, Hinge HH, Johansen O, Andersen CU, Lademann A, Gøtzsche PC. Double-blind study of naproxen vs placebo in the treatment of acute migraine attacks. *Cephalalgia* 1989;9:29-32.
12. Gøtzsche PC. Patients' preference in indomethacin trials: an overview. *Lancet* 1989;i:88-91.
13. Gøtzsche PC. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal, antiinflammatory drugs in rheumatoid arthritis. *Controlled Clin Trials* 1989;10:31-56 (amendment:356).
14. Gøtzsche PC. Multiple publication in reports of drug trials. *Eur J Clin Pharmacol* 1989;36:429-32.
15. Gøtzsche PC. Review of dose-response studies of NSAIDs in rheumatoid arthritis. *Dan Med Bull* 1989;36:395-9.
16. Gøtzsche PC. Meta-analysis of grip strength: most common, but superfluous variable in comparative NSAID trials. *Dan Med Bull* 1989;36:493-5.
17. Hørding M, Gøtzsche PC, Bygbjerg I, Pedersen M, Faber V, Berg K. Lack of immunomodulating effect of disulfiram in HIV positive patients. *Internat J Immunopharmacol* 1990;12:145-7.
18. Pedersen C, Gerstoft J, Tauris P, Lundgren JD, Gøtzsche PC, Buhl M, Salim Y, Schmidt K. Opportunistic infections and malignancies in 231 Danish AIDS patients. *AIDS* 1990;4:233-8.
19. Jørgensen A, Shao J, Maselle S, Yangi E, Thomsen A, Matunda S, Bygbjerg I, Gøtzsche P, Svendsen J, Skinhøj P, Faber V. Evaluation of simple tests for detection of HIV antibodies: analysis of interobserver variation in Tanzania. *Scand J Infect Dis* 1990;22:283-5.
20. Jørgensen AF, Mwakyusa D, Cegielski P, Gøtzsche P, Hørding M, Lallinger G, Mbaga I, Pallangyo K, Richter C, Shao J, Bygbjerg I, Skinhøj P, Faber V. The effect of fusidic acid on Tanzanian patients with AIDS. *AIDS* 1990;4:1037-8.
21. Jørgensen AF, Jensen VG, Shao JF, Maselle S, Mbaga IM, Mwakyusa DH, Gøtzsche PC, Richter C, Pallangyo K, Cegielski P, Lallinger G, Bygbjerg I, Skinhøj P, Faber V. Beta-2-microglobulin as a prognostic marker for patients with AIDS in Dar es Salaam, Tanzania. *AIDS* 1990;4:1168-9.
22. Gøtzsche PC. Sensitivity of effect variables in rheumatoid arthritis: a meta-analysis of 130 placebo controlled NSAID trials. *J Clin Epidemiol* 1990;43:1313-8.
23. Hørding M, Gøtzsche PC, Christensen LD, Bygbjerg IC, Faber V. Double-blind trial of bestatin in HIV-positive patients. *Biomed Pharmacother* 1990;44:475-8.

24. Pedersen C, Gerstoft J, Tauris P, Lundgren JD, Gøtzsche PC, Buhl M, Salim Y, Schmidt K, Nielsen JO. Trends in survival of Danish AIDS patients from 1981 to 1989. *AIDS* 1990;4:1111-6.
25. Gøtzsche PC, Kelbæk H, Vissing SF, Nielsen SL, Munck O, Christensen NJ, Lyngsøe J, Mathiesen ER. Acute cardiovascular effects of insulin in hyperglycaemic type I diabetics. *Scand J Clin Lab Invest* 1991;51:93-7.
26. Gøtzsche PC. Patients' views on the least acceptable increase in survival with zidovudine treatment. *Scand J Infect Dis* 1991;23:509-10.
27. Gjørup IE, Gøtzsche PC, Baden H, Andersen B. Surgical treatment of morbid obesity: a survey of overall outcome 1968-89. *Dan Med Bull* 1991;38:405-7.
28. Nielsen C, Nielsen CM, Petersen JL, Gøtzsche PC, Pedersen C, Arendrup M, Vestergaard BF. Isolation of HIV from cultures of purified CD4+ lymphocytes. *J Virol Methods* 1991;35:15-25.
29. Gøtzsche PC, Lange B. Comparison of search strategies for recalling double-blind trials from MEDLINE. *Dan Med Bull* 1991;38:476-8.
30. Nordic Medical Research Councils' HIV Therapy Group. Double-blind dose-response study of zidovudine in AIDS and advanced HIV infection. *BMJ* 1992;304:13-7 (manuscript and scientific coordinator: PC Gøtzsche).
31. Gøtzsche PC, Pødenphant J, Olesen M, Halberg P. Meta-analysis of second-line antirheumatic drugs: sample size bias and uncertain benefit. *J Clin Epidemiol* 1992;45:587-94.
32. Nielsen C, Gøtzsche PC, Nielsen CM, Gerstoft J, Vestergaard BF. Development of resistance to zidovudine in HIV strains isolated from CD4+ lymphocytes and plasma during therapy. *Antiviral Res* 1992;18:303-16.
33. Gøtzsche PC, Nielsen C, Gerstoft J, Nielsen CM, Vestergaard BF. Trend towards decreased survival in patients infected with HIV resistant to zidovudine. *Scand J Infect Dis* 1992;24:563-5.
34. Gøtzsche PC, Pødenphant J, Olesen M, Halberg P. Critique of meta-analysis of second-line antirheumatic drugs. *J Clin Epidemiol* 1993;46:319-21.
35. Rasmussen MH, Andersen T, Breum L, Gøtzsche PC, Hilsted J. Cimetidine suspension as adjuvant to energy restricted diet in treating obesity. *BMJ* 1993;306:1093-6.
36. Gøtzsche PC. Zidovudine in HIV infection. *Ann Med* 1993;25:213-4.
37. Rasmussen MH, Andersen T, Breum L, Hilsted J, Gøtzsche PC. Observer variation in measurements of waist-hip ratio and the abdominal sagittal diameter. *Int J Obes* 1993;17:323-7.
38. Gøtzsche PC. Meta-analysis of NSAIDs: contribution of drugs, doses, trial designs, and meta-analytic techniques. *Scand J Rheumatol* 1993;22:255-60.
39. Gøtzsche PC. Is there logic in the placebo? *Lancet* 1994;344:925-6.
40. Gøtzsche PC. Steroids and peptic ulcer: an end to the controversy? *J Intern Med* 1994;236:599-601.
41. The Standards of Reporting Trials Group. A proposal for structured reporting of randomized controlled trials. *JAMA* 1994;272:1926-31 (member of writing committee).
42. Gøtzsche PC, Gjørup I, Bonnén H, Brahe NEB, Becker U, Burcharth F. Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis. *BMJ* 1995;310:1495-8.
43. Ullum H, Gøtzsche PC, Victor J, Dickmeiss E, Skinhøj P, Pedersen BK. Defective natural immunity: an early manifestation of human immunodeficiency virus infection. *J Exp Med* 1995;182:789-99.
44. Mulward S, Gøtzsche PC. Sample size of randomized double-blind trials 1976-1991. *Dan Med Bull* 1996;43:96-8.
45. Gøtzsche PC, Liberati A, Luca P, Torri V. Beware of surrogate outcome measures. *Int J Technol Ass Health Care* 1996;12:238-46.
46. Gøtzsche PC, Hansen M, Stoltenberg M, Svendsen A, Beier J, Faarvang KL, et al. Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. *Scand J Rheumatol* 1996;25:194-9.
47. Ullum H, Diamant M, Victor J, Gøtzsche PC, Bendtzen K, Skinhøj P, Pedersen BK. Increased circulating levels of interleukin-6 in HIV seropositive subjects. *J AIDS* 1996;13:93-9.
48. Gøtzsche PC. Blinding during data analysis and writing of manuscripts. *Controlled Clin Trials* 1996;17:285-90.
49. Gøtzsche PC, Johansen HK. Antifungal prophylactic or empiric therapy vs placebo or no treatment in cancer patients with neutropenia (Cochrane Review). In: *The Cochrane Library, Issue 2*. Oxford: Update Software; 1997. Updated quarterly.
50. Gøtzsche PC. Somatostatin or octreotide vs placebo in bleeding oesophageal varices (Cochrane Review). In: *The Cochrane Library, Issue 3*. Oxford: Update Software; 1997. Updated quarterly.
51. Gøtzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis (Cochrane Review). In: *The Cochrane Library, Issue 3*. Oxford: Update Software; 1997. Updated quarterly.

52. Christensen PM, Gøtzsche PC, Brøsen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. *Eur J Clin Pharmacol* 1997;51:389-93.
53. Gøtzsche PC, Johansen HK. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. *BMJ* 1997;314:1238-44.
54. Gerstoft J, Melander H, Bruun JN, Pedersen C, Gøtzsche PC, Berglund O, et al. Alternating treatment with didanosine and zidovudine versus either drug alone for the treatment of advanced HIV infection: the ALTER study. *Scand J Infect Dis* 1997;29:121-8.
55. Ullum H, Victor J, Katzenstein TL, Gerstoft J, Gøtzsche PC, Bendtzen K, Skinhøj P, Pedersen BK. Decreased short-term production of tumor necrosis factor- α and interleukin-1 α in human immunodeficiency virus-seropositive subjects. *J Infect Dis* 1997;175:1507-10.
56. Ullum H, Cozzi-Lepri A, Bendtzen K, Victor J, Gøtzsche PC, Phillips AN, Skinhøj P, Klarlund Pedersen B. Low production of interferon gamma is related to disease progression in HIV infection: evidence from a cohort of 347 HIV-infected individuals. *AIDS Res Hum Retroviruses* 1997;13:1039-46.
57. Hammarquist C, Burr ML, Gøtzsche PC. House dust mites and control measures in the management of asthma (Cochrane Review). In: *The Cochrane Library, Issue 3*. Oxford: Update Software; 1998. Updated quarterly.
58. Gøtzsche PC. Somatostatin or octreotide vs placebo in bleeding oesophageal varices (Cochrane Review). In: *The Cochrane Library, Issue 1*. Oxford: Update Software; 1998. Updated quarterly.
59. Gøtzsche PC, Johansen HK. Meta-analysis of short term low dose prednisolone versus placebo and non-steroidal, anti-inflammatory drugs in rheumatoid arthritis. *BMJ* 1998;316:811-8.
60. Rønn AM, Rønne-Rasmussen J, Gøtzsche PC, Bygbjerg IC. Neuropsychiatric manifestations after mefloquine therapy for *Plasmodium falciparum* malaria: comparing a retrospective and a prospective study. *Trop Med Int Health* 1998; 3:83-8.
61. Gøtzsche PC, Hammarquist C, Burr M. House dust mite control measures in the management of asthma: meta-analysis. *BMJ* 1998;317:1105-10.
62. Hróbjartsson A, Gøtzsche PC, Gluud C. The controlled trial turns 100 years: Fibiger's trial of serum treatment of diphtheria. *BMJ* 1998;317:1243-5.
63. Christensen PM, Gøtzsche PC, Brøsen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis. *Pharmacogenetics* 1998;8:473-9.
64. Astrup A, Gøtzsche PC, van de Werken K, Ranneries C, Toubro S, Raben A, Buemann B. Meta-analysis of resting metabolic rate in formerly obese subjects. *Am J Clin Nutr* 1999;69:1117-22.
65. Johansen HK, Gøtzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. *JAMA* 1999;282:1752-9.
66. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 1999;2:430-6.
67. Gøtzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? *Lancet* 2000;355:129-34.
68. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. *BMJ* 2000;320:1058-61.
69. Gøtzsche PC. Do patients with osteoarthritis get the clinical research they need? *Ann Rheum Dis* 2000;59:407-8.
70. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2000;3:521-8 (updated).
71. Gøtzsche PC. Why we need a broad perspective on meta-analysis: It may be crucially important for patients. *BMJ* 2000;321:585-6.
72. Johansen HK, Gøtzsche PC. Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients (Cochrane Review). In: *The Cochrane Library, Issue 1*. Oxford: Update Software; 2000.
73. Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients (Cochrane Review). In: *The Cochrane Library, Issue 1*. Oxford: Update Software; 2000.
74. Johansen HK, Gøtzsche PC. Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia (Cochrane Review). In: *The Cochrane Library, Issue 1*. Oxford: Update Software; 2000.
75. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer (Cochrane Review). In: *The Cochrane Library, Issue 2*. Oxford: Update Software; 2000. (updated).
76. Olesen V, Engell L, Jensen KL, Gøtzsche PC. Randomised clinical trials in the Scandinavian Journal of Rheumatology. *Scand J Rheumatol* 2000;29:349-51.

77. Gøtzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software; 2001. (updated).
78. Gøtzsche PC. Reporting of outcomes in arthritis trials measured on ordinal and interval scales is inadequate in relation to meta-analysis. *Ann Rheum Dis* 2001;60:349-52.
79. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang T, for the CONSORT Group. The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. *Ann Intern Med* 2001;134:663-94.
80. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. *N Engl J Med* 2001;344:1594-602.
81. Gøtzsche PC, Johansen HK, Burr ML, Hammarquist C. House dust mite control measures for asthma (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software; 2001. (updated).
82. Olsen O, Middleton P, Ezzo J, Gøtzsche PC, Hadhazy V, Herxheimer A, et al. Quality of Cochrane reviews: assessment of sample from 1998. *BMJ* 2001;323:829-32.
83. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2001;5:800-7 (updated).
84. Hróbjartsson A, Gøtzsche PC. Core belief in powerful effects of placebo interventions is in conflict with no evidence of important effects in a large systematic review. *Adv Mind-Body Med* 2001;17:312-8.
85. Olsen O, Gøtzsche PC. Cochrane review on screening for breast cancer with mammography. *Lancet* 2001;358:1340-2.
86. Olsen O, Gøtzsche PC. Systematic review of screening for breast cancer with mammography. *Lancet* 2001 (<http://image.thelancet.com/extras/fullreport.pdf>).
87. Olsen O, Gøtzsche PC. Screening for breast cancer with mammography (Cochrane Review). In: The Cochrane Library, Issue 4. Oxford: Update Software, 2001.
88. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2001;6:894-901 (updated).
89. Gøtzsche PC. Somatostatin analogues for acute bleeding oesophageal varices (Cochrane Review). In: The Cochrane Library, Issue 1, 2002. Oxford: Update Software (updated).
90. Johansen HK, Gøtzsche PC. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients (Cochrane Review). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software. (updated).
91. Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients (Cochrane Review). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software. (updated).
92. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer (Cochrane Review). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software. (updated).
93. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2002;7:1063-70.
94. Mowatt G, Shirran L, Grimshaw JM, Rennie D, Flanagan A, Yank V, MacLennan G, Gøtzsche PC, Bero LA. Prevalence of honorary and ghost authorship in Cochrane reviews. *JAMA* 2002;287:2769-71.
95. Gøtzsche PC. Medicalisation of risk factors. *BMJ* 2002;324:890-1.
96. McDonald S, Lefebvre C, Antes G, Galandi D, Gøtzsche P, Hammarquist C, Haugh M, Jensen KL, Kleijnen J, Loep M, Pistotti V, Rütther A. The contribution of handsearching European general health care journals to the Cochrane Controlled Trials Register. *Evaluation & The Health Profession* 2002;25:65-76.
97. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2002;8:1203-11 (updated).
98. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2003;9:1292-300.
99. Hróbjartsson A, Gøtzsche PC. Placebo treatment versus no treatment (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software.
100. Kösters JP, Gøtzsche PC. Regular self-examination or clinical examination for early detection of breast cancer (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.
101. Gøtzsche PC. The debate on breast cancer screening with mammography is important. *J Am Coll Radiol* 2004;1:8-14.
102. Wienecke T, Gøtzsche PC. Paracetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 1, 2004. Chichester: John Wiley & Sons, Ltd.

103. Jørgensen KJ, Gøtzsche PC. Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study. *BMJ* 2004;328:148-51.
104. Gøtzsche PC. On the benefits and harms of screening for breast cancer. *Int J Epidemiol* 2004;33:56-64.
105. Johansen HK, Nørregaard L, Gøtzsche PC, Pressler T, Koch C, Høiby N. Antibody response to *Pseudomonas aeruginosa* in cystic fibrosis patients: A marker of therapeutic success?—A 30-year Cohort study of survival in Danish CF patients after onset of chronic *P. aeruginosa* lung infection. *Pediatr Pulmonol* 2004;37:427-32.
106. Chan A-W, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. *JAMA* 2004;291:2457-65.
107. Pildal J, Gøtzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. *Clin Infect Dis* 2004;39:38-46.
108. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2004;11:1551-9 (updated).
109. Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions (Cochrane Review). In: *The Cochrane Library*, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd (updated).
110. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. *J Intern Med* 2004;256:91-100.
111. Gøtzsche PC, Johansen HK, Schmidt LM, Burr ML. House dust mite control measures for asthma. *The Cochrane Database of Systematic Reviews* 2004, Issue 4. Art. No.: CD001187.
112. Ioannidis JPA, Evans SJW, Gøtzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D, for the CONSORT Group. Better reporting of harms in randomized trials: An extension of the CONSORT statement. *Ann Intern Med* 2004;141:781-8.
113. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2004;12:1702-10 (updated).
114. Schmidt LM, Gøtzsche PC. Of mites and men: reference bias in narrative review articles: a systematic review. *J Fam Pract* 2005;54:334-8.
115. Pildal J, Chan A-W, Hróbjartsson A, Forfang E, Altman DG, Gøtzsche PC. Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study. *BMJ* 2005;330:1049-52.
116. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2005;13:1525-32 (updated).
117. Karmisholt K, Gyntelberg F, Gøtzsche PC. Physical activity for primary prevention of disease: systematic reviews of randomised clinical trials. *Dan Med Bull* 2005;52:86-9.
118. Karmisholt K, Gøtzsche PC. Physical activity for secondary prevention of disease: systematic reviews of randomised clinical trials. *Dan Med Bull* 2005;52:90-4.
119. Gøtzsche PC. Research integrity and pharmaceutical industry sponsorship: trial registration, transparency and less reliance on industry trials are essential. *Med J Aust* 2005;182:549-50.
120. Gluud LL, Sørensen TIA, Gøtzsche PC, Gluud C. The journal impact factor as a predictor of trial quality and outcomes: cohort study of hepato-biliary randomized clinical trials. *Am J Gastroenterol* 2005;100:2431-5.
121. Haug C, Gøtzsche PC, Schroeder TV. Registries and registration of clinical trials. *N Engl J Med* 2005;353:2811-2.
122. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2005;14:1498-1505 (updated).
123. Jørgensen KJ, Johansen HK, Gøtzsche PC. Voriconazole versus amphotericin B in cancer patients with neutropenia. *The Cochrane Database of Systematic Reviews* 2006, Issue 1. Art. No.: CD004707.
124. Jørgensen KJ, Johansen HK, Gøtzsche PC. Flaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotations. *Trials* 2006;7:3.
125. Jørgensen KJ, Gøtzsche PC. Content of invitations to publicly funded screening mammography. *BMJ* 2006;332:538-41.
126. Gøtzsche PC. Lessons from and cautions about noninferiority and equivalence randomized trials. *JAMA* 2006;295:1171-3.
127. Hróbjartsson A, Gøtzsche PC. Unsubstantiated claims of large effects of placebo on pain: serious errors in meta-analysis of placebo analgesia mechanism studies. *J Clin Epidemiol* 2006;59:336-8.
128. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan A-W. Constraints on publication rights in industry-initiated clinical trials. *JAMA* 2006;295:1645-6.
129. Johansen HK, Gøtzsche PC, Keogan MT. Vaccines for preventing infection with *Pseudomonas aeruginosa* in people with cystic fibrosis. *The Cochrane Database of Systematic Reviews* 2006, Issue 2. Art. No.: CD001399 (updated).

130. Gøtzsche PC. Believability of relative risks and odds ratios in abstracts: cross-sectional study. *BMJ* 2006;333:231-4.
131. Due AK, Johansen HK, Gøtzsche PC. Fungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents. *BMC Medical Research Methodology* 2006;6:40.
132. Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. *BMJ* 2006;333:782-5.
133. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. *Cochrane Database of Systematic Reviews* 2006, Issue 4. Art. No.: CD001877.
134. Haedersdal M, Gøtzsche PC. Laser and photoepilation for unwanted hair growth. *Cochrane Database of Systematic Reviews* 2006, Issue 4. Art. No.: CD004684.
135. Zahl P-H, Gøtzsche PC, Andersen JM, Mæhlen J. Results of the Two-County trial of mammography screening are not compatible with contemporaneous official Swedish breast cancer statistics. *Dan Med Bull* 2006;53:438-40.
136. Gøtzsche PC, Mæhlen J, Zahl P-H. What is publication? *Lancet* 2006;368:1854-5.
137. Gøtzsche PC, Hrobjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Ghost authorship in industry-initiated randomised trials. *PLoS Med* 2007; 4(1):e19.
138. Gøtzsche PC, Hrobjartsson A, Maric K, Tendal B. Data extraction errors in meta-analyses that use standardized mean differences. *JAMA* 2007; 298(4):430-7.
139. Hrobjartsson A, Gøtzsche PC. Powerful spin in the conclusion of Wampold et al.'s re-analysis of placebo versus no-treatment trials despite similar results as in original review. *J Clin Psychol* 2007; 63(4):373-7.
140. Jørgensen KJ, Klahn A, Gøtzsche PC. Are benefits and harms in mammography screening given equal attention in scientific articles? A cross-sectional study. *BMC Med* 2007; 5:12.
141. Pildal J, Hrobjartsson A, Jørgensen KJ, Hilden J, Altman DG, Gøtzsche PC. Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. *Int J Epidemiol* 2007; 36(4):847-57.
142. Vandembroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Epidemiology* 2007; 18(6):805-35.
143. Vandembroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *PLoS Med* 2007; 4(10):e297.
144. Vandembroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Ann Intern Med* 2007; 147(8):W163-94.
145. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet* 2007; 370(9596):1453-7.
146. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Epidemiology* 2007; 18(6):800-4.
147. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Bull World Health Organ* 2007; 85(11):867-72.
148. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Prev Med* 2007; 45(4):247-51.
149. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ* 2007; 335(7624):806-8.
150. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *PLoS Med* 2007; 4(10):e296.
151. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med* 2007; 147(8):573-7.
152. Welch HG, Woloshin S, Schwartz LM, Gordis L, Gøtzsche PC, Harris R, Kramer BS, Ransohoff DF. Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. *Arch Intern Med* 2007; 167(21):2289-95.

153. Gøtzsche PC, Johansen HK. House dust mite control measures for asthma: systematic review. *Allergy* 2008 Jun;63(6):646-59.
154. Lundh A, Gøtzsche PC. Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies. *BMC Med Res Methodol* 2008 Apr 21;8:22.
155. Gøtzsche PC, Johansen HK. House dust mite control measures for asthma. *Cochrane Database Syst Rev* 2008; (2):CD001187.
156. Gøtzsche PC, Hróbjartsson A. Somatostatin analogues for acute bleeding oesophageal varices. *Cochrane Database Syst Rev* 2008; (3):CD000193.
157. Johansen HK, Gøtzsche PC. Vaccines for preventing infection with *Pseudomonas aeruginosa* in cystic fibrosis. *Cochrane Database Syst Rev* 2008; (4):CD001399.
158. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol* 2008 Apr;61(4):344-9.
159. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; Iniciativa STROBE. [The Strengthening the Reporting of Observational Studies in Epidemiology [STROBE] statement: guidelines for reporting observational studies]. *Gac Sanit* 2008 Mar-Apr;22(2):144-50.
160. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. [The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies]. *Rev Esp Salud Publica* 2008; 82(3):251-9.
161. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. [The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting of observational studies]. *Internist (Berl)* 2008; 49(6):688-93.
162. Zahl PH, Jørgensen KJ, Maehlen J, Gøtzsche PC. Biases in estimates of overdiagnosis due to mammography screening. *Lancet Oncol* 2008 Mar;9(3):199-201.
163. Jørgensen AW, Maric KL, Tendal B, Faurschou A, Gøtzsche PC. Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: differences in methodological quality and conclusions. *BMC Med Res Methodol* 2008; 8:60.
164. Chan A-W, Hróbjartsson A, Jørgensen KJ, Gøtzsche PC, Altman DG. Reporting of sample size calculations and data analysis methods in randomized trials: comparison of publications with protocols. *BMJ* 2008;337:1404-7.
165. Madsen MV, Gøtzsche PC, Hróbjartsson A. Acupuncture treatment for pain: systematic review of randomised clinical trials with acupuncture, placebo acupuncture, and no acupuncture groups. *BMJ* 2008;338:330-3.
166. Gøtzsche PC. Readers as research detectives. *Trials* 2009;10:2.
167. Gøtzsche P, Hartling OJ, Nielsen M, Brodersen J, Jørgensen KJ. Breast screening: the facts - or maybe not. *BMJ* 2009;338:446-8.
168. Krogsbøll LT, Hróbjartsson A, Gøtzsche PC. Spontaneous improvement in randomised clinical trials: meta-analysis of three-armed trials comparing no treatment, placebo and active intervention. *BMC Medical Research Methodology* 2009, 9:1.
169. Gøtzsche PC, Kassirer JP, Woolley KL, Wager E, Jacobs A, Gertel A, Hamilton C. What should be done to tackle ghostwriting in the medical literature? *PLoS Med* 2009;6(2):e23.
170. Jørgensen KJ, Brodersen J, Hartling OJ, Nielsen M, Gøtzsche PC. Informed choice requires information about both benefits and harms. *J Med Ethics* 2009;35(4):268-9.
171. Vandenbroucke JP, Von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; Iniciativa STROBE. [Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration]. *Gac Sanit.* 2009 Mar-Apr;23(2):158.
172. Jørgensen KJ, Gøtzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. *BMJ* 2009;339:b2587.
173. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *Ann Intern Med* 2009 Aug 18;151(4):W65-94.
174. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med* 2009 Jul 21;6(7):e1000100.
175. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol* 2009;62(10):e1-34.

176. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009 Jul 21;339:b2700.
177. Tendal B, Higgins JP, Jüni P, Hróbjartsson A, Trelle S, Nüesch E, Wandel S, Jørgensen AW, Gesser K, Ilsøe-Kristensen S, Gøtzsche PC. Disagreements in meta-analyses using outcomes measured on continuous or rating scales: observer agreement study. *BMJ* 2009 Aug 13;339:b3128.
178. Hróbjartsson A, Pildal J, Chan AW, Haahr MT, Altman DG, Gøtzsche PC. Reporting on blinding in trial protocols and corresponding publications was often inadequate but rarely contradictory. *J Clin Epidemiol*. 2009 Sep;62(9):967-73.
179. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. *Cochrane Database of Systematic Reviews* 2009, Issue 4. Art. No.: CD001877.
180. Jørgensen KJ, Hróbjartsson A, Gøtzsche PC. Divine intervention? A Cochrane review on intercessory prayer gone beyond science and reason. *J Negat Results Biomed* 2009 Jun 10;8:7.
181. Jørgensen KJ, Zahl P-H, Gøtzsche PC. Overdiagnosis in organised mammography screening in Denmark: a comparative study. *BMC Women's Health* 2009;9:36.
182. Jørgensen KJ, Gøtzsche PC. Who evaluates public health programmes? A review of the NHS Breast Screening Programme. *J R Soc Med* 2010;103:14-20.
183. Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. *Cochrane Database of Systematic Reviews* 2010, Issue 1. Art. No.: CD003974.
184. Jørgensen KJ, Zahl P-H, Gøtzsche PC. Breast cancer mortality in organised mammography screening in Denmark: comparative study. *BMJ* 2010;340:c1241.
185. Brodersen J, Jørgensen KJ, Gøtzsche PC. The benefits and harms of screening for cancer with a focus on breast screening. *Pol Arch Med Wewn* 2010;120:89-94.
186. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. *Obstet Gynecol* 2010 May;115(5):1063-70.
 - a. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *PLoS Med* 2010 Mar 24;7(3):e1000251.
187. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. *J Clin Epidemiol* 2010 Aug;63(8):834-40.
188. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. *Ann Intern Med* 2010 Jun 1;152(11):726-32.
189. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *BMC Med* 2010 Mar 24;8:18.
190. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *Trials* 2010 Mar 24;11:32.
191. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010 Mar 23;340:c332.
192. Gøtzsche PC, Berg S. Sleep apnoea: from person to patient, and back again. *BMJ* 2010 Mar 30;340:c360.
193. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010 Mar 23;340:c869.
194. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG; Consolidated Standards of Reporting Trials Group. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. *J Clin Epidemiol* 2010 Aug;63(8):e1-37.
195. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. [CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials (Chinese version)]. *Zhong Xi Yi Jie He Xue Bao* 2010;8(8):701-41.
196. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int J Surg* 2010;8(5):336-41.
197. Jørgensen AW, Jørgensen KJ, Gøtzsche PC. Unbalanced reporting of benefits and harms in abstracts on rofecoxib. *Eur J Clin Pharmacol* 2010 Apr;66(4):341-7.
198. Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. *Cochrane Database Syst Rev* 2010;(7):CD007851.
199. Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy: systematic review. *Dan Med Bull* 2010;57(9):A4175.

200. Lundh A, Barbateskovic M, Hrobjartsson A, Gøtzsche PC. Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue - cohort study. *PLoS Med* 2010;7(10):e1000354.
201. Gøtzsche PC, Delamothe T, Godlee F, Lundh A. Adequacy of authors' replies to criticism raised in electronic letters to the editor: cohort study. *BMJ* 2010 Aug 10;341:c3926.
202. Cordoba G, Schwartz L, Woloshin S, Bae H, Gøtzsche PC. Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review. *BMJ* 2010;341:c3920.
203. la Cour JL, Brok J, Gøtzsche PC. Inconsistent reporting of surrogate outcomes in randomised clinical trials: cohort study. *BMJ* 2010;341:c3653.
204. Lundh A, Gøtzsche PC. Sponsorship of medical textbooks by drug or device companies. *CMEJ* 2011;1:e10-7.
205. Gøtzsche PC. Time to stop mammography screening? *CMAJ* 2011;183:1957-8.
206. Gøtzsche PC, Jørgensen AW. Opening up data at the European Medicines Agency. *BMJ* 2011;342:d2686.
207. Gøtzsche PC, Jørgensen KJ. The Breast Screening Programme and misinforming the public. *J R Soc Med* 2011;104(9):361-9.
208. Gøtzsche PC. Niels Finsen's treatment for lupus vulgaris. *J R Soc Med* 2011;104(1):41-2.
209. Gøtzsche PC. Relation between breast cancer mortality and screening effectiveness: systematic review of the mammography trials. *Dan Med Bull* 2011;58(3):A4246.
210. Higgins JP, Altman DG, Gøtzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928.
211. Jørgensen KJ, Keen JD, Gøtzsche PC. Is mammographic screening justifiable considering its substantial overdiagnosis rate and minor effect on mortality? *Radiology* 2011;260(3):621-7.
212. Lundh A, Krogsbøll LT, Gøtzsche PC. Access to data in industry-sponsored trials. *Lancet* 2011;378(9808):1995-6.
213. Nielsen M, Gøtzsche P. An analysis of psychotropic drug sales. Increasing sales of selective serotonin reuptake inhibitors are closely related to number of products. *Int J Risk Saf Med* 2011;23(2):125-32.
214. Schroll JB, Moustgaard R, Gøtzsche PC. Dealing with substantial heterogeneity in Cochrane reviews. Cross-sectional study. *BMC Med Res Methodol* 2011;11:22.
215. Suhrke P, Maehlen J, Schlichting E, Jørgensen KJ, Gøtzsche PC, Zahl PH. Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data. *BMJ* 2011;343:d4692.
216. Tendal B, Nuesch E, Higgins JP, Juni P, Gøtzsche PC. Multiplicity of data in trial reports and the reliability of meta-analyses: empirical study. *BMJ* 2011;343:d4829.
217. Zahl PH, Gøtzsche PC, Maehlen J. Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study. *Lancet Oncol* 2011;12(12):1118-24.
218. Gøtzsche PC. Why we need easy access to all data from all clinical trials and how to accomplish it. *Trials* 2011;12(1):249.
219. Gøtzsche PC, Jørgensen KJ, Zahl PH, Maehlen J. Why mammography screening has not lived up to expectations from the randomised trials. *Cancer Causes Control* 2012;23:15-21.
220. Gøtzsche PC. Strengthening and opening up health research by sharing our raw data. *Circ Cardiovasc Qual Outcomes* 2012;5:236-7.
221. Grønhøj Larsen C, Jørgensen KJ, Gøtzsche PC. Regular health checks: cross-sectional survey. *PLoS One* 2012;7:e33694.
222. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG; CONSORT. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *Int J Surg* 2012;10:28-55.
223. Nielsen M, Hansen EH, Gøtzsche PC. What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. *Addict* 2012;107:900-8.
224. Lundh A, Krogsbøll LT, Gøtzsche PC. Sponsor's participation in conduct and reporting of industry trials: a descriptive study. *Trials* 2012;13:146.
225. Schroll JB, Maund E, Gøtzsche PC. Challenges in coding adverse events in clinical trials: a systematic review. *PLoS One* 2012;7:e41174.
226. Gøtzsche PC. Deficiencies in proposed new EU regulation of clinical trials. *BMJ* 2012;345:e8522.
227. Krogsbøll LT, Jørgensen KJ, Grønhøj Larsen C, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. *Cochrane Database Sys Rev* 2012;(10):CD009009.
228. Gøtzsche PC, Ioannidis JPA. Content area experts as authors: helpful or harmful for systematic reviews and meta-analyses? *BMJ (Online)* 2012;345:e7031.

229. Krogsbøll LT, Jørgensen KJ, Grønhøj Larsen C, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease: Cochrane systematic review and meta-analysis. *BMJ* (Online) 2012;345:e7191.
230. Gøtzsche PC. Big pharma often commits corporate crime, and this must be stopped. *BMJ* 2012;345:e8462.
231. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K et al. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. *Ann Intern Med* 2013;158:200-7.
232. Beller EM, Glasziou PP, Altman DG, Hopewell S, Bastian H, Chalmers I et al. PRISMA for Abstracts: reporting systematic reviews in journal and conference abstracts. *PLoS Med* 2013;10:e1001419.
233. Bindslev JBB, Schroll J, Gøtzsche PC, Lundh A. Underreporting of conflicts of interest in clinical practice guidelines: cross sectional study. *BMC Med Ethics* 2013;14:19.
234. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. *BMJ* (Online) 2013;346:e7586.
235. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. *Cochrane Database Syst Rev* 2013;(6):CD001877.
236. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. *JAMA* 2013;309:2489-90.
237. Nielsen M, Hansen EH, Gøtzsche PC. Dependence and withdrawal reactions to benzodiazepines and selective serotonin reuptake inhibitors. How did the health authorities react? *Int J Risk Saf Med* 2013;25:155-68.
238. Rasmussen K, Jørgensen KJ, Gøtzsche PC. Citations of scientific results and conflicts of interest: the case of mammography screening. *Evidence - Based Medicine* (English Edition). 2013;18:83-9.
239. Schroll JB, Bero L, Gøtzsche PC. Searching for unpublished data for Cochrane reviews: cross sectional study. *BMJ* (Online) 2013;346:f2231.
240. Wolfe N, Gøtzsche PC, Bero LA. Strategies for obtaining unpublished drug trial data: a qualitative interview study. *Syst Rev* 2013;2:31.
241. Zahl P-H, Juhl Jørgensen K, Gøtzsche PC. Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis. *Br J Cancer* 2013;109:2014-9.
242. Chan AW, Song F, Vickers A, Jefferson T, Dickersin K, Gøtzsche PC, Krumholz HM, Gherzi D, van der Worp HB. Increasing value and reducing waste: addressing inaccessible research. *Lancet* 2014;383:257-66.
243. Smith R, Gøtzsche PC, Groves T. Should journals stop publishing research funded by the drug industry? *BMJ* 2014 ;348:g171.
244. Maund E, Tendal B, Hróbjartsson A, Lundh A, Gøtzsche PC. Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study. *BMJ* 2014;348:g3555.
245. Maund E, Tendal B, Hróbjartsson A, Jørgensen KJ, Lundh A, Schroll J, Gøtzsche PC. Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications. *BMJ* 2014;348:g3510.
246. Gøtzsche PC. Questionable research and marketing of a combination drug for smoker's lungs. *J R Soc Med* 2014;107:256-7.
247. Gøtzsche PC. Why I think antidepressants cause more harm than good. *Lancet Psychiatry* 2014;1:104-6.
248. Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients. *Cochrane Database Syst Rev* 2014;(9):CD002033.
249. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. *Cochrane Database Syst Rev* 2014;(9):CD000026.
250. Gøtzsche PC. "Human guinea pig" asks for animal studies. *BMJ* (Online) 2014;349:g6714.
251. Gøtzsche PC. Our prescription drugs kill us in large numbers. *Polskie Archiwum Medycyny Wewnętrznej* 2014;124:628-34.
252. Johansen HK, Gøtzsche PC. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. *Cochrane Database Syst Rev* 2014;(9):CD000239.
253. Johansen HK, Gøtzsche PC. Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia. *Cochrane Database Syst Rev* 2014;(9):CD000969.
254. Jørgensen KJ, Gøtzsche PC, Dalbøge CS, Johansen HK. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia. *Cochrane Database Syst Rev* 2014;(2):CD004707.
255. Jørgensen AW, Lundstrøm LH, Wetterslev J, Astrup A, Gøtzsche PC. Comparison of results from different imputation techniques for missing data from an anti-obesity drug trial. *PLoS One* 2014;9:e111964.

256. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Int J Surg* 2014;12:1500-24.
257. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. *Int J Surg* 2014;12:1495-99.
258. Zahl P-H, Jørgensen KJ, Gøtzsche PC. Lead-time models should not be used to estimate overdiagnosis in cancer screening. *J Gen Intern Med* 2014;29:1283-6.
259. Gøtzsche PC. Does long term use of psychiatric drugs cause more harm than good? *BMJ* 2015;350:h2435.
260. Gøtzsche PC. Mammography screening is harmful and should be abandoned. *J R Soc Med* 2015;108:341-5.
261. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med* 2015;162:777-84.
262. Johansen HK, Gøtzsche PC. Vaccines for preventing infection with *Pseudomonas aeruginosa* in cystic fibrosis. *Cochrane Database Syst Rev* 2015;(8):CD001399.
263. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. Screening with urinary dipsticks for reducing morbidity and mortality. *Cochrane Database Syst Rev* 2015;(1):CD010007.
264. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1.
265. Rasmussen KM, Schroll J, Gøtzsche PC, Lundh A. Under-reporting of conflicts of interest among trialists: a cross-sectional study. *J R Soc Med* 2015;108:101-7.
266. Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. *Cochrane Database Sys Rev* 2016;(9):CD007851.
267. Johansson M, Brodersen J, Gøtzsche PC, Juhl Jørgensen K. Screening for reducing morbidity and mortality in malignant melanoma (Protocol). *Cochrane Database Sys Rev* 2016;(9):CD012352.
268. Bielefeldt AØ, Danborg PB, Gøtzsche PC. Precursors to suicidality and violence on antidepressants: systematic review of trials in adult healthy volunteers. *J R Soc Med* 2016;109:381-92.
269. Davis C, Lexchin J, Jefferson T, Gøtzsche P, McKee M. "Adaptive pathways" to drug authorisation: adapting to industry? *BMJ* 2016;354:i4437.
270. Jørgensen KJ, Gøtzsche PC. Breast cancer: Updated screening guidelines - much ado about small improvements. *Nat Rev Clin Oncol* 2016;13:139-40.
271. Schroll JB, Penninga EI, Gøtzsche PC. Assessment of adverse events in protocols, clinical study reports, and published papers of trials of orlistat: a document analysis. *PLoS Med* 2016;13:e1002101.
272. Sharma T, Guski LS, Freund N, Gøtzsche PC. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. *BMJ* 2016;352:i65.
273. Simonsen AL, Danborg PB, Gøtzsche PC. Persistent sexual dysfunction after early exposure to SSRIs: Systematic review of animal studies. *Int J Risk Saf Med* 2016;28:1-12.
274. Maund E, Guski LS, Gøtzsche PC. Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports. *CMAJ* 2017;189:E194-203.
275. Jørgensen KJ, Gøtzsche PC, Kalager M, Zahl PH. Breast cancer screening in Denmark: a cohort study of tumor size and overdiagnosis. *Ann Intern Med* 2017;166:313-23.
276. Danborg PB, Simonsen AL, Gøtzsche PC. Impaired reproduction after exposure to ADHD drugs: Systematic review of animal studies. *Int J Risk Saf Med* 2017;29(1-2):107-24.
277. Sharma T, Gøtzsche PC, Kuss O. The Yusuf-Peto method was not a robust method for meta-analyses of rare events data from antidepressant trials. *J Clin Epidemiol* 2017;91:129-36.
278. Boesen K, Saiz LC, Erviti J, Storebø OJ, Gluud C, Gøtzsche PC, Jørgensen KJ. The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder. *Evid Based Med* 2017;22:143-7.
279. Gøtzsche PC, Gøtzsche PK. Cognitive behavioural therapy halves the risk of repeated suicide attempts: systematic review. *J R Soc Med* 2017;110:404-10.
280. Rasmussen K, Bero L, Redberg R, Gøtzsche PC, Lundh A. Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors. *BMJ* 2018;363:k3654.
281. Jørgensen L, Gøtzsche PC, Jefferson T. The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias. *BMJ Evid Based Med* 2018;23:165-8.
282. Marquardsen M, Ogden M, Gøtzsche PC. Redactions in protocols for drug trials: what industry sponsors concealed. *J R Soc Med* 2018;111:136-41.

283. Jørgensen L, Gøtzsche PC, Jefferson T. Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies: a necessary basis to address reporting bias in a systematic review. *Syst Rev* 2018;7:8.
284. Gøtzsche PC. Patients not patents: Drug research and development as a public enterprise. *Eur J Clin Invest* 2018;48(2):e12875.
285. Gøtzsche PC. A totally new system is needed for drug research and development. *Eur J Clin Invest* 2018;48(2):e12883.
286. Jørgensen L, Doshi P, Gøtzsche PC, Jefferson T. Challenges of independent assessment of potential harms of HPV vaccines. *BMJ* 2018;362:k3694.
287. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. *Cochrane Database Syst Rev* 2019;1:CD009009.
288. Börjesson J, Gøtzsche PC. Effect of lithium on suicide and mortality in mood disorders: A systematic review. *Int J Risk Saf Med* 2019;30(3):155-166.
289. Danborg PB, Gøtzsche PC. Benefits and harms of antipsychotic drugs in drug-naïve patients with psychosis: A systematic review. *Int J Risk Saf Med* 2019 Sep 14. doi: 10.3233/JRS-195063. [Epub ahead of print].
290. Danborg PB, Valdersdorf M, Gøtzsche PC. Long-term harms from previous use of selective serotonin reuptake inhibitors: A systematic review. *Int J Risk Saf Med* 2019;30(2):59-71.
291. Gøtzsche PC. What is the moral collapse in the Cochrane Collaboration about? *Ind J Med Ethics* 2019 Oct-Dec;4(4) NS:303-9.
292. Gøtzsche PC. Cochrane authors on drug industry payroll should not be allowed. *BMJ Evid Based Med* 2019 Apr 11.
293. Gøtzsche PC. Institute for Scientific Freedom. *BMJ Evid Based Med* 2019 Aug;24(4):123-4.
294. Johansson M, Brodersen J, Gøtzsche PC, Jørgensen KJ. Screening for reducing morbidity and mortality in malignant melanoma. *Cochrane Database Syst Rev* 2019 Jun 3;6:CD012352.
295. Jørgensen L, Gøtzsche PC, Jefferson T. Increased incidence of cervical cancer in Sweden: an unlikely link with human papillomavirus (HPV) vaccination. *BMJ Sex Reprod Health* 2019 Sep 18. pii: bmjsrh-2018-200245. doi: 10.1136/bmj-srh-2018-200245. [Epub ahead of print].
296. Paludan-Müller AS, Ogden MC, Marquardsen M, Vive J, Jørgensen KJ, Gøtzsche PC. Do protocols for new randomised trials take previous similar trials into account? Cohort study of contemporary trial protocols. *BMJ Open* 2019;9:e026661.
297. Gøtzsche PC, Vinther S, Sørensen A. Forced medication in psychiatry: Patients' rights and the law not respected by Appeals Board in Denmark. *Clin Neuropsychiatry* 2019;16:229-33.
298. Sharma T, Guski LS, Freund N, Meng DM, Gøtzsche PC. Drop-out rates in placebo-controlled trials of antidepressant drugs: A systematic review and meta-analysis based on clinical study reports. *Int J Risk Saf Med* 2019;30:217-32.
299. Gøtzsche PC, Dinnage O. What have antidepressants been tested for? A systematic review. *Int J Risk Saf Med* 2020;31:157-163.
300. Paludan-Müller AS, Sharma T, Rasmussen K, Gøtzsche PC. Extensive selective reporting of quality of life in clinical study reports and publications of placebocontrolled trials of antidepressants. *Int J Risk Saf Med* 2020 (in press).
301. Gøtzsche PC. Long-term use of antipsychotics and antidepressants is not evidence-based. *Int J Risk Saf Med* 2020;31:37-42.
302. Gøtzsche PC. Long-term use of benzodiazepines, stimulants and lithium is not evidence-based. *Clin Neuropsychiatry* 2020;17:281-3.

Articles without peer review

1. Gøtzsche PC. Vandtæggers respirationsforhold (Heteroptera, Hydrocorisae). Special subject, University of Copenhagen, Faculty for Natural Sciences, 1974, 83 pp.
2. Gøtzsche PC, Marinelli K, Gylding-Sabroe JP, Larsen N-E, Sørensen K. Bioavailability of naproxen tablets and suppositories in steady state. *Scand J Rheumatol* 1983;suppl 50:1-9.
3. Gøtzsche PC, Gjørup IE. Virkninger af moderat lakridsindtagelse. *Ugeskr Læger* 1983;145:3902-4.
4. Gøtzsche PC, Karlsen FØ, Andersen B. Dosis-respons bias. *Nord Med* 1986;101:24-5.
5. Jørgensen FR, Gøtzsche PC, Hein P, Jensen CM, Nielsen BM, Nielsen FM, Rønholt EB, Tranberg FH. Naproxen (Naprosyn) og mobilisering ved behandling af akut ankeldistorsion. *Ugeskr Læger* 1986;148:1266-8.
6. Gøtzsche PC. Vurdering af kliniske lægemiddelundersøgelser. *Ugeskr Læger* 1986;148:2417-20.
7. Ørnkov F, Gøtzsche PC. Lodtrækningsprincippet. Et forsøg på en medicinsk-etisk analyse. *Ugeskr Læger* 1988;150:897-900.

8. Gøtzsche PC. Oversigtsartikler og meta-analyser (leder). Ugeskr Læger 1988;150:1765-6.
9. Olesen B, Gøtzsche PC, Bygbjerg IC, Møller LH, Faber V. Hospitalsomkostninger ved diagnostik og behandling af AIDS-patienter. De første 33 patienter på Rigshospitalet. Ugeskr Læger 1988;150:2250-2.
10. Jørgensen PE, Forrest M, Hermann GG, Gøtzsche PC, Andersen B. Videnskabelige artikler i Ugeskrift for Læger gennem 25 år. Artikeltype og forsøgsdesign. Ugeskr Læger 1989;151:218-20.
11. Gøtzsche PC, Forrest M, Hermann GG, Jørgensen PE, Andersen B. Videnskabelige artikler i Ugeskrift for Læger gennem 25 år. Analyse og tolkning af forsøgsresultater. Ugeskr Læger 1989;151:220-2.
12. Gøtzsche PC. Medicinske studenters holdning til lodtrækning og selvvalg ved brystkræftkirurgi og forslag om et nyt design. Ugeskr Læger 1989;151:2719-21.
13. Mandrup-Poulsen T, Gøtzsche PC, Ott P, Pedersen BK, Sørensen JB. Dansk intern medicin i en brydningstid på tærsklen til det 21. århundrede. Bibliotek for Læger 1991;183:69-82.
14. Gøtzsche PC. Biasproblemer i kort- og langtidsdobbelblindforsøg og forslag til forbedringer. Månedsskr Prakt Lægegern 1992;70:159-64.
15. Gøtzsche PC. Metaanalyser: metodologiske og forskningsetiske overvejelser. Bibliotek for Læger 1993;185:17-29.
16. Gøtzsche PC. Det Nordiske Cochrane Center: samarbejde om systematiske oversigter over behandlingers effekter. Nord Med 1994;109:244-5.
17. Gøtzsche PC. Meta-analyser og kvalitetssikring. Journal 1994;2:16-7.
18. Gøtzsche PC. Er placebobegrebet logisk? Bibl Læger 1995;187:71-8.
19. Rigshospitalets Forskningspolitik, 1994, 16 pp.
20. Gøtzsche PC. Supplement til Rigshospitalets Forskningspolitik, 1994, 40 pp.
21. Gøtzsche PC. Kontrollerede kliniske forsøgs troværdighed - randomiseringsproblemet. Ugeskr Læger 1995;157:597-8.
22. Gøtzsche PC, Krog JW, Moustgaard R. Bibliometrisk analyse af dansk sundhedsvidenskabelig forskning 1988-1992. Ugeskr Læger 1995;157:5075-81.
23. Gøtzsche PC. Patientbehandling og sikkerhed - Cochrane-databasernes betydning. Ugeskr Læger 1995;157:6247.
24. Gøtzsche PC. Det sundhedsvidenskabelige grundlag for medicinsk teknologivurdering. København: Det Ethiske Råd; 1996:1-32.
25. Gøtzsche PC. Det Nordiske Cochrane Center og Netværk: Nordisk samarbejde om systematiske oversigter over behandlingers effekter. Social- og Hälsovårdsnytt i Norden 1996;13:10-11.
26. Gøtzsche PC. Anvendte procedurer skal være videnskabeligt dokumenterede. Lægen 1996;14:10-2.
27. Hallas J, Gøtzsche PC. Det Nordiske Cochrane Center og Netværk - et samarbejde om systematiske oversigter over behandlingseffekter. Farmakoepi-Nyt 1996;nov:4-5.
28. Olsen O, Gøtzsche PC. Nødvendigheden af elektronisk opdaterede metaanalyser: Doppler-ultralyd i obstetrikken som eksempel. Ugeskr Læger 1997;159:27-8.
29. Gøtzsche PC. Fibigers forsøg om serumbehandling af difteri. Bibl Læger 1997;189:143-6.
30. Gøtzsche PC, Jensen KL, Hammarquist C. Randomiserede kliniske forsøg i Ugeskrift for Læger 1948-1995. Ugeskr Læger 1997;159:4762-5.
31. Gøtzsche PC. Cochrane-samarbejdets betydning for evidensbaseret medicin. Ugeskr Læger 1997;159:6721-4.
32. Gøtzsche PC. Hjælp til et evidensbaseret sundhedsvæsen. Social- & Hälsovårdsnytt i Norden 1998;2:12-13 og www.shn.dk/2-98/cochrane.htm.
33. Gøtzsche PC. Randomisering og blinding i sundhedsvidenskabelig forskning. Bibl Læger 1998;190:369-80.
34. Gøtzsche PC. Lus i skindpelsen. Ugeskr Læger 1998;160:7610-1.
35. Gøtzsche PC. Det Nordiske Cochrane Center: Status efter 5 år og fremtidsperspektiver. Ugeskr Læger 1999;161:932-4.
36. Olsen O, Gøtzsche PC. Der er noget galt i mammografistudierne! Ingen støtte til konklusionen at brystkræftscreening har gavnlige effekt. Läkartidningen 2000;97:286-7.
37. Gøtzsche PC. Cochranesamarbetets betydelse för evidensbaserad medicin. Läkartidningen 2000;97:3180-2.
38. Wille-Jørgensen PA, Gøtzsche PC. Evidensbaseret kirurgi. Ugeskr Læger 2001;163:737-40.
39. Olsen O, Gøtzsche PC. Mister flere kvinder brystet efter screening - og hvornår må vi diskutere det? Ugeskr Læger 2001;163:1576.
40. Pedersen T, Gluud CN, Gøtzsche PC, Matzen P, Wille-Jørgensen P. Hvad er evidensbaseret medicin? Ugeskr Læger 2001;163:3769-72.
41. Gøtzsche PC, Olsen O. Screening for mammacancer - to år efter. Ugeskr Læger 2002;164:204-6.

42. Gøtzsche PC, Jørgensen KJ. Screening for brystkræft - et tveægget sværd. *Ugeskr Læger* 2005;167:1312-4.
43. Gøtzsche PC. Uafhængig klinisk interventionsforskning er meget påkrævet. *Ugeskr Læger* 2005;167:1491-4.
44. Gøtzsche PC. COX-2-hæmmere og andre nonsteroid antiinflammatoriske stoffer - hvad er fremtiden? *Ugeskr Læger* 2006;168:1972-3.
45. Gøtzsche PC. Paracetamol har samme effekt som nonsteroid antiinflammatoriske stoffer ved akutte skader i bevægeapparatet. *Ugeskr Læger* 2006;168:1981-2.
46. Gøtzsche PC. [Freedom of expression and editorial independence: Four firings and a Kafkaian process]. *Ugeskr Læger* 2008 Apr 28;170(18):1537-8.
47. Brodersen J, Hartling O, Nielsen M, Gøtzsche P. Det informerede samtykke ved screening for brystkræft. *Månedsskr Prakt Lægegern* 2008;86 (maj):551-7.
48. Gøtzsche PC. Kasuistiske meddelelser: fortsat en hovedkilde til forvirring, men nu på patientgruppeniveau. *Bibl Læger* 2009;201:87-91.
49. Gøtzsche PC, Johansen HK, Haahr MT, Altman DG, Chan A-W. Videnskabelig uredelighed. *Ugeskr Læger* 2009;171:1206-9.
50. Gøtzsche PC. Atter fri adgang til Cochrane-biblioteket for alle danskere. *Ugeskr Læger* 2009;171:932-3.
51. Gøtzsche PC, Hartling O, Nielsen M, Jørgensen KJ, Brodersen J. Invitation til brystkræftscreening: propaganda eller information? *Ugeskr Læger* 2009;171:1963.
52. Gøtzsche PC, Lundh A. Industrisponsoreret efteruddannelse hører ikke hjemme i et evidensbaseret sundhedsvæsen. *Ugeskr Læger* 2009;171:2228-9.
53. Gøtzsche PC, Jørgensen KJ. [Honest information about mammography screening, please!]. *Lakartidningen*. 2009;106(44):2860-1.
54. Gøtzsche PC. Evidensbaseret medicin: Ankestyrelsen mod Sundhedsstyrelsen om husstøvmider. *Ugeskr Læger* 2009;171:3727.
55. Jørgensen AW, Gøtzsche PC. [Insufficient access to research data not acceptable]. *Ugeskr Læger* 2010 May 24;172(21):1585.
56. Gøtzsche PC. Lovforslaget om kliniske forsøg viger uden om de allerstørste problemer. *Ugeskr Læger* 2011;173(11):840.
57. Gøtzsche PC. Hvorfor fejlinformerer Sundhedsstyrelsen om mammografiscreening? *Videnskab.dk* 2011; <http://videnskab.dk/krop-sundhed/hvorfor-fejlinformerer-sundhedsstyrelsen-om-mammografiscreening>.
58. Gøtzsche PC. Medicinalindustriens forskningsfusk og de købte læger. 2011; <http://videnskab.dk/kultur-samfund/medicinalindustriens-forskningsfusk-og-de-kobte-laeger>.
59. Gøtzsche PC. Åbent brev til Lundbeck om antidepressiva og selvmord. *Videnskab.dk* 2011; <http://videnskab.dk/krop-sundhed/abent-brev-til-lundbeck-om-antidepressiva-og-selv-mord>.
60. Gøtzsche PC, Tendal B, Clarke M. Review production in The Cochrane Collaboration - where is it happening and why? *Cochrane Database Syst Rev* 2011;Suppl 1:16-9.
61. Gøtzsche PC. We need access to all data from all clinical trials. *Cochrane Database Syst Rev* 2011;12:ED000035.
62. Gøtzsche PC. Hvorfor så snævre grænser for omfang i Ugeskriftet? *Ugeskr Læger* 2012;174:297.
63. Gøtzsche PC, Hartling OJ, Nielsen M, Brodersen J. Screening for breast cancer with mammography. The Nordic Cochrane Centre 2012. Available from: <http://nordic.cochrane.org/>
64. Gøtzsche PC, Hartling OJ, Nielsen M, Brodersen J. Screening for brystkræft med mammografi. The Nordic Cochrane Centre 2012. Available from: <http://nordic.cochrane.org/>
65. Jørgensen KJ, Gøtzsche PC. [Mortality in breast cancer is decreasing - but not because of screening. Time to abolish the mammography screening]. *Läkartidningen* 2012;109:690-2.
66. Jørgensen KJ, Gøtzsche PC. Rintasyöpäkuolleisuus vähenee, muttei seulonnan ansiosta. *Suomen Lääkärilehti* 2012;11:856-8.
67. Gøtzsche PC. Mammografiscreening gør raske kvinder syge. *Fokus på Kræft og sygepleje* 2012;2:18-20.
68. Gøtzsche PC. Lægers råd om medicin er ikke sunde. *Politikens kronik* 2012 Nov 29.
69. Gøtzsche PC. Vores lykkepille-epidemi er dybt skadelig. *Berlingskes kronik* 2012 Dec 16.
70. Gøtzsche PC. Overdiagnostik og overmedicinering i børnepsykiatrien. *Pædagogisk Psykologisk Tidsskrift* 2013;50:95-100.
71. Gøtzsche PC. Bør bekendtgørelsen om videnskabelig uredelighed revideres endnu en gang? *Ugeskr Læger* 2013;175:2512-3.
72. Gøtzsche PC. Alvorlige skadevirkninger af HPV-vaccinen. *HPV-magasinet* 2016;1:18-9.

73. Gøtzsche PC. De mange usynlige medicindødsfald: Et chokerende højt antal mennesker dør på grund af den medicin, de tager. Men ofte er de dødsfald usynlige før lægen. Løsningen er at bruge mindre medicin. Ugeskr Læger 2016;10:990-1.
74. Gøtzsche PC, Lund K. Tvangsmedisinering må forbys. Kritisk Juss 2016;2:118-57.
75. Gøtzsche PC. What do we know about the safety of the HPV vaccines? Tidsskr Nor Lægeforen 2017;137:11-2.
76. Gøtzsche PC. Hvad er der kommet ud af kræftindsatserne? Dagens Medicin 2017;2:8-9.
77. Gøtzsche PC. Chemical or Psychological Psychotherapy? 2017; Jan 29. www.madinamerica.com/.
78. Gøtzsche PC. Editorial Misconduct: Finnish Medical Journal Rejects Paper on Suicide Risk. 2017; Feb 22. www.madinamerica.com/.
79. Gøtzsche PC. Vi kan og bør undvære antidepressiv medicin: kritik af Sundhedsstyrelsen. www.deadlymedicines.dk.
80. Gøtzsche PC. DSAM-formand på afveje om antidepressiva. Dagens Medicin 2017; 3. marts.
81. Gøtzsche PC. Svar til: DepressionsForeningen: Medicin bliver ofte det eneste mulige valg. <http://videnskab.dk/> 2017; 8. marts.
82. Gøtzsche PC. Medikamentfri behandling. Dagens Medicin 2017; 10. marts.
83. Gøtzsche PC. Antidepressiva bör inte användas till barn och ungdomar. Läkartidningen 2017; 12. marts.
84. Gøtzsche PC. Antidepressiva skader mere end de gavner. Dagens Medicin 2017;15. marts.
85. Gøtzsche PC. Norske Renate Hoel døde pludseligt og uventet i juli 2005, 34 år gammel. Ugeskr Læger 2017; 23. marts.
86. Toft B, Gøtzsche PC. Psykofarmakaepidemien kan bekæmpes. Information 2017; 3. april.
87. Jørgensen KJ, Gøtzsche PC, Jørgensen T. Tilstrækkelig evidens til at undlade tjek. Dagens Medicin 2017;7:23.
88. Gøtzsche PC. Private virksomheder skal også kunne undersøges for videnskabelig uredelighed. Ugeskr Læger 2017;179:633.
89. Gøtzsche PC. Røgfrit Danmark. 2017; 28. april. www.deadlymedicines.dk.
90. Gøtzsche PC. Kræftens Bekæmpelse vildleder. Dagens Medicin 2017; 17. marts.
91. Gøtzsche PC. Ingen pålitlig evidens visar att läkemedel kan förebygga självmord. Läkartidningen 2017; 1. maj.
92. Gøtzsche PC. Medicin mod Alzheimer virker ikke. Ugeskr Læger 2017; 8. maj.
93. Gøtzsche PC. Måske kan du blive medicinfri. Kronik. Jyllands-Posten 2017; 13. maj.
94. Gøtzsche PC. Skal angst behandles med piller? Angstavisen 2017; nr. 57, juni:4-6.
95. Gøtzsche PC. Depressionspiller gør større skade end gavn. Politiken 2017; 25. juni.
96. Gøtzsche PC. Hun fik den sidste kemo på vej til kapellet. Kronik. Politiken 2017; 2. juli.
97. Gøtzsche PC. Antidepressants increase the risk of suicide, violence and homicide at all ages. BMJ 2017; Sept 3. <http://www.bmj.com/content/358/bmj.j3697/rr-4>.
98. Gøtzsche PC. Psychiatry Ignores an Elephant in the Room. 2017; Sept 21. www.madinamerica.com/.
99. Gøtzsche PC. Din overvægt er en selvskabt plage - derfor skal du selv betale. Berlingske 2017; 12. aug.
100. Gøtzsche PC. What is it like being on the Governing Board? 2017; Sept 27. <http://community.cochrane.org/news/what-it-being-governing-board>.
101. Gøtzsche P. Medicinfri psykiatri. <http://tidsskriftet.no/comment-view/11179>. 2017 (ingen dato).
102. Gøtzsche PC, Toft B, Rüdinger B, Kortegaard L, Runciman O, Sørensen A. Hvordan skal man trappe ud af psykofarmaka? Kronik. Jyllands-Posten 2017; 10. okt.
103. Danborg PB, Simonsen AL, Hróbjartsson A, Gøtzsche PC. Long-term changes in observed behaviour after exposure to psychiatric drugs: a systematic review of animal studies. Nordic Cochrane Centre 2017; Nov 14. <http://nordic.cochrane.org/>.
104. Gøtzsche PC, Toft B, Rüdinger B, Kortegaard L, Runciman O, Sørensen A. Learning About Psychiatric Drug Withdrawal. 2017; Nov 16. <https://www.madinamerica.com/>.
105. Gøtzsche PC. Psychiatrists Roadblock Psychiatric Drug Withdrawal Initiatives: Part 1. 2017; Dec 4. <https://breggin.com/>.
106. Gøtzsche PC, Toft B, Rüdinger B, Kortegaard L, Runciman O, Sørensen A. Udtrapning af psykofarmaka: En opfordring til de praktiserende læger. Practicus 2017; 17. dec:48-50.
107. Jørgensen KJ, Gøtzsche PC. Lægemedelstyrelsen og lægemiddelindustrien ligner et lukket kredsløb. Ugeskr Læger 2017;179:2336-7.
108. Gøtzsche PC. What do we know about the safety of the HPV vaccines? Tidsskr Nor Lægeforen 2017;137:11-2.
109. Jørgensen KJ, Gøtzsche PC. Lægemedelstyrelsen og lægemiddelindustrien ligner et lukket kredsløb. Ugeskr Læger 2017;179:2336-7.
110. Jørgensen KJ, Gøtzsche PC. Lægemedelstyrelsens nonchalante holdning til kræftmedicin og interessekonflikter. Ugeskr Læger 2018;180:170-1.

111. Jørgensen KJ, Gøtzsche PC. Uhæderlighed og interessekonflikter er to forskellige ting, Henrik Ullum. Ugeskr Læger 2018;180:172.
112. Jørgensen KJ, Gøtzsche PC. Arbejder Lægemiddelstyrelsen for patienterne? Politikens Kronik 2018; 5 febr.
113. Jørgensen KJ, Gøtzsche PC. Interessekonflikter er allerede diskvalificerende. Heldigvis. Ugeskr Læger 2018;180:268.
114. Boesen K, Simonsen AL, Danborg PB, Jørgensen KJ, Gøtzsche PC. Lægemedelannoncer i Ugeskrift for Læger bør ikke forekomme. Ugeskr Læger 2018;180:1596-7.
115. Jørgensen L, Gøtzsche PC, Jefferson T. The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias: Response to the Cochrane editors. BMJ Evidence-Based Medicine. 2018; 17 September.
116. Gøtzsche PC. Moralsk ledelseskriser i Cochrane-samarbejdet. Politikens Kronik 2018; 27. sept.
117. Gøtzsche PC. Cochrane—no longer a Collaboration. <https://blogs.bmj.com/bmj/2018/11/08/peter-c-gotzsche-cochrane-no-longer-a-collaboration/>. 2018; 8 Nov.
118. Gøtzsche PC. It's Unlikely That 'Antidepressants' Have a True Effect on Depression. <https://www.madinamerica.com/2018/01/antidepressants-effect-depression/>. 2018; 8 Jan.
119. Gøtzsche PC. Psychiatrists Roadblock Psychiatric Drug Withdrawal Initiatives: Part 2.
120. Gøtzsche PC. <https://breggin.com/psychiatrists-roadblock-psychiatric-drug-withdrawal-initiatives-part-2/>. 2018 (not dated).
121. Gøtzsche PC. Endnu et tragisk selvmord på depressionspiller. Jyllands-Postens Kronik 2018; 3. feb.
122. Gøtzsche PC. Rewarding the Companies That Cheated the Most in Antidepressant Trials. March 7, 2018 <https://www.madinamerica.com/2018/03/rewarding-companies-cheated-most-antidepressant-trials/>. 2018; 7 March.
123. Gøtzsche PC. Forbruget af depressionspiller er næsten halveret hos børn og unge i Danmark. <http://www.deadlymedicines.dk/forbruget-af-depressionspiller-er-naesten-halveret-hos-born-og-unge-i-danmark/>. 2018; 1 maj.
124. Gøtzsche PC. Usage of depression pills almost halved among children in Denmark. <https://www.madinamerica.com/2018/05/usage-depression-pills-almost-halved-among-children-denmark/>. 2018; 4 May.
125. Davies J, Read J, Hengartner MP, Cosci F, Fava G, Chouinard G, van Os J, Nardi A, Gøtzsche P, Groot P, Offidani E, Timimi S, Moncrieff J, Spada M, Guy A. Clinical guidelines on antidepressant withdrawal urgently need updating. BMJ 2019 May 20;365:l2238.
126. Gøtzsche PC. The harmful myth about the chemical imbalance causing psychiatric disorders. CrossFit 2019 June 28.
127. Gøtzsche PC. "Trust me, I'm a doctor". CrossFit 2019 June 16.
128. Gøtzsche PC. Expert Report. Effect of DTP Vaccines on Mortality in Children in Low-Income Countries. 2019 June 19.
129. Gøtzsche PC. Forced drugging with antipsychotics is against the law: decision in Norway. Mad in America 2019 May 4. <https://www.madinamerica.com/2019/05/forced-drugging-antipsychotics-against-law/>
130. Gøtzsche PC. Institutional corruption in the Cochrane Collaboration. Mad in America 2019 Feb 14.
131. Gøtzsche PC. Norsk ombudsmand har afgjort, at tvangsmedicinering ikke kan begrundes. Psykiatriavisen 2019 Jan 27.
132. Gøtzsche PC. The depression pill epidemic. CrossFit 2019 June 4.
133. Gøtzsche PC. Why we're establishing an Institute for Scientific Freedom. Mad in America 2018 Dec 30.
134. Gøtzsche PC, Runcimann O, Bækgaard J, Sørensen A, Toft BS. Fem læger, psykologer og farmaceuter: Skru ned for psykofarmaka. Piller er ikke løsningen. Politikens kronik 2019 Sept 8.
135. Gøtzsche PC, Runcimann O, Bækgaard J, Sørensen A, Toft BS. The epidemic of psychiatric drug usage – taper off the pills. Deadly Medicines 2019 Oct 22.
136. Gøtzsche PC. Surviving psychiatry: a typical case of serious psychiatric drug harms. Mad in America 2020 Jan 7.

Book chapters

1. Gøtzsche PC. Problemer og muligheder ved lægemiddelundersøgelser ved reumatoid artrit. I: Järner D, Friis J, eds. Dansk Reumatologisk Selskab: postgraduat kursus om arthritis rheumatoides. København: Astra, 1992:18-30.
2. The Cochrane Collaboration Handbook. Sackett D, Chalmers I, Silagy C, Gøtzsche PC, Dickersin K, Oxman A, eds. 1994.

3. Gøtzsche PC. Clinical practice should reflect clinical science. In: Gordon C, Christensen JP, eds. *Health Telematics for Clinical Guidelines and Protocols*. Amsterdam: IOS Press, 1995:17-25.
4. Gøtzsche PC. Meta-analyses: assets and limitations. In: Rose C, Larsen S, Hansen O, Bergh J, Andersen J, eds. *Recent advances in breast cancer*. Colloquium, Scandinavian Breast Group, Hindsgavl, Oct 11-14. Bristol-Myers Squibb, 1996:139-45.
5. Kleijnen J, Gøtzsche PC, Kunz RH, Oxman A, Chalmers I. So what's so special about randomisation? In: Maynard A, Chalmers I, eds. *Non-random reflections on health services research: on the 25 anniversary of Archie Cochrane's Effectiveness and Efficiency*. London: BMJ Books, 1997:231-49.
6. Gøtzsche PC. Hjælp til selvhjælp: Hvad kan Cochrane-samarbejdet tilbyde sundhedsvæsenet, og hvad kan sundhedsvæsenet tilbyde Cochrane-samarbejdet? I: *Evidensbaseret sundhedsvæsen. Rapport fra II symposium om evidensbaseret sundhedsvæsen*. København: Institut for Sundhedsvæsen, DSI rapport 98.04, 1998:119-25.
7. Gøtzsche PC. Metaanalyse - begreber og metoder. I: Andersen D, Almind G, Bock E, Havsteen B, Hørdér M, Riis P. *Sundhedsvidenskabelig forskning*, 5. udg. København: FADL's Forlag, 1999:303-14.
8. Gøtzsche PC. Eettisiä näkökulmia systemaattisiin kirjallisuuskatsauksiin. Helsinki: Stakes, FinOHTAn raportti 11, 1999:19-24.
9. Gøtzsche PC, red. *Introduktion til forskning*. http://www.dadlnet.dk/dok/?/2videnskab/bibliotekforlaeger/frz_forskning.htm, april 2000.
10. Gøtzsche PC. Det Nordiske Cochrane Center og dets samarbejde med klinisk praksis. I: MTV, sundhedstjenesteforskning og klinisk praksis. Rapport fra et symposium om evidensbaseret sundhedsvæsen. København: Statens Institut for Medicinsk Teknologivurdering, 2000. p. 38-44.
11. Johansen HK, Gøtzsche PC Lægemedelindustrien og ytringsfriheden. I: Høiby (red): *Råb op og sig stop*. http://www.laegersytringsfrihed.dk/pdf/Yderligere_indlaeg.pdf. 2005.
12. Gøtzsche PC. Screeningsindustrien og ytringsfriheden. I: Høiby (red): *Råb op og sig stop*. http://www.laegersytringsfrihed.dk/pdf/Yderligere_indlaeg.pdf. 2005.
13. Gøtzsche PC. Assessment bias. In: Kotz S, Balakrishnan N, Read CB, Vidakovic B, eds. *Encyclopedia of statistical sciences*, 2nd ed. Hoboken, New Jersey: John Wiley & Sons, 2006;vol 1:237-40.
14. Also published in: *Wiley Encyclopedia of Clinical Trials*, 2007. DOI: 10.1002/9780471462422.eoct062.
15. Gøtzsche PC. Commercial interests versus common goods. In: Lötjönen S, von Troil H, eds. *Bioethics, Politics and Business*. Copenhagen: Nordic Council of Ministers, TemaNord 2008:125-32. ISBN 978-92-893-1728-3.
16. Gøtzsche PC. Alternativ behandling. I: Ove B. Schaffalitzky de Muckadell, Stig Haunsø og Hendrik Vilstrup, red. *Medicinsk Kompendium*, 17. udg. København: Nyt Nordisk Forlag, 2009, kap. 75. ISBN 978-87-17-03933-9.
17. Brodersen J, Hartling O, Nielsen M, Gøtzsche P. Informerat samtykke ved mammografiscreening. I: Brodersen J, Hovelius B, Hvas L, eds. *Skapar värden ohälsa? Allmänmedicinske reflektioner*. Lund: Studentlitteratur AB, 2009:167-75.
18. Brodersen J, Hartling O, Nielsen M, Gøtzsche P. Det informerede samtykke ved screening for brystkræft. I: Brodersen J, Hovelius B, Hvas L, eds. *Kan sundhedsvæsenet skabe usundhed? Refleksioner fra almen praksis*. København: Månedsskrift for Praktisk Lægegering, 2009:153-162.
19. Gøtzsche PC. Alternativ behandling. I: Ove B. Schaffalitzky de Muckadell, Stig Haunsø og Hendrik Vilstrup, red. *Medicinsk Kompendium*. 18. udg. København: Nyt Nordisk Forlag; 2013, kap. 73.
20. Gøtzsche PC. Overdiagnostik og overbehandling i psykiatrien. I: Brinkmann S and Petersen, eds. *Diagnoser*. Aarhus: Klim; 2015:kapitel 7.
21. Gøtzsche PC. Psychopharmacology is not evidence-based medicine. In: Davies J, ed. *The sedated Society*. London: Palgrave Macmillan; 2017:23-50.
22. Gøtzsche PC, Lund K. Intet kunnskapsgrunnlag for tvangsmedisinerer. In: Kolstad A, Kogstad R, eds. *Medikalisering av psykosociale problemer*. Oslo: Abstrakt Forlag; 2019: 175-210.

Correspondence, book reviews and similar

1. Gøtzsche PC, Gjørup IE. Virkninger af moderat lakridsindtagelse. *Ugeskr Læger* 1984;146:207.
2. Gøtzsche PC. Turnusordningen - eller hvordan tre måneder bliver til ingenting. *Ugeskr Læger* 1984;146:2765.
3. Gøtzsche PC, Karlsen FØ. Buprenorfin og morfin. *Ugeskr Læger* 1985;147:1786.
4. Gøtzsche PC, Bygbjerg IC. Leverbiopsi ved AIDS? *Ugeskr Læger* 1988;150:173-4.
5. Gøtzsche PC. Enalapril, atenolol, and hydrochlorothiazide in hypertension. *Lancet* 1986;iii:38-9.

6. Gøtzsche PC, Karlsen FØ. Lodtrækningsprincippet. Ugeskr Læger 1988;150:1899-1990.
7. Gøtzsche PC, Hørding M. Kondomers sikkerhed. Ugeskr Læger 1988;150:1000.
8. Gøtzsche PC, Hørding M. Kondomers sikkerhed. Ugeskr Læger 1988;150:1697.
9. Gøtzsche PC. Ditiocarb in HIV infection. Lancet 1988;Oct 29:1024.
10. Jørgensen PE, Forrest M, Hermann GG, Gøtzsche PC, Andersen B. (U)videnskabeligt bogholderi. Ugeskr Læger 1989;151:901.
11. Gøtzsche PC. Forskningsmetodologisk lærestykke 2. Ugeskr Læger 1989;151:319.
12. Gøtzsche PC. Forskningsmetodologiske lærestykker 4. Vurdering af korrelationer. Ugeskr Læger 1989;151:456-7.
13. Gøtzsche PC (book review). Duodenal ulcer. Analyses of 293 randomized trials. Stat Med 1990;9:1225-6.
14. Rosenberg R, Gøtzsche PC. Urigtig påstand om naturmedicin. Ugeskr Læger 1991;153:3027.
15. Gøtzsche PC (boganmeldelse). Schou I, ed. Good clinical practice. Kvalitetskrav til klinisk undersøgelse. Ugeskr Læger 1991;153:3636.
16. Gøtzsche PC. P-piller giver ikke brystkræft. Ugeskr Læger 1992;154:1437.
17. Gøtzsche PC. Kommentar (til artikel om placebo). Ugeskr Læger 1992;154:2452.
18. Gøtzsche PC. Placeboeffekt? Ugeskr Læger 1992;154:3006.
19. Rasmussen MH, Andersen T, Breum L, Gøtzsche PC, Hilsted J. Cimetidine and weight loss. BMJ 1993;307:446-7.
20. Gøtzsche PC. Trials of homeopathy. Lancet 1993;June 12:1533.
21. Gøtzsche PC. Zidovudine dosage. BMJ 1993;307:682-3.
22. Gøtzsche PC. Randomiseret undersøgelse af oxytocin? Ugeskr Læger 1994;156:201.
23. Gøtzsche PC (boganmeldelse). Skrabanek P, McCormick J. Follies and fallacies in medicine, anden udgave. Ugeskr Læger 1994;156:7386.
24. Gøtzsche PC. Metaanalyse af magnesiumbehandling af myokardieinfarkt. Ugeskr Læger 1995;157:2727-8.
25. Gøtzsche PC (book review). Xenotransplantation. J Med Ethics 1995:190-1.
26. Gøtzsche PC (boganmeldelse). Chalmers I, Altman DG, eds. Systematic reviews. Ugeskr Læger 1995;157:4364-5.
27. Gøtzsche PC. Ekspertviden eller medicinsk teknologivurdering? Ugeskr Læger 1996;158:6291-2.
28. Gøtzsche PC. Det sundhedsvidenskabelige grundlag for medicinsk teknologivurdering. Ugeskr Læger 1997;159:68-9.
29. Gøtzsche PC. Ekspertviden eller medicinsk teknologivurdering II. Ugeskr Læger 1997;159:70-1.
30. Gøtzsche PC, Johansen HK. Prophylactic and empirical antifungal treatment in cancer complicated by neutropenia. BMJ 1997;315:489.
31. Johansen HK, Gøtzsche PC. Meta-analysis of prophylactic or empirical antifungal therapy in cancer with neutropenia. Topics Supp Care Oncol 1997;26:9-10.
32. Johansen HK, Gøtzsche PC. Use of odds ratio in calculation of number needed to treat was inappropriate. BMJ 1997;315:879.
33. Gøtzsche PC. Screening for colorectal cancer. Lancet 1997;349:356.
34. Gøtzsche PC. Greenhalgh T: How to read a paper: the basics of evidence based medicine (boganmeldelse). Ugeskr Læger 1998;160:305-6.
35. Gøtzsche PC. Løgn, forbandet løgn og ... metaanalyse (svar). Ugeskr Læger 1998;160:896-7.
36. Gøtzsche PC. Somatostatin for acute oesophageal variceal bleeding. Lancet 1998;351:911.
37. Gøtzsche PC, Johansen HK. Intermittent low dose prednisolone is safe in rheumatoid arthritis. BMJ 1998;316:1606-7.
38. Gøtzsche PC. Statusartikel om antibiotikas effekt ved halsbetændelse. Ugeskr Læger 1998;160:5376.
39. Gøtzsche PC. Hvad er relationen mellem randomiserede forsøg og evidensbaseret medicin? Ugeskr Læger 1999;161:624.
40. Gøtzsche PC. Probability without equations (book review). Stat Med 1999;18:622-3.
41. Gøtzsche PC, Hammarquist C, Burr M. Control of house dust mite in managing asthma. BMJ 1999;318:871.
42. Gøtzsche PC. Var zoneterapiforsøget randomiseret? Ugeskr Læger 1999;161:2224.

43. Gøtzsche PC. Cochranologiens vokseværk. Ugeskr Læger 1999;161:2690-1.
44. Gøtzsche PC. Om Cochrane og brugen af albumin. Ugeskr Læger 1999;161:5552-4.
45. Gøtzsche PC. Skal radikal prostatektomi indføres? Ugeskr Læger 1999;161:3472-3.
46. Gøtzsche PC. Radikal prostatektomi er udokumenteret. Ugeskr Læger 1999;161:5691-2.
47. Gøtzsche PC, Olsen O. Screening mammography re-evaluated. Lancet 2000;355:752.
48. Johansen HK, Gøtzsche PC. Improving the conduct and reporting of clinical trials. JAMA 2000;283:2789.
49. Gøtzsche PC. "Skarp kritik af mammografiscreening"(svar). Ugeskr Læger 2000;162:817.
50. Gøtzsche PC. Openness about the Swedish breast cancer screening trials is needed. Läkartidningen 2000;97:3105-6.
51. Gøtzsche PC, Olsen O. God begrundelse for mammografiscreening. Ugeskr Læger 2000;162:4166-7.
52. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. BMJ 2000;321:568-9.
53. Gøtzsche PC. Openness about the Swedish breast cancer screening trials is needed (author's reply). Läkartidningen 2000;97:3105.
54. Gøtzsche PC, Olsen O. More on mammography. Lancet 2000;356:1276.
55. Gøtzsche PC. Albumin: et vigtigt princip i behandlingen af dekomenseret leversygdom (svar). Ugeskr Læger 2001;163:63-4.
56. Olsen O, Gøtzsche PC. Mister flere kvinder brystet efter screening - og hvornår må vi diskutere det? Ugeskr Læger 2001;163:1576.
57. Gøtzsche PC. Er evidensbaseret medicin evidensbaseret? (svar). Ugeskr Læger 2001;163:182.
58. Gøtzsche PC, Olsen O. Postoperativ strålebehandling øger mortaliteten hos kvinder, der får diagnosticeret brystkræft ved screening. Läkartidningen 2001;98:347.
59. Wille-Jørgensen PA, Gøtzsche PC. Angående evidensbaseret kirurgi (svar). Ugeskr Læger 2001;163:1450.
60. Pedersen T, Møller AM, Gøtzsche PC. Albumin, evidens og metaanalyse: kan dommen appelleres (svar)? Ugeskr Læger 2001;163:1719-20.
61. Gøtzsche PC. Mortalitet efter humant albumin. Ugeskr Læger 2001;163:2260-1.
62. Gøtzsche PC. Debate on screening for breast cancer is not over. BMJ 2001;323:693.
63. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? N Engl J Med 2001;345:1278-9.
64. Gøtzsche PC. Office of NHS cancer screening programme misrepresents Nordic work in breast screening row. BMJ 2001;323:1131.
65. Gøtzsche PC. Cochrane-rapport om mammografiscreening. Ugeskr Læger 2001;163:6768.
66. Pildal, Gøtzsche PC. Kritikken er berettiget. Läkartidningen 2001;98:5625.
67. Gøtzsche PC. Screening for breast cancer with mammography. Lancet 2001;358:2167-8.
68. Gøtzsche PC. Kritik af Cochrane-oversigt om screening med mammografi er uberettiget. Ugeskr Læger 2002;164:653-4.
69. Gøtzsche PC. Trends in breast-conserving surgery in the Southeast Netherlands: Comment on article by Ernst and colleagues Eur J Cancer 2001, 37, 2435-2440. Eur J Cancer 2002;38:1288.
70. Gøtzsche PC. Update on effects of screening mammography. Lancet 2002;360:338-9.
71. Gøtzsche PC. Terlipressin for acute esophageal variceal hemorrhage. Comment on Cochrane Review. In: The Cochrane Library, Issue 3. Oxford: Update Software; 2002.
72. Gøtzsche PC. Beyond randomized controlled trials. Cancer 2002;94:578.
73. Gøtzsche PC. Mammographic screening: no reliable supporting evidence? Lancet 2002;359:706.
74. Gøtzsche PC. Alarmerande att screeningsförsöken inte ger minskad cancerdödlighet. Läkartidningen 2002;99:945.
75. Hróbjartsson A, Gøtzsche PC. Placebo og bevisbyrde. Ugeskr Læger 2002;164:1525-6.
76. Gøtzsche PC. Misvisende fremstilling af vort arbejde om screening med mammografi. Läkartidningen 2002;99:75-6.
77. Gøtzsche PC. Albumin ved dekomenseret levercirrose. Ugeskr Læger 2002;164:1203-4.
78. Gøtzsche PC. Screening mammography: setting the record straight. Lancet 2002;359:440-1.
79. Gøtzsche PC. Misleading paper on mastectomy rates in a screening programme. <http://bmj.com/cgi/eletters/325/7361/418#24972>, 26 Aug 2002.

80. Gøtzsche PC. How to swallow one's words with a standard deviation. <http://bmj.com/cgi/eletters/325/7366/682#26186>, 11 Oct 2002.
81. Gøtzsche PC. Grønt lys for udokumenteret behandling. Ugeskr Læger 2002;164:3568-9.
82. Gøtzsche PC. WHO og The Lancet: ja til mammografiscreening (svar). Ugeskr Læger 2002;164:3082-3.
83. Gøtzsche PC. Invited response to "The mammographic screening trials: commentary on the recent work by Olsen and Gøtzsche". J Surg Oncol 2002;81:162-3.
84. Gøtzsche PC. Placebokirurgi: artroskopisk lavage og débridement ved slidgigt. Ugeskr Læger 2002;164:5151.
85. Gøtzsche PC. Kræftens Bekæmpelse, screening og troværdigheden. Ugeskr Læger 2003;165:611-2.
86. Gøtzsche PC. Screening mammography and mortality. Med J Aust 2003;178:189-90.
87. Gøtzsche PC, Hartling O. Er oplysninger om brystkræftscreening troværdige? Ugeskr Læger 2003;165:1068-70.
88. Gøtzsche PC. Uærlighed i lægemiddelfoprøvningskoster samfundet dyrt. Ugeskr Læger 2003;165:1691-2.
89. Gøtzsche PC. Breast cancer screening. International Agency for Research on Cancer (IARC) Handbooks of Cancer Prevention (book review). Int J Epidemiol 2003;32:472.
90. Gøtzsche PC. Screening for breast cancer. Ann Intern Med 2003;138:769-70.
91. Gøtzsche PC, Hartling O. Svar på debatindlæg "Mister kvinder unødigt brystet, hvor der screenes for brystkræft?". Ugeskr Læger 2003;165:2586-7.
92. Gøtzsche PC. Uærlighed i lægemiddelfoprøvningskoster samfundet dyrt (svar). Ugeskr Læger 2003;165:2673-4.
93. Gøtzsche PC, Hartling O. Svar på "Ingen evidens for at mammografiscreening fører til overbehandling". Ugeskr Læger 2003;165:3026-7.
94. Gøtzsche PC. Uærlighed i lægemiddelforskning og Cochrane Centeret (svar). Ugeskr Læger 2003;165:3098-9.
95. Gøtzsche PC. Skadelig screening for kræft. Politiken 2003; 1. juni, 3. sektion, s. 9.
96. Gøtzsche PC. Mammographic screening for breast cancer. N Engl J Med 2003;349:611.
97. Gøtzsche PC. Mortality reduction by breast-cancer screening. Lancet 2003;362:246.
98. Gøtzsche PC. Mammographic service screening and mortality. Lancet 2003;362:329-30.
99. Gøtzsche PC. Hvornår er noget skadeligt? Politiken 2003; 31. august, 3. sektion, s. 9.
100. Hróbjartsson A, Gøtzsche PC. Unreliable analysis of placebo analgesia in trials of placebo pain mechanisms. Pain 2003;104:714-5.
101. Gøtzsche PC. "Behandlingen er veldokumenteret". Politiken 2003; 5. oktober, 3. sektion, s. 9.
102. Gøtzsche PC. Medicinalindustrien har alt for let spil. Politiken 2003; 23. november, 3. sektion, s. 9.
103. Gøtzsche PC. Ikke-evidensbaseret kommentar om nytten af madrasbetræk ved astma med husstøvmideallergi. Ugeskr Læger 2003;165:4234-5.
104. Gøtzsche PC, Johansen HK, Burr M. Are encasings effective in asthma caused by house dust mite allergens (letter)? J Allergy Clin Immunol 2003;112:220.
105. Gøtzsche PC. Martin Bland and Janet Peacock, Statistical questions in evidence-based medicine (book review). Stat Med 2003;22:2817-20.
106. Gøtzsche PC. Hendes Majestæt Dronning Ingrid XI Festforelæsning, 2003. SØLK 2003;27(9):16-20.
107. Gøtzsche PC. Ondt i ryggen og muskelrelaksantia (reply). Ugeskr Læger 2004;166:1034.
108. Jørgensen KJ, Gøtzsche PC. Websites on screening for breast cancer (authors' reply). BMJ 2004;328:769-70.
109. Gøtzsche PC. Vær forsigtig med videnskabelig uredelighed. Politiken 2004; 25. januar, 3. sektion, s. 9.
110. Gøtzsche PC, Vestergård B. Åbent bibliotek om virkninger og bivirkninger. Politiken 2004; 9. maj, 3. sektion, s. 9.
111. Gøtzsche PC. What to conclude when treatments are harmful. CoRect News, Newsletter, The Cochrane Colorectal Cancer Group 2004;8:2-4.
112. Hróbjartsson A, Gøtzsche PC. Tesen om the powerless placebo. Ugeskr Læger 2004;166:2693-4.
113. Jørgensen KJ, Gøtzsche PC. Overfortolkning af inkonklusivt populationsstudie om brystkræft. Ugeskr Læger 2004;166:2822.
114. Gøtzsche PC. Kreativ markedsføring af margarine og medicin. Politiken 2004; 15. aug., 3. sektion, s. 9.

115. Gøtzsche P. Niels Finsen's treatment for lupus vulgaris. James Lind Library (www.jameslindlibrary.org). © Peter Gøtzsche, 2004.
116. Gøtzsche PC. Re: Trends in the treatment of ductal carcinoma *in situ* of the breast. *J Natl Cancer Inst* 2004;96:1257.
117. Gøtzsche PC, Jørgensen KJ. Mammografiscreening uden overdiagnostik (reply). *Ugeskr Læger* 2004;166:3737-8.
118. Gøtzsche PC, Møller A, Pedersen T. Albumin eller fysiologisk saltvand til volumendepleterede intensivpatienter? *Ugeskr Læger* 2004;166:3835.
119. Gøtzsche PC, Hróbjartsson A. Undocumented editorial on placebos. <http://bmj.bmjournals.com/cgi/eletters/329/7472/927>, 2004.
120. Gøtzsche PC. Reply: What to conclude when treatments are harmful (reply). *CoRect News, Newsletter, The Cochrane Colorectal Cancer Group* 2004;8(2):4.
121. Gøtzsche PC. Misleading quotations and other errors persist in rejoinder on breast cancer screening. *Int J Epidemiol* 2004;33:1404.
122. Gøtzsche PC. Does exercise training lower mortality in patients with chronic heart failure? <http://bmj.bmjournals.com/cgi/eletters/328/7433/189>, 2005.
123. Gøtzsche PC, Jørgensen KJ, Thornton H. Benefits and harms of breast cancer screening. <http://bmj.bmjournals.com/cgi/eletters/330/7485/220>, 2005.
124. Gøtzsche PC, Jørgensen KJ, Hartling O. Mammografiscreening - igen. *Ugeskr Læger* 2005;167:783-4.
125. Gøtzsche PC, Wille-Jørgensen P. Ghost authorship in evidence-based medicine. <http://bmj.bmjournals.com/cgi/eletters/330/7484/163>, 2005.
126. Gøtzsche PC, Jørgensen KJ. Outcomes of screening mammography: information to support informed choices. <http://bmj.bmjournals.com/cgi/eletters/bmj.38398.469479.8Fv1>, 2005.
127. Gøtzsche PC. Reporting bias: any consequences for Methods and Results sections in Cochrane Reviews? *Cochrane News* 2005;33:1+8. Also published in: *The Cochrane Collaboration Methods Groups Newsletter* 2005;9:5.
128. Gøtzsche PC. Screening for brystkræft. *Ugeskr Læger* 2005;167:1871.
129. Gøtzsche PC, Jørgensen KJ, Thornton H. Presentation of benefits and harms needs to be balanced. *BMJ* 2005;330:1024.
130. Pedersen T, Møller AM, Gøtzsche PC. Human albumin in critically ill patients. *Crit Care Med* 2005;33:1183.
131. Gøtzsche PC. Klinisk interventionsforskning: to ledere og et indlæg. *Ugeskr Læger* 2005;167:2308-9.
132. Gøtzsche PC, Jørgensen KJ. Information needs to support informed choices. *BMJ* 2005;331:350-1.
133. Gøtzsche PC. Uafhængig klinisk interventionsforskning - eller evidence biased medicine? *Ugeskr Læger* 2005;167:2916-7.
134. Gøtzsche PC. ALLHAT - epokegørende? *Ugeskr Læger* 2005;167:3422-3.
135. Gøtzsche PC. The mammography controversy (book review). *Lancet* 2005;366:1519-20.
136. Gøtzsche PC, Johansen HK. Misleading statements in industry-sponsored meta-analysis of itraconazole. *J Clin Oncol* 2005;23:9428-9.
137. Gøtzsche PC. Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden. *Int J Cancer* 2005; 15 Oct: DOI 10.1002/ijc.21632 (and 2006;118:2648).
138. Gøtzsche PC. Screening and breast cancer. *N Engl J Med* 2006;354:768.
139. Gøtzsche PC. Ramifications of screening for breast cancer: overdiagnosis in the Malmö trial was considerably underestimated. *BMJ* 2006;332:727.
140. Haug C, Gøtzsche PC, Schroeder TV. Clinical trials report card (reply). *N Engl J Med* 2006;354:1429.
141. Gøtzsche PC, Jørgensen KJ. Estimate of harm/benefit ratio of mammography screening was five times too optimistic. <http://bmj.bmjournals.com/cgi/eletters/332/7543/691>, 2006.
142. Hróbjartsson A, Gøtzsche PC. Follow-up commentary. *J Clin Epidemiol* 2006;59:340-1.
143. Gøtzsche PC. Disclosures should not be delayed. *WHO International Clinical Trials Registry Platform (ICTRP)* 2006, March 31 (http://www.who.int/ictrp/006-Peter_Gøtzsche_31March06.pdf)
144. Gøtzsche PC. No double standards in research, please. <http://bmj.bmjournals.com/cgi/eletters/333/7564/374>, 2006.

145. Gøtzsche PC, Jørgensen KJ. Mammografiscreening - ideologi kontra videnskab (svar). *Ugeskr Læger* 2006;168:2263-5.
146. Gøtzsche PC. Tvivlsom dokumentation for effekten af akupunktur. *Ugeskr Læger* 2006;168:3635.
147. Gøtzsche PC. Tvivlsom dokumentation for effekten af akupunktur 2. *Ugeskr Læger* 2006;168:4331-2.
148. Hróbjartsson A, Gøtzsche PC. Were patients with unfavorable outcomes deleted in a covert duplicate publication reporting effect of placebo on hypertension? *Am J Hypertens* 2006;19:655.
149. Gøtzsche PC, Hróbjartsson, Marić K, Tendal B. Comment on Cochrane review CD004878. *Cochrane Database of Systematic Reviews* 2007.
150. Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews and other meta-analyses, authors' reply. <http://bmj.bmjournals.com/cgi/eletters/333/7572/782>, 2006.
151. Gøtzsche PC. Mammography screening leads to an increase in mastectomies, not a decrease. <http://www.annals.org/cgi/eletters/146/7/511>, 2007.
152. Gøtzsche PC. Comment on: A Martí-Carvajal, G Salanti, AF Cardona. Human recombinant activated protein C for severe sepsis. *Cochrane Database of Systematic Reviews* 2007, Issue 3. Art. No.: CD004388.
153. Gøtzsche P, Hróbjartsson A, Johansen HK, Altman DG, Chan AW. Criticism is unwarranted: Please read our paper again. September 12, 2007. <http://medicine.plosjournals.org/perlserv/?request=read-response&doi=10.1371/journal.pmed.0040019#r1759>, 2007.
154. Gøtzsche PC. Asthma guidelines on house dust mites are not evidence-based. *Lancet* 2008; 370(9605):2100-1.
155. Gøtzsche PC. Mammographic screening from age 40 years. *Lancet* 2007; 369(9563):737-8.
156. Gøtzsche PC, Bjarnason NH. COX-2 inhibitor. *Rheumatology (Oxford)* 2007; 46(10):1623-4.
157. Gøtzsche PC, Maehlen J, Zahl PH. Undeclared motives in withdrawing a publication. *Lancet* 2007; 369(9574):1690.
158. Gøtzsche PC. Covert duplicate publication and misleading sample size calculation: commentary on Lee et al. (2008). *Int J Nurs Stud* 2008; 45(9):1398.
159. Gøtzsche PC. [Non-useful cancer survival statistics following the Danish Cancer Control Plan]. *Ugeskr Laeger* 2008; 170(43):3442.
160. Gøtzsche PC. Osteoarthritis of the knee: Topical NSAIDs have unknown effectiveness. *BMJ* 2008; 336(7640):344.
161. Jørgensen KJ, Hróbjartsson A, Gøtzsche PC. Comment on review of intercessory prayer for the alleviation of ill health (Roberts L, Ahmed I, Hall S. Intercessory prayer for the alleviation of ill health). *Cochrane Database of Systematic Reviews* 2009, Issue 2. Art. No.: CD000368.
162. Gøtzsche PC, Hartling OJ, Nielsen M, Brodersen J, Jørgensen KJ. Estimate of breast screening benefit was 6 times too large. http://www.bmj.com/cgi/eletters/338/jan27_2/b86. 2009.
163. Gøtzsche PC, Jørgensen KJ. Stephen Duffy's claims on the benefits and harms of breast screening are seriously wrong. http://www.bmj.com/cgi/eletters/338/jan27_2/b86#212985. 2009.
164. Gøtzsche P. Are new drugs for schizophrenia better than old ones? *Lancet* 2009;373:1248.
165. Gøtzsche PC, Jørgensen KJ, Maehlen J, Zahl PH. Estimation of lead time and overdiagnosis in breast cancer screening. *Br J Cancer* 2009;100(1):219.
166. Berry DA, Baines CJ, Baum M, Dickersin K, Fletcher SW, Gøtzsche PC, Jørgensen KJ, Junod B, Maehlen J, Schwartz LM, Welch HG, Woloshin S, Thornton H, Zahl PH. Flawed inferences about screening mammography's benefit based on observational data. *J Clin Oncol* 2009;27(4):639-40.
167. Gøtzsche PC. Quackery, chiropractic and alternative medicine. *BMJ* 2009: http://www.bmj.com/cgi/eletters/339/jul08_4/b2766.
168. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Svar til Lif. *Ugeskr Læger* 2009;171:1308.
169. Hróbjartsson A, Gøtzsche PC. Acupuncture for pain: our result is robust to trial selection, and our threshold for minimal clinically effect is low. *BMJ rapid responses* (17 March); 2009.
170. Hróbjartsson A, Gøtzsche PC. Authors' reply: The quality of the acupuncture interventions was considered in our systematic review. *BMJ rapid responses* (5 October); 2009.
171. Hróbjartsson A, Gøtzsche PC. Effect of acupuncture and placebo acupuncture. *BMJ rapid responses* (3 March); 2009.
172. Hróbjartsson A, Gøtzsche PC. Reply to Linde. *FACT* 2009;14:105.

173. Gøtzsche PC, Johansen HK. Authors' reply on 'House dust mite control measures for asthma'. *Allergy* 2009;64:190.
174. Jørgensen KJ, Brodersen J, Nielsen M, Hartling OJ, Gøtzsche PC. Fall in breast cancer deaths. A cause for celebration, and caution. *BMJ*. 2009 May 27;338:b2126.
175. Jørgensen KJ, Gøtzsche PC. Fundamental mistakes in estimate of lives saved by breast screening. *BMJ* 2009: http://www.bmj.com/cgi/eletters/339/jul21_2/b2922.
176. Jørgensen KJ, Gøtzsche PC. Fundamental errors in estimate of lives saved by screening. *BMJ* 2009 Aug 25;339:b3359.
177. Jørgensen KJ, Gøtzsche PC. It is time for a new paradigm for overdiagnosis with screening mammography. http://www.bmj.com/cgi/eletters/339/jul09_1/b2587.
178. Jørgensen KJ, Gøtzsche PC. Wald et al.'s estimate of the effect of breast screening is about 10 times higher than the most reliable evidence shows. http://www.bmj.com/cgi/eletters/339/aug25_1/b3359#220390.
179. Jørgensen KJ, Gøtzsche PC. Overdiagnosis with breast screening was seriously underestimated. http://www.annals.org/content/151/10/727.full/reply#annintmed_el_120127. 2009, 20 Nov.
180. Gøtzsche PC, Johansen HK. Alpha1-antitrypsin deficiency. *N Engl J Med*. 2009;361(21):2101-2.
181. Gøtzsche PC, Jørgensen KJ. [Overdiagnosis with mammography screening is a serious problem]. *Lakartidningen*. 2009;106(47):3180.
182. Jørgensen KJ, Gøtzsche PC. No visible effect of mammography screening in Denmark. http://www.bmj.com/cgi/eletters/340/mar23_1/c1241.
183. Jørgensen KJ, Gøtzsche PC. Mammography screening hasn't lived up to expectations. http://www.bmj.com/cgi/eletters/340/mar23_1/c1241.
184. Gøtzsche PC. Overdiagnosis with mammography screening is around 25-50%, not 10%. http://www.bmj.com/cgi/eletters/340/jun24_1/c3106.
185. Gøtzsche P. Depression severity and effect of antidepressant medications. *JAMA* 2010 Apr 28;303(16):1597.
186. Gøtzsche PC. [When one doesn't WANT to see the evidence?]. *Ugeskr Laeger* 2010 Mar 1;172(9):733.
187. Jørgensen KJ, Gøtzsche PC. The background review for the USPSTF recommendation on screening for breast cancer. *Ann Intern Med* 2010 Apr 20;152(8):538-9.
188. Jørgensen KJ, Gøtzsche PC. Where is the effect of mammography screening? *BMJ* 2010. http://www.bmj.com/cgi/eletters/341/aug11_1/c3620.
189. Baum M, Thornton H, Gøtzsche PC, Bewley S, Jørgensen KJ, Barratt A, et al. Breast cancer awareness month. Still awaiting screening facts. *BMJ* 2010;341:c6152.
190. Gøtzsche PC, Lundh A. [The rheumatologists' conflict of interest and biological medicines]. *Ugeskr Laeger* 2010;172(45):3126.
191. Gøtzsche PC, Jørgensen KJ, Zahl PH. Breast screening: why estimates differ by a factor of 20-25. *J Med Screen* 2010;17(3):158-9.
192. Gøtzsche PC. Lessons from the mammography wars. *N Engl J Med* 2010;363(26):2569.
193. Gøtzsche PC, Jørgensen KJ. Kopans, Smith and Duffy Misrepresent Facts about Mammographic Screening. *Radiology* 2011; http://pubs.rsna.org/doi/suppl/10.1148/radiol.11110716/suppl_file/110716supp.pdf.
194. Gøtzsche PC, Lundh A. Vigtig deklarering af interessekonflikter. *Dagens Medicin* 2011;13:27.
195. Gøtzsche PC. [Control should be counteracted]. *Ugeskr Laeger* 2011;173(33):1991.
196. Gøtzsche PC. Mammography screening ten years on: reflections on a decade since the 2001 review. *The Cochrane Collaboration* 2011; <http://www.cochrane.org/news/blog/mammography-screening-ten-years-reflections-decade-2001-review>.
197. Gøtzsche PC. Stop medicinudgifternes himmelflugt. *Politiken* 5 marts 2011. <http://politiken.dk/debat/kroniker/ECE1214179/stop-medicinudgifternes-himmelflugt/>
198. Gøtzsche PC. UK drug regulator destroys all evidence after 15 years. *BMJ* 2011;343:d4203.
199. Gøtzsche PC. Unreliable studies are quoted instead of reliable ones. *CMAJ* 2011;183:1957-8.
200. Jørgensen KJ, Gøtzsche PC. Elementary flaws in the FH01 study. *Lancet Oncol* 2011;12(3):215-6.
201. Jørgensen KJ, Gøtzsche PC. The proposed review will not be independent without NICE. *BMJ* 2011;343:d7533.

202. Jørgensen KJ, Hrobjartsson A, Gøtzsche PC. Leibovici's non-study must be excluded from the Cochrane review. [http://www.cochranefeedback.com/cf/cda/citation do?id=10133#10133](http://www.cochranefeedback.com/cf/cda/citation%20do?id=10133#10133) 2011;
203. Jørgensen KJ, Zahl PH, Gøtzsche PC. More on screening mammography. *N Engl J Med* 2011;364(3):284-6.
204. Krogsboll LT, Jørgensen KJ, Gøtzsche PC. [Should the population be offered general health screenings?]. *Ugeskr Laeger* 2011;173(23):1671.
205. Lunde IM, Gøtzsche PC. [Transparency, reliability and conflict of interest]. *Ugeskr Laeger* 2011;173(33):1989.
206. Gøtzsche PC. Psykiaterne har ukritisk accepteret ssri-præparaterne. *Dagens Medicin* 2011;<http://www.dagensmedicin.dk/opinion/debat/psykiaterne-har-ukritisk-accepteret-ssri-praparaterne/>.
207. Gøtzsche PC. RE: Peter Gøtzsche burde anerkende det vigtige forsknings samarbejde, der foregår mellem læger og medicinalindustrien. *Ugeskr Laeger* 2011;173(8):599-600.
208. Gøtzsche PC. Selektiv rapportering er et stort problem. *Ugeskr Laeger* 2011;173(15):1154.
209. Gøtzsche PC. Vigtig debat om gavnlige og skadelige virkninger. *Dagens Medicin* 2011;14:29.
210. Gøtzsche PC, Jørgensen KJ. RE: Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data. *BMJ* 2011;343:d7017.
211. Gøtzsche PC, Jørgensen KJ. RE: RE: Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data. *BMJ* 2011;343:d7017.
212. Gøtzsche PC. Cancer specific mortality is biased in breast screening trials. *BMJ* 2011;343:d6395.
213. Gøtzsche PC. Total mortality should be the primary outcome in cancer screening trials. *BMJ* 2011;(343):d6397.
214. Suhrke P, Maehlen J, Schlichting E, Jørgensen KJ, Gøtzsche PC, Zahl PH. RE: Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data. *BMJ* 2011;343:d4692.
215. Gøtzsche PC. Kopans' arguments are untruthful. 2011 Aug 18. Available at: www.auntminnie.com/index.aspx?sec=log&URL=http%3a%2f%2fwww.auntminnie.com%2findex.aspx%3fsec%3dsup%26sub%3dwom%26pag%3ddis%26ItemID%3d96204 (accessed 1 Sept).
216. Gøtzsche PCRE: Etisk analyse på automatpilot. *Dagens Medicin* 2012;<http://www.dagensmedicin.dk/blog/kristians-blog/blog-etisk-analyse-pa-automatpilot/>.
217. Jørgensen KJ, Gøtzsche PG. Breast Cancer Screening. An independent review is under way. *BMJ* 2012; 24 April. <http://www.bmj.com/content/343/bmj.d6843?tab=responses>
<http://www.bmj.com/content/343/bmj.d6843/rapid-responses>.
218. Jørgensen KJ, Keen JD, Zahl PH, Gøtzsche PC. The Two-County breast screening trial cannot provide a reliable estimate of the effect of breast cancer screening. *Radiology* 2012;262:729-30.
219. Gøtzsche PC. Why does the BMJ support donations of pulse oximeters when they have no effect? *BMJ* 2012;344:e409.
220. Gøtzsche PC, Jørgensen KJ. Effect of population-based screening on breast cancer mortality. *Lancet* 2012;379:1297.
221. Jørgensen KJ, Gøtzsche PC. Mammografiscreening redder ikke liv. *Dagens Medicin* 2012;28 Sept.
222. Gøtzsche PC. Screening for tvangstanker, depression og ADHD?. *Ugeskr Læger* 2013;175:77.
223. Gøtzsche PC. Developing a new drug costs less than \$100m, not \$900m. *BMJ* 2013;346:f398.
224. Jørgensen KJ, Gøtzsche PC. Effect of screening mammography on breast cancer incidence. *N Engl J Med* 2013;368:677-8.
225. Gøtzsche PC. The EMA should continue its new openness policy despite current lawsuits. <http://www.bmj.com/content/346/bmj.f2961?tab=responses> 2013;21 June.
226. Gøtzsche PC, Maund E. Re: Restoring invisible and abandoned trials: a call for people to publish the findings. <http://www.bmj.com/content/346/bmj.f2865/rr/650915> 2013;21 June.
227. Gøtzsche PC. AbbVie considers harms to be commercially confidential information: sign a petition. *BMJ* (Online) 2013;347:f7569.
228. Gøtzsche PC. Developing a new drug costs less than \$100m, not \$900m. *BMJ* 2013;346:f398.
229. Gøtzsche PC. Roche continues to drag its feet on access to Tamiflu data. *BMJ* (Online) 2013;346:f3001.

230. Jørgensen KJ, Gøtzsche PC. Effect of screening mammography on breast cancer incidence. *N Engl J Med* 2013;368:677-8.
231. Jørgensen KJ, Brodersen J, Gøtzsche PC. Thirteen years of breast screening had no measurable effect on breast cancer mortality in Norway. *Int J Cancer* 2013;132:1725-6.
232. Krogsbøll L, Juhl Jørgensen K, Gøtzsche PC. Social ulighed i sundhed. *Ugeskr Læger* 2013;175:74-5.
233. Zahl P-H, Suhrke P, Jørgensen KJ. Overdiagnosis of breast cancer in Norway: what have the authors adjusted for? *Int J Cancer* 2013;133:2754-5.
234. Gøtzsche PC. Nye cancermidler er ikke bedre end gamle. *Ugeskr Læger* 2013;175:2138.
235. Gøtzsche PC. Screening for tvangstanker, depression og ADHD? *Ugeskr Læger* 2013;175:77.
236. Gøtzsche PC. Tvivlsomt om lokalt appliceret NSAID har nogen effekt. *Ugeskr Læger* 2013;175:377-8.
237. Gøtzsche PC. Vildledning fra Kræftens Bekæmpelse om mammografiscreening. *Ugeskr Læger* 2013;175:1056.
238. Gøtzsche PC. Vores forskning om lægemiddelindustrien er veldokumenteret. *Ugeskr Læger* 2013;175:3048.
239. Gøtzsche PC. Der er ikke effekt af drotrecogin alfa ved svær sepsis. *Ugeskr Læger* 2013;175:903-4.
240. Gøtzsche PC, Jørgensen KJ. The benefits and harms of breast cancer screening. *Lancet* 2013;381:799.
241. Krogsbøll LT, Jørgensen KJ. Helbredstjek - igen. *Ugeskr Læger* 2013;175:532.
242. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. Universal health checks should be abandoned. *BMJ (Online)* 2013;347:f5227.
243. Gøtzsche PC. Mammography screening increases non-breast cancer mortality. *Trials* 2013;14:368.
244. Gøtzsche PC. The drug industry is similiary harmful as the tobacco industry. *BMJ* 2013;347:f5193.
245. Gøtzsche PC. Treatment of urinary incontinence with antimuscarinic drugs is pointless. *BMJ* 2013;347:f5170.
246. Gøtzsche PC. "I don't want the truth, I want something I can tell Parliament!" *BMJ* 2013;347:f5222.
247. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. Health check check. *The Times* 2013;Aug 20:25.
248. Gøtzsche PC. Incorrect statements by Novo Nordisk. *BMJ* 2013;347:f4386.
249. Gøtzsche PC. SSRI kan føre til selvmord. *Dagens Medicin* 2013;3Maj .
250. Gøtzsche PC. Whistleblowere skal beskyttes. *Berlingske* 2013;5Aug:21.
251. Gøtzsche PC. GlaxoSmithKline and Roche won't disclose their results. *BMJ* 2013;346:f819.
252. Gøtzsche PC. Comment on risk of bias tool. www.thecochranelibrary.com/details/editorial/5655441.2014;10 Jan.
253. Gøtzsche PC. Medicinalindustriens mange løgne. *Jyllands-Postens kronik* 2014;4 Jan..
254. Gøtzsche PC. Psykiatri på afveje. *Politiken, kronik*, 2014;6 Jan.
255. Gøtzsche PC. Lykkepille-epidemien: skyd ikke budbringeren, men se budskabet. www.epracticus.dk/flx/debat/?FID=2&MID=30 ?. 2014;13 Jan.
256. Gøtzsche PC. Toneangivende psykiatere er fortsat på afveje. *Politiken, kronik*, 2014;21 Jan .
257. Gøtzsche PC. Brug psykofarmaka mindre og bedre. *Weekendavisen* 2014;31 Jan.
258. Gøtzsche PC. Vi skal bruge mindre psykofarmaka. *Ugeskriftet.dk* 2014;6 Feb .
259. Gøtzsche PC. Om statistik og bias. *Ugeskr Læger* 2014;176:273.
260. Gøtzsche PC. Unwarranted criticism of "Psychiatry Gone Astray". davidhealy.org/get-real-peter-gotzsche-responds/ 2014;17 Feb .
261. Gøtzsche PC. Vildledende forskning og markedsføring. *Ugeskr Læger* 2014;176:373.
262. Gøtzsche PC. Fejleiteringer om psykiatri. *Berlingske* 2014;23 Feb.
263. Gøtzsche PC. Fup eller fakta om dødelig medicin. *Dagens Medicin* 2014;28 Feb .
264. Gøtzsche PC. Screening virker ikke. *Jyllands-Posten* 2014;8 Mar.
265. Gøtzsche PC. Screening af gravide for depression. *Månedsskr Almen Praksis* 2014;326-8.
266. Auken M, Gøtzsche PC. Kun via EU sikrer vi åbenhed i medicinalindustrien. *Information* 2014;5 April.
267. Auken M, Gøtzsche PC. Hyklerisk medicinalindustri. *Information* 2014;9 April.
268. Gøtzsche PC. Misvisende oplysninger om Cochrane. *Altinget* 2014;8 April.
269. Gøtzsche PC. Lægger ikke luft til mig. *Politiken* 2014;9 April.

270. Gøtzsche PC. Cochrane-fjeren, der blev til fem høns. Dagens Medicin 2014;11 April.
271. Gøtzsche PC. Antidepressiv medicin bør undgås til børn og unge. OCD-nyt 2014;1-14:7.
272. Gøtzsche PC. Nyhed om Cochrane var misvisende. <http://ugeskriftet.dk/nyhed/cochrane-laegger-afstand-til-goetzsche#comment-354>. 2014;8 Apr.
273. Gøtzsche PC. Adverse effects of statins are very common. 2014;21 May .
www.bmj.com/content/348/bmj.g3306/rr/698864.
274. Gøtzsche PC. Sundhedstjek: Den politiserende Sundhedsstyrelse. Dagens Medicin 2014;10 Okt.
275. Bewley S, Rose L, Gøtzsche P, Blennerhassett M, Colquhoun D, Pryke M, et al. Time to halt an out of control trial with ineffective oversight. B M J (Online) 2014;349:g5601.
276. Gøtzsche PC, Jørgensen KJ, Krogsbøll LT. Authors' reply to Lauritzen and colleagues, Newton and colleagues, and Mangin. B M J (Online) 2014;349:g4790.
277. Gøtzsche PC. Muscular adverse effects are common with statins. BMJ (Online) 2014;348:g3724.
278. Gøtzsche PC, Jørgensen KJ, Krogsbøll LT. General health checks don't work. BMJ (Online) 2014;348:g3680.
279. Gøtzsche PC. Questionable research and marketing of a combination drug for smoker's lungs. J R Soc Med 2014;107:256-7.
280. Gøtzsche PC. Study of study of changes in antidepressant use after FDA warnings is not reliable. BMJ (Online) 2014;349:g5623.
281. Gøtzsche PC, Jørgensen KJ, Zahl P-H. Lead-Time Models Produce Far Too Low Estimates of Overdiagnosis With Mammographic Screening. JACR 2014;11:1098.
282. Gøtzsche PC. Przepisywane leki przyczyną zgonu rzeszy pacjentów. Pol Arch Med Wewn 2014;124:750-6.
283. Gøtzsche PC. Antidepressiva bør ikke bruges til børn og unge. Ugeskr Læger 2015;18 Maj.
284. Gøtzsche PC. Atomoxetin til ADHD er værre end sit rygte. Ugeskr Læger 2015;177:1301-2.
285. Gøtzsche PC. Author's reply to Tovey and colleagues. BMJ 2015;350:h2955.
286. Gøtzsche PC. Comment on "Our prescription drugs kill us in large numbers". Author's reply. Pol Arch Med Wewn 2015;125:106-7.
287. Gøtzsche PC. Correction to "Author's reply to Tovey and colleagues". BMJ 2015;350:h3138.
288. Gøtzsche PC. Days tomme postulatere om psykiatrien. Berlingske Tidende 2015;12 Sep;16.
289. Gøtzsche PC. Gøtzsche melder psykiater til Lægeetisk Nævn. Dagens Medicin 2015;9 Okt;16:1.
290. Gøtzsche PC. Hvor stor en rolle spiller antipsykotika i overdødeligheden ved skizofreni? Ugeskr Læger 2015;177:895-6.
291. Gøtzsche PC. Psychiatric drugs should not be used in demented people. BMJ 2015;350:h369.
292. Gøtzsche PC. Psykiateren prøver at skyde budbringeren. Dagens Medicin 2015;9 Okt;16:1.
293. Gøtzsche PC. RE: Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. BMJ 2015;351:h6019.
294. Gøtzsche PC. Re: Suicide risk assessment and intervention in people with mental illness. BMJ 2015;351:h4978.
295. Gøtzsche PC. Re; Does long term use of psychiatric drugs cause more harm than good?: Maudsley debate and guild interests. BMJ 2015;351:h2435.
296. Gøtzsche PC. Screening doesn't reduce the occurrence of advanced cancers. BMJ 2015;350:h867.
297. Gøtzsche PC. Svar: Børn behandlet med stimulanser udvikler ofte hjerneatrofi. Ugeskr Læger 2015;4 Nov .
298. Gøtzsche PC. Svar: Dokumentationen for, at antidepressiva forårsager selvmord. Ugeskr Læger 2015;177:1649.
299. Gøtzsche PC. Svar: Selvmord forårsaget af antidepressiva skal frem i lyset. Ugeskr Læger 2015;177:1303.
300. Gøtzsche PC. Svar: Tavshedspligt, akademisk dannelse, lægelig pli. Ugeskr Læger 2015;18 Jun.
301. Gøtzsche PC. Tre psykiatrisprofessorer på afveje. Politiken 2015;4 Sep.
302. Gøtzsche PC. Tvang i psykiatrien bør forbydes. Politiken 2015;5 Aug.
303. Gøtzsche PC. Usandheder i psykiaterformands boganmeldelse. Ugeskr Læger 2015;7 Okt 7.
304. Jørgensen KL, Gøtzsche PC. Helbredstjek til lavtuddannede er skadeligt. Ugeskr Læger 2015;11 Feb.

305. Jørgensen KJ, Zahl P-H, Gøtzsche PC. Influence of mammography screening on use of mastectomies in Denmark. *Acta Oncol* 2015;133:54.
306. Gøtzsche PC. SVAR: Begrebet interessekonflikter bør ikke udvandes (svar på Kronik: Interessekonflikter – mere end ussel mammon). *Ugeskr Læger* 2016;19:1840.
307. Boesen K, Gøtzsche PC, Juhl Jørgensen K. Re: Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. *Cochrane Database Sys Rev* 2016;(1):CD005041.
308. Boesen K, Gøtzsche PC. Quality of life of adult patients with attention-deficit/hyperactivity disorder taking methylphenidate. *Arch Gen Psychiatry* 2016;73:533-4.
309. Gøtzsche PC. Abolishing forced treatment in psychiatry is an ethical imperative [Online] 2016 [Citeret 2016 jun. 17] <https://www.madinamerica.com/2016/06/abolishing-forced-treatment-in-psychiatry-is-an-ethical-imperative/>
310. Gøtzsche PC. Antidepressants are addictive and increase the risk of relapse. *BMJ* 2016;352:i574.
311. Gøtzsche PC. Antidepressants increase the risk of suicide and violence at all ages [Online] 2016 [Citeret 2016 nov. 16] <https://www.madinamerica.com/2016/11/antidepressants-increase-risk-suicide-violence-ages/>
312. Gøtzsche PC. Author's reply to Dubicka and colleagues and Stone. *BMJ* 2016;352:i915.
313. Gøtzsche PC. Bliv hjemme, næste gang du får en invitation til brystkræftscreening. *Politiken* 2016;31 Maj:1.
314. Gøtzsche PC. Bred afvisning af mere tvang på bosteder. *Ugeskr Læger* 2016;13 Sep:9.
315. Gøtzsche PC. Fakta om sundhedstjek er mørkelagt (kronik). *Politiken* 2016;14 Jan.
316. Gøtzsche PC. Forced admission and treatment in psychiatry are violations of basic human rights and must be abolished. Lecture in Anchorage 2 June 2016. <http://psychrights.org/education/GoetzscheJune2016/160602PeterGoetzscheAnchorageTalkTranscript.htm>.
317. Gøtzsche PC. Forårsager benzodiazepiner demens? *Ugeskr Læger* 2016;178:693.
318. Gøtzsche PC. Hvad er der kommet ud af vore indsatser mod kræft?: Hvad har fremskridtet på kræftområdet så været i virkeligheden? Med enkelte undtagelser ikke ret meget. *Dagens Medicin* 2016;6 Dec .
319. Gøtzsche PC. Medicin og screening mod demens virker ikke: Sundhedsministeren ønsker tidlig opsporing af demens. Men det kan gøre mere skade end gavn. *Ugeskr Læger* 2016;178:1291.
320. Gøtzsche PC. Polyfarmaci med antipsykotika øger dødeligheden: Studier, der viser, at antipsykotika med polyfarmaci ikke medfører øget dødelighed, er fejlbehæftede, mener Peter Gøtzsche. *Ugeskr Læger* 2016;178:397.
321. Gøtzsche PC. Praktiserende læger er guld værd (kronik). *Jyllands-Posten* 2016;9 Nov .
322. Gøtzsche PC Prescription drugs are the third leading cause of death [Online] 2016 [Citeret 2016 jun. 16] <http://blogs.bmj.com/bmj/2016/06/16/peter-c-gotzsche-prescription-drugs-are-the-third-leading-cause-of-death/>
323. Gøtzsche PC. Psykofarmaka øger risikoen for vold: Noget bør laves om i retspsykiatrien. *Ugeskr Læger* 2016;178:2039.
324. Gøtzsche PC. Seks ting der er værd at vide om masseskyderier. *Videnskab.dk* 2016;1 Jun.
325. Gøtzsche PC. Tvangslovene i psykiatrien skal afskaffes. *Psykologernes Fagmagasin* 2016;17 Mar.
326. Gøtzsche PC Tvangsbehandling med elektrochok bør forbydes [Online] 2016 [Citeret 2016 mar. 12] Tilgængelig fra: URL:<http://www.deadlymedicines.dk/tvangsbehandling-med-elektrochok-bor-forbydes/>
327. Gøtzsche PC. Unblinding in SSRI trials due to side effects is an important source of bias. *Br J Psychiatry* 2016;208.
328. Jørgensen KJ, Gøtzsche PC. Breast Cancer Screening: Benefit or Harm? *JAMA* 2016;315:1402.
329. Gøtzsche PC. Antidepressiva øger risikoen for selvmord og vold i alle aldre. *Medicinsk Tidsskrift* 2016; 20 Nov:506.
330. Gøtzsche PC. Patients should have free and immediate access to all information related to clinical trials. *BMJ* 2017;356:j1221.
331. Jørgensen KJ, Gøtzsche PC, Kalager M, Zahl P-H. Breast Cancer Screening in Denmark. *Ann Inter Med* 2017;167:524.
332. Gøtzsche PC. Hyllning till en enastående psykiatriker. Forord til: Breggin PR. Att sluta med psykofarmaka. Stockholm: Karneval Förlag, 2018.
333. Gøtzsche PC. What is it like being on the Governing Board? <http://community.cochrane.org/news/what-it-being-governing-board>. 2017; 27 Sept.

334. Gøtzsche PC. Akupunktur virker ikke. Det er ikke dokumenteret, at akupunktur har nogen klinisk relevant effekt på noget som helst. Dagens Medicin 2018; 7 feb.
335. Gøtzsche PC. Nej, jeg står ikke bag 'uhyrlige påstande'. Politiken 2018; 30. april.
336. Gøtzsche PC. Psychiatry is a disaster area in healthcare that we need to focus on. <http://www.bmj.com/content/360/bmj.k9/rr-15>. 2018; 10 Jan.
337. Gøtzsche PC. Skærpet tilsyn med psykiatere kan være nødvendigt. Dagens Medicin 2018; 9. feb.
338. Gøtzsche PC. Selvmordene forårsaget af depressionspiller vil fortsætte – man bør simpelthen undgå dem. Jyllands-Posten 2018; 11. feb.
339. Gøtzsche PC. Om depression, videnskabelig debat og Cochrane. Jyllands-Posten 2018; 20. feb.
340. Gøtzsche PC. Cipriani review does not add anything. Council for Evidence-based Psychiatry. 2018; 22 Feb.
341. Gøtzsche PC. Learning to live with hearing voices – an authoritative statement lacks documentation. BMJ 2018;361:k2018.
342. Gøtzsche PC. Comment on: "My OCD story: evidence-based medicine to the rescue!" Evidently Cochrane 2019 May 29.
343. Gøtzsche PC, Hengartner MP, Davies J, Read J, Guy A, Timimi S, Kinderman P. Esketamine for depression? No thanks, please. BMJ 2019 Oct 3.
344. Gøtzsche PC, Hengartner MP, Davies J, Read J, Guy A, Timimi S, Kinderman P. Re: Esketamine for treatment resistant depression. BMJ 2019 Oct 11.
345. Gøtzsche PC, Hengartner MP, Davies J, Read J, Guy A, Timimi S, Kinderman P. Re: Esketamine for treatment resistant depression. BMJ 2019 Oct 22.
346. Jørgensen KJ, Gøtzsche PC, Krogsbøll LT. Ønskedrømme til en høj pris. Dagens Medicin 2019 June 25.
347. Urato AC, Abi-Jaoude E, Abramson J, et al. National Partnership for Maternal Safety: consensus bundle on venous thromboembolism. Obstet Gynecol 2019;134:1115-7.

Secondary publications in Danish

1. Gøtzsche PC. Reference-bias. Ugeskr Læger 1988;150:228-9.
2. Nordic Medical Research Councils' HIV Therapy Group. Dobbeltblind dosis-responsundersøgelse af zidovudin ved AIDS og fremskreden HIV-infektion. Ugeskr Læger 1993;155:104-7.
3. Gøtzsche PC, Nielsen C, Gerstoft J, Nielsen CM, Vestergaard BF. Patientoverlevelse ved zidovudinresistent HIV. Ugeskr Læger 1994;156:185-6.
4. Gøtzsche PC, Gjørup I, Bonnén H, Brahe NEB, Becker U, Burcharth F. Randomiseret undersøgelse og metaanalyse af somatostatin overfor placebo ved blødende øsofagusvaricer. Ugeskr Læger 1996;158:2393-6.
5. Gøtzsche PC. Vigtigheden af et bredt perspektiv på metaanalyse: kan have afgørende betydning for patienterne. Ugeskr Læger 2000;162:5601.
6. Gøtzsche PC. Bredt perspektiv på metaanalyse af afgørende betydning for patienten. Läkartidningen 2000;97:5882-3.
7. Gøtzsche PC. Bredt perspektiv på metaanalyse - kan have afgørende betydning for patienterne. Tidsskr Nor Lægeforen 2000;120:2810-1.
8. Hróbjartsson A, Gøtzsche PC. Hvad er effekten af placebobehandling? Ugeskr Læger 2002;164:329-33.
9. Jørgensen KJ, Gøtzsche PC. Information om brystkræftscreening på internetsider er ensidig og mangelfuld - sekundærpublikation. Ugeskr Læger 2005;167:174-8.
10. Gøtzsche PC. Forbedret rapportering af skadevirkninger i randomiserede forsøg: udvidelse af CONSORT-vejledningen. Ugeskr Læger 2005;167:1520-2.
11. Hróbjartsson A, Chan A-W, Haahr MT, Gøtzsche PC, Altman DG. Selektiv rapportering af effektmål i randomiserede forsøg. Sekundærpublikation. Ugeskr Læger 2005;167:3189-91.
12. Haug C, Gøtzsche PC, Schroeder T. Register og registrering af kliniske forsøg. Sekundærpublikation. Ugeskr Læger 2006;168:457-8.
13. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Begrænsninger i publikationsrettighederne i industriinitierede kliniske forsøg - sekundærpublikation. Ugeskr Læger 2006;168:2467-9.
14. Jørgensen KJ, Gøtzsche PC. Er invitationer til mammografiscreening et rimeligt udgangspunkt for det informerede samtykke? Sekundærpublikation. Ugeskr Læger 2006;168:1658-60.

15. Gøtzsche PC. Er relative risici og oddsratioer i resumeer troværdige? Sekundærpublikation. Ugeskr Læger 2006;168:2678-80.

Teaching

Pregraduate courses

1988-89	Junior lecturer, Theory of Science, University of Copenhagen.
1990-2012	Lecturer, Theory of Science, University of Copenhagen.
1992-93	Lecturer, internal medicine, Hvidovre Hospital.
1993, 13 May	Course in research methodology, human biology, University of Copenhagen.
1994, 2-3 Feb	Course in research methodology, human biology, University of Copenhagen.
2003, 2 Sept	When is one drug better than another? Denmark's Pharmaceutical University.
2003, 20 Oct	Meta-analyses and their role in systematic reviews. Students in Public Health, Copenhagen.
2015, 15 April	Lectures on Theory of Science for pharmacy students.
2016, 8 Dec	Vore lægemidler er den 3. hyppigste dødsårsag. Farmaceutstuderende, København.
2017, 7 Dec	Kliniske forsøg. Farmaceutstuderende, København.
2018, 30 Apr	Psykiatriske diagnoser og depressionsmedicin. Psykologistuderende, København.
2018, 11 Oct	Kliniske forsøg. Farmaceutstuderende, København.

See also Lectures below, which include many for students.

Postgraduate courses

C: course manager.

- Controlled clinical trials of drugs, Rigshospitalet, 3-5 Nov 1986.
- C Statistics and epidemiology. Scandinavian Diploma Course in Tropical Medicine, University of Copenhagen, 28 Oct 1987.
- A-course in research methodology. National Board of Health, 15 Nov 1988.
- A-course in clinical decision theory. National Board of Health, 17 Apr 1989.
- C Statistics and epidemiology. Scandinavian Diploma Course in Tropical Medicine, University of Copenhagen, 2 Nov 1989.
- C Transdisciplinary course in medical ethics. Danish Society for Theory in Medicine, Copenhagen, 29 Apr 1989.
- C Transdisciplinary course in medical ethics. Danish Society for Theory in Medicine, Copenhagen, 29 Apr 1990.
- Course on meta-analyses. Medicom, Copenhagen, 21 May 1990.
- C Transdisciplinary course in medical ethics. Danish Society for Theory in Medicine, Copenhagen, 10 Nov 1990.
- PhD course in medical ethics. University of Southern Denmark, 17 May 1991.
- Course on rheumatoid arthritis. Danish Rheumatological Society, 27 Okt 1991.
- Course in clinical trials. Apothecary Society, Hillerød, 5 Nov 1991.
- C Litterature evaluation for pharmacists, Hillerød, 2-4 Dec 1991.
- Bias. Course in pharmacodynamics. Danish Society for Clinical Pharmacology, 6 Dec 1991.
- C Rigshospitalet's course in clinical trials. Hillerød, 2-6 Mar 1992.
- A-course in clinical pharmacology. National Board of Health, 3 Mar 1992.
- Research methodology for back diseases. Back research group, Copenhagen, 2 Apr 1992.
- A-course in clinical pharmacology. National Board of Health, 5 May 1992.

19. PhD course in medical ethics. University of Southern Denmark, 8 May 1992.
20. A-course in clinical pharmacology. National Board of Health, 6 Oct 1992.
21. C Rigshospitalet's course in clinical trials. Hillerød, 19-23 Oct 1992.
22. A-course in rheumatology. National Board of Health, 24 Nov 1992.
23. A-course in clinical pharmacology. National Board of Health, 8 Dec 1992.
24. A-course in rheumatology. National Board of Health, 9 Feb 1993.
25. A-course in clinical pharmacology. National Board of Health, 2 Mar 1993.
26. PhD course in medical ethics. University of Southern Denmark, 26 Mar 1993.
27. C Rigshospitalet's course in clinical trials. Hillerød, 31 Mar-2 Apr 1993.
28. Course on Systematic Reviews. Swedish Council for Technology Assessment in Health Care, Stockholm, 19-20 Oct 1993.
29. A-course in clinical pharmacology. National Board of Health, 1 Mar 1994.
30. C PhD course in systematic reviews. Panum Institute, 11-12 Apr 1994.
31. C PhD course in systematic reviews. Panum Institute, 13-14 Apr 1994.
32. C Rigshospitalet's course in clinical trials. Hillerød, 18-22 Apr 1994.
33. Rigshospitalet's research policy. Rigshospitalet, 18 Aug 1994.
34. Course in biological psychiatric research. Bispebjerg Hospital, 17 Jan 1995.
35. Scientific dishonesty. University hospitals' Centre for Nursing Research. Rigshospitalet, 23 Feb 1995.
36. Course on Systematic Reviews. Swedish Council for Technology Assessment in Health Care, Copenhagen, 27-29 Mar 1995.
37. Post Conference Course in Evidence-based Health Care: critical appraisal of evidence. International Society for Technology Assessment in Health Care, Dalarna, Sweden, 7-10 June 1995.
38. Use of research results. Rigshospitalet's course in quality development, 15 June 1995.
39. Course on Systematic Reviews. Swedish Council for Technology Assessment in Health Care, Stockholm, 29-31 Oct 1995.
40. Course in quality development. Rigshospitalet, 13 Dec 1995.
41. C Course on systematic reviews. Panum Institute, 14-15 Dec 1995.
42. Meta-analyses and evaluation of the quality of research. Danish Society for Internal Medicine. Sundby Hospital, 27 Mar 1996.
43. C Workshop on Handsearching. Nordic Cochrane Centre, 16 Apr 1996.
44. C Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 17 Apr 1996.
45. C Workshop on Systematic Reviews for Cochrane Reviewers. Getting a review into Review Manager. Nordic Cochrane Centre, 18 Apr 1996.
46. Workshop on Systematic Reviews. Swedish Council for Technology Assessment in Health Care, Stockholm, 12-14 May 1996.
47. C Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 12 Sept 1996.
48. C Workshop on Systematic Reviews for Cochrane Reviewers. Getting a review into Review Manager. Nordic Cochrane Centre, 13 Sept 1996.
49. Course on systematic reviews. Swedish Council for Technology Assessment in Health Care, Stockholm, 4-6 Dec 1996.
50. C Course on systematic reviews. Swedish Council for Technology Assessment in Health Care, Göteborg, 17 Dec 1996.
51. The controlled clinical trial and meta-analysis. Danish Society for Internal Medicine. Sundby Hospital, 10 Mar 1997.
52. Meta-analyses and the international Cochrane Collaboration. PhD course in clinical intervention research. MEDIF/MEFA, 13 Mar 1997.
53. Second Nordic Course in Evidence-based Medicine. Oslo, 1-5 June 1997.
54. Minicourse in evidence-based medicine and the Cochrane Library. Rigshospitalet, 5 Nov 1997.
55. C Workshop on Handsearching. Nordic Cochrane Centre, 12 Nov 1997.

56. C Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 13 Nov 1997.
57. Course in evidence-based medicine. Rigshospitalet, 30 Apr-2 May 1998.
58. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 27 May 1998.
59. C Workshop on Handsearching. Nordic Cochrane Centre, 9 July 1998.
60. C Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Helsinki, 21 Sept 1998.
61. Course in evidence-based medicine. Rigshospitalet, 9-12 Nov 1998.
62. C Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 1 Mar 1999.
63. C Workshop on Handsearching. Nordic Cochrane Centre, 3 Mar 1999.
64. Course in evidence-based medicine. Panum, 14-17 June 1999.
65. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 21 Mar 2000.
66. Workshop on Handsearching. Nordic Cochrane Centre, 22 Mar 2000.
67. C Evidence-based medicine. Ringe Back Centre, 14 Apr 2000.
68. C Evidence-based cardiology. Society for Younger Cardiologists, 15 Apr 2000.
69. Workshop on controversial issues related to clinical trials and systematic reviews. Barcelona, 30 June 2000.
70. Workshop on Handsearching. Nordic Cochrane Centre, 11 Sept 2000.
71. Quantitative epidemiology: perspectives and limitations. Research School for Animal Reproduction and Health, 31 Jan 2001.
72. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 27 Mar 2001.
73. Meta-analyses - use and misuse. Danish Drug Industry Association, 30 May 2001.
74. C Workshop on Cochrane editing. Hotel Marina, 6-8 Sept 2001.
75. Quantitative epidemiology: perspectives and limitations. Research School for Animal Reproduction and Health, Karrebæksminde, 6 Feb 2002.
76. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 23 Apr 2002.
77. Course in evidence-based medicine. Rigshospitalet, 3-4 og 17-18 June 2002.
78. C Workshop on Cochrane editing. Hotel Marina, 12-14 Sept 2002.
79. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 7 Oct 2002.
80. Meta-analysis and potential and limitations of evidence-based medicine. 6. Lübecker course, Lübeck, 9-10 Oct 2002.
81. PhD course, Panum Institute, 12 Dec 2002.
82. Quantitative epidemiology: perspectives and limitations. Research School for Animal Reproduction and Health, Tune Landbrugsskole, 29 Jan 2003.
83. Prioritisation and evidence-based medicine. Nordjyllands Amtsråd, Ålborg, 13 Feb 2003.
84. C Workshop on Cochrane editing. Nordic Cochrane Centre, 18-19 Sept 2003.
85. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 6 Oct 2003.
86. C Quality of allocation concealment. 11th Cochrane Colloquium, Barcelona, 28 Oct 2003.
87. PhD course, Panum Institute, 24 Nov 2003.
88. Workshop on research in alternative medicine, Rigshospitalet, 30-31 Mar 2004.
89. Course in evidence-based medicine. Panum Institute, 1-2 og 14-15 June 2004.
90. C PhD course in systematic reviews and meta-analyses. Rolighed, 8-11 Nov 2004.
91. PhD course, Panum Institute, 1 Dec 2004.

92. Quantitative epidemiology: perspectives and limitations. Research School for Animal Reproduction and Health, KVL, 24 Aug 2005.
93. Course in infection pathogenesis. Rigshospitalet, 5 Sept 2005.
94. Doctors' Annual Gathering (Lægedage). Copenhagen, 18 Nov 2005.
95. PhD course in planning clinical research. Panum Institute, 21 Feb 2006.
96. PhD course in epidemiology. Køge, 30 Mar 2006.
97. Reporting of harms. GCP units in Denmark, Nyborg, 31 Mar 2006.
98. PhD course. Pharmaceutical University, 13 June 2006.
99. Doctors' Annual Gathering (Lægedage). Copenhagen, 11 Nov 2006.
100. Systematic reviews. Advanced seminar, Madrid, 16-17 Nov 2006.
101. Seminar on peer review and scientific misconduct. Karolinska Institute, Stockholm, 30 Nov 2006.
102. PhD course, Research ethics. Copenhagen Business School, 19 Mar 2007.
103. Course in clinical decision theory. National Board of Health, Copenhagen, 8 May 2007.
104. PhD course, Ethics in science. Faculty of life sciences, Copenhagen, 13 Aug 2007.
105. Evidence-based medicine. WHO, delegation from Uzbekistan, Hillerød, 21 Sept 2007.
106. Course for clinical microbiologists. National Board of Health, Copenhagen, 24 Sept 2007.
107. PhD course, Research ethics. Copenhagen Business School, 31 Oct 2007.
108. PhD course, Research ethics. Copenhagen Business School, 31 Mar 2008.
109. Course in Clinical Pharmacology, National Board of Health, 17 April 2008.
110. PhD course in planning clinical research. University of Copenhagen, 31 May 2008.
111. Workshop: Clinical trials registration & results reporting: The CONSORT guidelines and beyond. 2nd South Asian Regional Symposium on Evidence Informed Health Care. Vellore, India, 9 April 2008.
112. Course in clinical decision theory. National Board of Health, Copenhagen, 7 and 20 May 2007.
113. PhD course in clinical epidemiology. Køge, 9 Oct 2008.
114. Course in clinical decision theory. National Board of Health, Copenhagen, 19 Nov 2008.
115. Course in clinical decision theory. National Board of Health, Copenhagen, 24 Nov 2009.
116. PhD course in planning clinical research. University of Copenhagen, 21 Jan 2010.
117. Course in clinical decision theory. National Board of Health, Copenhagen, 18 May 2010.
118. Course in clinical pharmacology. National Board of Health, Copenhagen, 1 Apr 2011.
119. Forskeruddannelsesnetværket. Korsør, 17 May 2011.
120. PhD course. Herlev, 16 June 2011.
121. Highlights i reumatologien. Korsør, 1 Sept 2011.
122. PhD course, systematic reviews. University of Copenhagen, 26-29 Sept 2011.
123. Lægemiddelinformation – fup eller fakta? DULM-kursus, 20 April 2012.
124. PhD course, Good scientific practice and reporting, University of Copenhagen, 26-28 Sept 2012.
125. Screening. Speciallægeuddannelsen, Sundhedsstyrelsen, Rigshospitalet, 12 May 2016.
126. Screening. Speciallægeuddannelsen, Sundhedsstyrelsen, Bispebjerg, 10 Nov 2016.
- 127.C Myter, misforståelser og skader i psykiatrien. Heldagsseminar, Sydhavnen, 15 Dec 2016.
- 128.C Myter, misforståelser og skader i psykiatrien. Heldagsseminar, Fredericia, 25 April 2017.
- 129.C Udtræpning af psykofarmaka. Heldagskursus, København, 12 June 2017.
130. Withdrawal of psychiatric drugs, Göteborg, 18-20 Oct 2017.
131. Varför SSRI & liknande antidepressiva bör utgå. Swedish Psychiatrists, Göteborg, 25 Jan 2018.
- 132.C Seminar om udtræpning af psykofarmaka. Nyborg, 16 March.
- 133.C Seminar om udtræpning af psykofarmaka. Nyborg, 16 March. (seminar held twice the same day).
- 134.C Research seminar about depression pills. Copenhagen, 14 June.
135. Power versus rationality: fighting conflicts of interest. Oxford, 19 June 2019.
- 136.C Vejen ud af medicinens fængslende greb. Heldagsseminar, Kolding, 9 June 2020.

Lectures

IS: invited speaker; more recent titles have been translated into English, for convenience.

1. IS Steady state pharmacokinetics of naproxen in rheumatoid arthritis. XV congrès international de rhumatologie, Paris, 21-27 June 1981.
2. Dosis-respons forhold ved rheumatoid artrit. Ribe amts lægekredsförening, 5 nov 1982.
3. Klinisk farmakologi af naproxen (Naprosyn). Aftenmøder den 7, 11, 12, 19, 25 og 26 april 1983 på hhv. Store Kro, Fredensborg, Hotel H. C. Andersen, Odense, Hotel Impala, Silkeborg, Mogenstrup kro, Hotel Sheraton, København og Rold Storkro.
4. Månedens forskningsproblem: bedre end sig selv. Staff-meeting, amtssygehuset i Herlev, 24 okt 1985.
5. IS Reference bias. En undersøgelse af litteraturreferencemønstret i offentliggjorte lægemiddelundersøgelser. Dansk Selskab for Klinisk Farmakologi, 27 jan 1987.
6. IS Værdien af mikrobiologiske undersøgelser hos HIV-inficerede patienter. Dansk Selskab for Klinisk Mikrobiologi, 7 dec 1987.
7. Yield of diagnostic investigations of opportunistic infections in 33 AIDS patients. European Conference on Clinical Aspects of HIV Infection, Bruxelles, 10-11 Dec 1987.
8. IS Bias i dobbeltblinde undersøgelser af NSAID's med perspektiver for meta-analyser. Dansk Selskab for Medicinsk Reumatologi, 17 feb 1989.
9. IS Meta-analyse af antirheumatica behandling. Møde om den kontrollerede kliniske undersøgelses metodologi: status og perspektiver. Rigshospitalet, 28 apr 1989.
10. IS Meta-analyse af non-steroide antiinflammatoriske stoffer. Dansk Selskab for Intern Medicin, amtssygehuset i Herlev, 13 okt 1989.
11. IS Hvordan stiller man forsøg op, og hvordan analyserer man resultaterne? Årsmøde i Den Danske Klub for Centralsterilisering og Sygehushygiejne, Hotel Frederik II, Slagelse, 10 nov 1989.
12. IS Valg af NSAID ud fra kliniske studier. Specialistmøde for reumatologer, Novo Nordisk, København, 3 maj 1990.
13. IS Meta-analysis of second-line antirheumatic drugs: sample size bias and uncertain benefit. 23rd Nordic Congress of Rheumatology, Tampere, 15 June 1990.
14. IS Bias. Fællesundervisning for den medicinske blok, Hvidovre Hospital, 19 sept 1990.
15. IS Bias in NSAID trials. Italian Meeting on Meta-analysis within Hepatology. Erice, Sicilien, 3-5 Dec 1990.
16. IS Meta-analysis of multiple clinical trials: biases revealed by analysis of trials on first- and secondline antirheumatic drugs. 75th Anniversary of the Danish Association for Internal Medicine, København, 24 Jan 1991.
17. IS Muligheder og farer ved meta-analyser. Dansk Selskab for Medicinsk Filosofi, Etik og Metode, København, 13 feb 1991.
18. IS Hvilket NSAID er bedst? Møde arrangeret af medicinsk afdeling C med de praktiserende læger, amtssygehuset i Herlev, 9 apr 1991.
19. IS Præliminære resultater fra AIDSDOSE studiet. Dansk Selskab for Infektionsmedicin, Rigshospitalet, 30 apr 1991.
20. IS Detection of bias problems through the use of meta-analysis with examples from drug trials in rheumatology. Society for Clinical Drug Trials and Society for Medical Statistics, Stockholm, 22 May 1991.
21. IS Meta-analysis of DMARD's: are they effective? DAK's Rheuma Meeting in Tivoli, 23 Aug 1991.
22. IS Dobbelt-blind dosis responsundersøgelse af zidovudin ved AIDS og fremskreden HIV infektion, Statens Sundhedsvidenskabelige Forskningsråd, 12 nov 1991.
23. IS Internationella och nordiska erfarenheter av zidovudinbehandling. XLVIII Läkaresällskapets Riksstämman, Stockholm, 27 nov 1991.
24. Clinimetric problems in arthritis. Seminar on Bias and Controversies in Clinical Research, Rigshospitalet, 28 Feb 1992.
25. IS Problems and opportunities in drug trials with DMARDs. 24th Scandinavian Congress of Rheumatology, Malmö, 1 June 1992.

26. Meta-analysis is more than a combination of odds ratios. 13th International Meeting of International Society for Clinical Biostatistics, København, 18 Aug 1992.
27. IS Faldgruber i den klinisk kontrollerede undersøgelse. Medicinsk Selskab for Fyns Stift, Odense, 2 nov 1992.
28. IS Statistiske og filosofiske aspekter ved score systemer. Reumatologisk symposium, Nyborg, 12 mar 1993.
29. IS Good Clinical Practice. Ph.d.-studerende på Hvidovre Hospital, 30 sept 1993.
30. The Scandinavian Cochrane Centre. Dansk Selskab for Medicinsk Filosofi, Etik og Metode og Dansk Selskab for Medicinsk Prioritering, København, 13 okt 1993.
31. Det etiske grundlag for det danske sundhedsvæsen. Folkeuniversitetet, 9 november 1993.
32. IS NSAID og gastrointestinal tractus. Metodologiske problemer: er der forskelle mellem midlerne af klinisk relevans? Dansk Gastroenterologisk Selskabs E-kursus, København, 11 jan 1994.
33. IS Clinical practice should reflect clinical science. EU meeting, AIMCOM, Bruxelles, 24 Apr 1994.
34. IS Systematic reviews of clinical trials in policy making and health planning. Nordisk konference om kritiske valg i sundhedssektoren, Dansk Sygehus Institut, 26 Apr 1994.
35. IS Bias in statistical reporting: should the data analyst be blinded? Society for Clinical Trials, 15th annual meeting, Houston, Texas, 9 May 1994.
36. IS Meta-analyses in rheumatology. 25th Scandinavian Congress of Rheumatology, Lillehammer, 2 June 1994.
37. IS Cochrane Center på Rigshospitalet - meta-analyser i klinikken. Dansk Medicinsk Selskabs 75-års jubilæumsmøde, København, 26 aug 1994.
38. IS Orientering om Det Nordiske Cochrane Center. GCP-selskabet, Gentofte, 2 feb 1995.
39. IS Forskningen som prioriteringsgrundlag. Dansk Selskab for Medicinsk Prioritering, Svendborg, 28 apr 1995.
40. IS Meta-analysis of continuous data - NSAIDs as an example. Dansk Epidemiologisk Selskab, København, 2 June 1995.
41. IS Philosophy of sciences - in meta-analysis. 4th Nordic Conference for Medical Libraries, København, 24 Aug 1995.
42. IS Det internationale Cochrane-samarbejde. Nordisk medicinaldirektørmøde, Hornbæk, 1 sept 1995.
43. IS Cochrane Collaboration: implementering i *evidence based medicine*. Prioritering i sundhedsvæsenet, Ringkøbing amtskommune, 27 sept 1995.
44. Cochrane centres. 3rd Annual Cochrane Colloquium, Oslo, 6 Oct 1995.
45. IS Meta-analyses: assets and limitations. Recent Advances in Breast Cancer, Scandinavian Breast Cancer Group, Hindsgavl, 13 Oct 1995.
46. IS A randomized trial of withdrawal of slow acting antirheumatic drugs. Dansk Reumatologisk Selskab, København, 20 okt 1995.
47. IS Forskning som grundlag for indførelse af nye behandlingsmetoder. Temadag om prioritering i sundhedsvæsenet. Nordjyllands amt, Rebild, 1 nov 1995.
48. IS What is sound evidence for decision making? *Medicine* 96, Finnish Medical Association (Duodecim), Helsinki, 10 Jan 1996.
49. IS Cochrane Collaboration and the health care technology assessment. *Medicine* 96, Finnish Office for Health Care Technology Assessment, Helsinki, 11 Jan 1996.
50. IS Metaanalyse og kvalitetssikring. Dansk Selskab for Medicinsk Onkologi, Helsingør, 19 jan 1996.
51. Cochrane Centret, Rigshospitalet. Staff-meeting, Sundby Hospital, 23 jan 1996.
52. IS Nordic Cochrane Centre. H:S Forskningsråd, København, 12 mar 1996.
53. Cochrane-samarbejdet. Staff-meeting, Sankt Elisabeths Hospital, 9 apr 1996.
54. IS Bibliometrisk analyse af publikationer udgået fra danske intern medicinske afdelinger 1988-92. Dansk Selskab for Intern Medicins konference om forskningens vilkår i intern medicin, Hillerød, 12 apr 1996.
55. IS Hvad ved vi, og hvad gør vi? Temadag om tværfaglige specialeråd, Rigshospitalet, 2 maj 1996.
56. IS The Cochrane Collaboration. Cochrane Hepato-Biliary Group Meeting, Genève, 25 Aug 1996.
57. IS Medicinsk teknologivurdering og lægemidler. MEDIF's direktørseminarium, Hornbæk, 4 sept 1996.
58. Cochrane-samarbejdet. Staff-meeting, Hvidovre Hospital, 17 sept 1996.

59. IS Meta-analyser. Det Medicinske Selskab i København, Domus Medica, 24 sept 1996.
60. IS Debate: Within ten years, all health decisions will be evidence-based. 4th Annual Cochrane Colloquium, Adelaide, 24 Oct 1996.
61. IS Hvad skal diagnosen bruges til? Dansk Selskab for Klinisk Mikrobiologi, Kolding, 8 nov 1996.
62. Omsorg som effektiv behandling? Næstekærlighed, placebo og alternativ medicin. Dansk Selskab for Medicinsk Filosofi, Etik og Metode, Domus Medica, 14 nov 1996.
63. IS MTV - en nødvendighed i sundhedsvæsenet. Dansk Selskab for Sygehusledelse, Kolding, 28 nov 1996.
64. IS Is the Norwegian Minister of Health correct in saying that the Cochrane Collaboration has made a fetish of the randomised controlled trial? Annual Meeting for The Nordic Cochrane Centre and Network, Oslo, 17 Jan 1997.
65. IS Det Nordiske Cochrane Center. H:S Bestyrelse, København, 29 jan 1997.
66. IS Cochrane centeret. Sundhedsministeriet, København, 30 jan 1997.
67. IS Evidensbaseret medicin. Foreningen af Læger i Erhvervslivet, København, 19 mar 1997.
68. IS The Cochrane Collaboration. Svensk Internmedicinsk förenings vårmöte, Umeå, 20 mar 1997.
69. IS Hvilken sundhedsforskning har vi brug for? (paneloplæg). Forskningsudvalgets og Sundhedsudvalgets høring om sundhedsforskning, Folketinget, 2 apr 1997.
70. IS Nordiska Cochrane-centrat i Köpenhamn. Karolinska Institutet och Stockholm läns landsting, 3 apr 1997.
71. IS Beware of surrogate outcome measures. Dansk hypertensionsselskabs årsmøde, Svendborg, 11 Apr 1997.
72. IS The Cochrane Collaboration. 3rd Cochrane Hepato-Biliary Group meeting, 32nd annual EASL meeting, London, 12 Apr 1997.
73. IS Systematic review: somatostatin and octreotide in bleeding oesophageal varices. 3rd Cochrane Hepato-Biliary Group meeting, 32nd annual EASL meeting, London, 12 Apr 1997.
74. IS Quality and relevance of clinical trials. European Headache Federation 5th Summer School. Rungsted, 25 Apr 1997.
75. IS Sammenfattende vurderinger af behandlingsmetoders værdi - metaanalyser. Møde mellem medlemmerne af de regionale videnskabetiske komiteer og Den Centrale Videnskabetiske Komité. Kolding, 21 aug 1997.
76. IS "Evidence Based Medicine". Overlægeföreningens Årsmøde. Nyborg Strand, 29 Aug 1997.
77. The Cochrane Collaboration. WHO's European Office, Programme Manager's Meeting. København, 3 Sept 1997.
78. Cochrane-samarbejdet. Lægemeddelstyrelsen. København, 16 sept 1997.
79. IS Rigshospitalets forskningsproduktion i 1994-96. Temadag om budgettering af forsknings- og udviklingsmidler, Rigshospitalet, 23 sept 1997.
80. IS Scopes and topic lists of Review Groups. 5th Annual Cochrane Colloquium, Amsterdam, 9 Oct 1997.
81. IS Hjælp til selvhjælp: Hvad kan Cochrane-samarbejdet tilbyde sundhedsvæsenet, og hvad kan sundhedsvæsenet tilbyde Cochrane-samarbejdet? Institut for Sundhedsvæsen, Symposium, Køge, 24 okt 1997.
82. IS Evidence based medicine - oplæg og diskussion. H:S Sundhedsfaglige råd, Rigshospitalet, 28 okt 1997.
83. IS Vad är - och hur arbetar - Cochrane Collaboration? Regiondag om Evidence Based Medicine, Södra sjukvårdsregionen, Malmö, 21 nov 1997.
84. Cochrane-samarbetet. Läkemedelsverket, Uppsala, 5 dec 1997.
85. IS Evidence-based medicine: the present and the future. Duodecim, 10th Anniversary Seminar of the Physician's Desk Reference and Database, Helsinki, 28 Jan 1998.
86. IS Ethical aspects in the use of systematic reviews in health care. Workshop on systematic reviews, Stakes & FinOHTA, Helsinki, 30 Jan 1998.
87. IS Præsentation af Cochrane-projektet. Nordisk Ministerråd, Hellerup, 25 mar 1998.
88. IS Getting the message across. 7th European Stroke Conference, Edinburgh, 29 May 1998.
89. IS RCT, status og visioner. Dansk Selskab for Medicinsk Filosofi, Etik og Metode. Festmøde, København, 17 sept 1998.
90. IS Evidensbaseret medicin. Farmaciens Dag, Danmarks Farmaceutiske Selskab, København, 2 okt 1998.

91. IS Demonstrating evidence in action: a case study. 6th Annual Cochrane Colloquium, Baltimore, 25 Oct 1998.
92. IS Bias i randomiserade försök och meta-analyser. Svenska Läkarsällskapets Riksstämman, Göteborg, 24 nov 1998.
93. IS Det Nordiske Cochrane Center og dets samarbejde med klinisk praksis. Statens Sundhedsvidenskabelige Forskningsråd og Statens Institut for Medicinsk Teknologivurdering, Middelfart, 11 feb 1999.
94. IS Evidens fra systematiske reviews. Dansk Endokrinologisk Selskab, Domus Medica, 22 feb 1999.
95. IS Overall status of the Cochrane Collaboration. Cochrane Colorectal Cancer Group meeting, København, 19 Mar 1999.
96. Det Nordiske Cochrane Center og evidensbaseret medicin. Folketingets Sundhedsudvalg, 24 mar 1999.
97. IS Evidensbaseret klinisk praksis. Områdeledelsens Stab og Sekretariat, Odense Universitetshospital, 8 apr 1999.
98. IS Hvad kan Cochrane-databasen bruges til? Dansk Kirurgisk Selskabs Forårsmøde, Herlev, 15 apr 1999.
99. Presentation of The Cochrane Collaboration. Exploratory meeting to consider establishing a Russian Branch of The Nordic Cochrane Centre. Hotel Akademicheskaya, Moskva, 7-8 June 1999.
100. IS Mega-trials or meta-analysis? European Society for Paediatric Research, Panum Institutet, 28 June 1999.
101. IS Hvad er rationel farmakoterapi? Dansk Selskab for Medicinsk Filosofi, Etik og Metode, København, 22 okt 1999.
102. IS The Cochrane Collaboration i Norden. SBU, Evidensbaseret sjukvård. Stockholm, 27 jan 2000.
103. IS Hvad vil det sige, at behandlingen er evidensbaseret? Jydsk Medicinsk Selskab, Århus, 5 apr 2000.
104. IS Meta-analyser, systematiske reviews. Kursus i evidensbaseret klinik. Frederiksberg hospital, 9 juni 2000.
105. IS Systematic review of breast cancer screening. Meeting with local minister of health and specialist societies. Barcelona, 29 June 2000.
106. IS History of The Cochrane Collaboration. 8th Cochrane Colloquium, Cape Town, 25 Oct 2000.
107. IS Er det alvorlige mangler ved det vitenskapelige grunnlaget for mammografi-screeningen? Årsmøde i Norsk Patologforening, Oslo, 10 nov 2000.
108. IS Är mammografiscreening värdefull? Svensk förening för radiologisk bröstdiagnostik, Rigshospitalet, 16 nov 2000.
109. IS Systematic review of mass screening for breast cancer with mammography. Dansk Selskab for Medicinsk Onkologi, Panum, 20 Nov 2000.
110. IS Hvornår er ændret klinisk praksis nødvendig? Dansk Selskab for Medicinsk Filosofi, Etik og Metode, København, 23 nov 2000.
111. IS Evidensbaseret medicin. KAS Herlev, 28 nov 2000.
112. IS Fallstudie Mammographie Screening. Bern's Universität, 6 Dec 2000.
113. IS Cochrane Collaboration. SBU, Stockholm, 7 feb 2001.
114. IS Utility of mammographic screening for detection of breast cancer and the measurement of the placebo effect. São Paulo, 23 Feb 2001.
115. IS Screening for breast cancer with mammography: a systematic review. Breast and Cervical Cancer Screening Conference, Bielefeld, 6 Apr 2001.
116. IS Concept and methods in Cochrane reviews. Dansk Selskab for Psykiatrisk Epidemiologi, 20 apr 2001.
117. IS Putting the evidence into breast cancer care - challenges and controversies for the future. National Breast Cancer Coalition's Annual Meeting, Washington, 6 May 2001.
118. IS Ankelligament-metaanalyse. Dansk Fod- og Ankelkirurgisk Selskab, Gjern, 18 aug 2001.
119. Misleading publications of major mammography screening trials in major medical journals. Fourth International Congress on Peer Review in Biomedical Publication, Barcelona, 14 Sept 2001.
120. IS Cochrane reviews - the clinical application of evidence. Skandinavisk Forening af Oral og Maxillofacial Kirurger, 21 Sept 2001.
121. IS Hvilke problemer ved screeningsmetoder er politikere ikke blevet informeret om? Dansk Selskab for Medicinsk Prioritering og Dansk Selskab for Almen Medicin, København, 30 okt 2001.

122. IS Mammografiscreening - undersøgt i en metaanalyse. Dansk Selskab for Almen Medicins Risikogruppe, Silkeborg, 23 nov 2001.
123. IS Metaanalyse. Foredrag efter modtagelse af Niels A Lassen prisen, Bispebjerg Hospital, 7 dec 2001.
124. IS Metaanalyse, styrke og svaghed, metodologiske betragtninger. Gruppen af Yngre Gastroenterologer På Vej, København, 12 dec 2001.
125. IS Metaanalyser - hvad kan og skal de bruges til? Selskabet for Teoretisk og Anvendt Terapi, København, 7 feb 2002.
126. IS The old vs the new review. Second Asian-Pacific Conference on Evidence Based Medicine, Chengdu, China, 9 Apr 2002.
127. IS The importance of the published, peer reviewed protocol. Second Asian-Pacific Conference on Evidence Based Medicine, Chengdu, China, 9 Apr 2002.
128. IS Problemer ved vurderingen af lægemiddelundersøgelser. Dansk Reumatologisk Selskab, Horsens, 19 apr 2002.
129. IS Conflict of interest. Cochrane Colorectal Cancer Group's Status Meeting, København, 19 Apr 2002.
130. IS Lægers videnskabelige ytringsfrihed, interkollegiale problemer. Dansk Selskab til Sikring af Lægers Ytringsfrihed, København, 3 juni 2002.
131. IS Things to be cautious about when making policy recommendations based on systematic reviews, randomised trials, cohort studies, and expert opinion. Delegates from The Ministry of Health, China, Rigshospitalet, 20 Aug 2002.
132. IS Forskning er ikke fuldstændig objektiv - den kan drejes og vendes, så den passer politisk. Kursus for journalister, København, okt 2002.
133. IS Mammascreeing: a critical analysis. Wenckebach Symposium, Groningen, 5 Nov 2002.
134. IS Dissemination experiences in the Cochrane Collaboration. Nordic Campbell Center inauguration seminar, Helsingør, 13 Nov 2002.
135. IS Hva kan epidemiologer bidra med i deatten om mammografiscreening? Den tiende norske epidemiologikonferansen, Trondheim, 14 nov 2002.
136. IS Unambiguous and comparable results as quality measures in health related research. Is randomisation a necessity to obtain reliable knowledge? How are self-selection and self-conscious efforts handled? Konfernce arrangeret af Videns- og Forskningscenter for Alternativ Behandling, Århus, 27 Nov 2002.
137. IS Ten years of the Cochrane Collaboration. Seminar for Finnish doctors, Biomedicum, Helsinki, 23 Jan 2003.
138. IS Dronning Ingrid's Festforelæsning. Hvad er vore behandlinger værd? Åbenrå Sygehus, 8 maj 2003.
139. IS Temaeftermiddag. Evidensbaseret forebyggelse og behandling. Ålborg Sygehus, 9 sept 2003.
140. IS Plenary lecture. Pitfalls in evidence based medicine. 4th Congress, European Federation of Internal Medicine, Berlin, 11 Sept 2003.
141. IS Debate. Population based breast cancer screening. ECCO 12, Federation of European Cancer Societies, København, 25 Sept 2003.
141. Evidensbaseret forbrugeroplysning. Konference arrangeret af Forbrugerrådet og Det Nordiske Cochrane Center, Christiansborg, København, 22 okt 2003.
142. IS Plenary lecture. Conflicts of interest. XIth Cochrane Colloquium, Barcelona, 27 Oct 2003.
143. IS Evidensbaseret medicin: eksempler og betydning. Møde om medicinforsøg, arrangeret af Institut for Rationel Farmakoterapi, København, 19 nov 2003.
144. Discrepancies between protocols and publications: Evidence of outcome reporting bias in randomised trials. De Videnskabetiske komitéer for Københavns og Frederiksbergs kommuner, 11 dec 2003.
145. IS Experiences within the Cochrane Collaboration. WHO workshop on grading of evidence, København, 16 Dec 2003.
146. IS Evidensbaseret medicin. Sosial- og helsedirektoratet, Oslo, 15 jan 2004.
147. IS Why is the practice of evidence-based medicine more difficult than it seems? Læknadager 2004, Reykjavik, 23 Jan 2004.
148. IS Doctor, should I have a mammography? (debate). Læknadager 2004, Reykjavik, 23 Jan 2004.
149. IS The management of hypertension, should we rely on the good old drugs? (debate). Læknadager 2004, Reykjavik, 23 Jan 2004.

150. IS Evidence-based microbiology. Dansk Selskab for Klinisk Mikrobiologi, uddeling af Wyeth-prisen for 2003, København, 27 jan 2004.
151. IS Mammografi-screening, contra. Foreningen af Yngre Gynækologer og Obstetrikere Forårsmøde, Odense, 18 marts 2004.
152. IS Evidensgrundlag. Institut for Rationel Farmakoterapi, møde om kriterier for rationelt valg af lægemidler, Kolding, 30 april 2004.
153. IS Hvad er vore behandlinger værd? Gentofte-Vangede Rotary Klub, 26 aug 2004.
154. IS Empirical evidence for selective reporting of outcomes in randomised trials. Den Centrale Videnskabetiske Komité, København, 27 aug 2004.
155. IS Risikovurdering og formidling omkring screening, og industrisponsoreret forskning. Det Ethiske Råd, København, 16 sept 2004.
156. IS Fortsat udbredelse af mammografiscreening. Nordjyllands amtsråd, Ålborg, 19 nov 2004.
157. IS Harry Boström föreläsningen: Cochrane-samarbetet och evidensbaserad medicin. Riksstämman, Svensk Internmedicinsk Förening, Göteborg 25 nov 2004.
158. IS Nutidens og fremtidens krav om evidens for det lægelige arbejde. Nordjyllands Lægekredsforenings 150 års jubilæum, Ålborg, 26 nov 2004.
159. IS Blinding. Expert Discussion Workshop. Institute of Public Health, Cambridge, 17 maj 2005.
160. Sponsorship, bias and methodology: Cochrane Reviews compared with industry-sponsored meta-analyses of the same drugs. 5th International congress on peer review and biomedical publication, Chicago, 17 Sept 2005.
161. Are relative risks and odds ratios in abstracts believable? 5th International congress on peer review and biomedical publication, Chicago, 18 Sept 2005.
162. IS Medical statistics in practice: Dr Jekyll and Mr Hyde. 10 year celebration, Centre for Statistics in Medicine, Oxford, 20 Sept 2005.
163. IS Introduction to key concepts and principles of evidence-based medicine. Moscow Medical Academy, 13 Oct 2005.
164. Constraints on academic freedom in industry-initiated clinical trials. XIII Cochrane Colloquium, Melbourne, 22-26 Oct 2005.
165. IS Should we believe in epidemiology? Scientific seminar, Royal Veterinary and Agricultural University, Copenhagen, 14 Nov 2005.
166. IS Evidence in health care. Health Administration, Copenhagen County, 28 April 2006.
167. IS Commercial interests versus common goods. Nordic Committee on Bioethics, Malmö, 16 Oct 2006.
168. Far too many excluded studies listed in Cochrane Reviews. XIV Cochrane Colloquium, Dublin, 23-26 Oct 2006.
169. IS Cochrane Library. Ministry of Health, Warszawa, 18 Dec 2006.
170. IS Editorial misconduct. Finnish Medical Association, Helsinki, 25 Jan 2007.
171. IS Evidence-based health care. Institute for Competence Development, Copenhagen, 27 Feb 2007.
172. IS Commercial interests. Institute of Technology, Copenhagen, 14 Mar 2007.
173. IS Screening. Danish Society for Pathology, Copenhagen, 23 Mar 2007.
174. IS Selective reporting. Dutch Cochrane Centre's 12.5-year anniversary, Amsterdam, 18 April 2007.
175. IS Evidence-based health care. Aalborg University Hospital, 26 Sept 2007.
176. IS Bias in drug trials. Eur Assoc Clin Pharmacol, Amsterdam, 29 Aug 2007.
177. IS Commercial influence on clinical research. University of Southern Denmark, 15 Nov 2007.
178. IS Evidence-based medicine. Clinical microbiologists, Copenhagen, 21 Nov 2007.
179. IS Evidence for prevention. National Board of Health, Nyborg, 26 Nov 2007.
180. IS Can we trust clinical research results? Medical Society of Copenhagen, 27 Nov 2007.
181. IS Tainted evidence: drug companies and the power of marketing. 2nd South Asian Regional Symposium on Evidence Informed Health Care. Vellore, India, 9 April 2008.
182. IS Research collaboration. Danish Society for Theory in Medicine, Panum, 21 Apr 2008.
183. IS Mammography screening. Dept of Obstetrics, Rigshospitalet, 15 May 2008.
184. IS The corruption of drug research. Swiss Soc Intern Med, Lausanne, 21 May 2008.

185. IS Credibility of clinical research. Central Ethics Committee, Copenhagen, 13 June 2008.
186. IS The burdens of screening. Euroscience Open Forum, Barcelona, 21 July 2008.
187. IS Unhealthy health care. Distinguished scholar lecture, University of Minneapolis, 9 Sept 2008.
188. IS Unhealthy health care. Visiting scientist, University of Dartmouth, 11 Sept 2008.
189. IS Off-label use of drugs. Danish Pharmaceutical Society, Copenhagen, 29 Oct 2008.
190. IS Bias in drug trials. Danish Society for Psychiatric Epidemiology, Copenhagen, 6 Nov 2008.
191. IS Screening for lung cancer. Symposium, Focus on Lung Cancer, Copenhagen, 17 Nov 2008.
192. IS Screening for lung cancer. Danish Society for Pulmonary Medicine, Kolding, 28 Nov 2008.
193. IS Commercial interests. Institute of Technology, Copenhagen, 17 Dec 2008.
194. IS Screening and ethics. Clinical Ethics Committee, Frederiksberg Hospital, 2 Apr 2009.
195. IS Reflexions on screening. Region Middle Jutland, 15 Apr 2009.
196. IS Is the university trustworthy? LIFE, The Bioscientific Faculty, 6 May 2009.
196. IS Mammography screening. Nordic Congress in General Medicine, Copenhagen, 15 May 2009.
197. IS Opening lecture, Evidence-Based Medicine. 8th Congress of European Federation of Internal Medicine, Istanbul, 27 May 2009.
198. IS Cancer screening. Heinrich-Heine University, Düsseldorf, 17 June 2009.
199. IS Overdiagnosis of breast cancer. Cancer Intervention and Surveillance Modelling Network (CISNET), Rotterdam, 24 June 2009.
200. IS Good quality of drug trials. GCP meeting, Gentofte Hospital, 21 Sept 2009.
201. IS Forskningspolitisk debat, cancer screening. Forskningsens dag, Herlev Hospital, 28 Okt 2009.
202. IS Breast screening. Norwegian-Danish Seminar, Oslobåden, 2 Nov 2009.
203. IS Breast screening - the facts. Royal College of Obstetricians, London, 9 Nov 2009.
204. IS Er det dyreste det bedste? Region Sjælland, Sørup Heregård, 1 Dec 2009.
205. IS Randomisering i praksis. Trygfondens Forebyggelsescenter, 14 Jan 2010.
206. IS Mammographie-Screening. Berlin, German Cancer Society, 25 Feb 2010.
207. IS Klinisk relevans, hvad er det? Danish Society for Clinical Pharmacology, 2 Mar 2010.
208. IS Evidence: conflict of interest. Auckland, 22 Mar 2010.
209. IS Lægers interaktioner med medicinalindustrien. Region Nordjylland, 4 May 2010.
210. IS Fungal infections. Rigshospitalet, 12 May 2010.
211. IS Arguments for RCTs. Nordic Gastroenterology Congress, Copenhagen, 11 June 2010.
212. IS Ghostwriting is scientific misconduct. Polish Academy of Sciences, 8 Oct 2010.
213. IS Conflicts of interest. Danish University Antidepressant Group, Nyborg, 5 Nov 2010.
214. IS Bioethics: access to data and mammography screening. EU Parliament, Strassbourg, 24 Nov 2010.
215. IS Hvem har mest gavn af lægens medicinudskrivning? Patientforeningen Danmark, 18 Jan 2011.
216. IS Ethical aspects of public vs private research. Nordic Committee on Bioethics, Helsinki, 1 Nov 2011.
217. IS Strengthening and opening up EU's health research. EU Parliament, Brussels, 30 Nov 2011.
218. IS Medicinalindustrien. EU Parliament, Brussels, Social democrats, 1 Feb 2012.
219. IS Access to data from regulatory authorities. Paris, 19 April 2012.
220. IS European Drug Regulators' meeting. Why we need easy access to all data from all clinical trials and how to accomplish it. Copenhagen, 26 April 2012.
221. IS Why we need to open up health research by sharing our raw data. EU Parliament, Brussels, 6 June 2012.
222. IS Access to medical research data in the EU. HAI Europe, Amsterdam, 12 Oct 2012.
223. IS Rethinking clinical practice. Danish University Antidepressant Group, Nyborg, 9 Nov 2012.
224. IS Open access to all data is a moral obligation towards the patients. EU Parliament, Brussels, 13 Nov 2012.
225. IS Introductory statement. European Medicines Agency, London, 22 Nov 2012.
226. IS Time to stop mammography screening. Selling sickness, Washington DC, 21 Feb 2013.
227. IS Transparency saves lives. EU Parliament, Brussels, 10 Apr 2013.

228. IS Medical data transparency. Ombudsman meeting, EU Parliament, Brussels, 23 Apr 2013.
229. IS Overblik over børn med psykisk sygdom/diagnoser. Sundhedsudvalget, Folketinget, 27 May 2013.
230. IS Gavnfulde og skadelige virkninger ved medicinering af børn med psykisk sygdom. Sundhedsudvalget, Folketinget, 27 May 2013.
231. IS Mammografiscreening er skadelig og bør stoppes. Dagens Medicin, Folketinget, 31 May 2013.
232. IS What will we do about overdiagnosis? Dartmouth Institute for Health Policy & Clinical Practice, 12 Sept 2013.
233. IS Deadly medicines and organised crime. Johns Hopkins School of Public Health, Baltimore, 13 Sept 2013.
234. IS Deadly medicines and organised crime. Georgetown University, Washington DC, 16 Sept 2013.
235. IS Why drugs are the third leading cause of death. University College, London, 2 Oct 2013.
236. IS Early diagnosis. University College, London, 2 Oct 2013.
237. IS Psykiatri: medicinalindustriens paradys. Dispuk, Helsingør, 3 Oct 2013.
238. IS Working with evidence. Dansk Selskab for Obstetrik og Gynækologi, Roskilde, 7 Oct 2013.
239. IS 12 usandheder om depression til skade for patienterne. Psykovision, København, 7 Nov 2013.
240. IS Deadly medicines and organised crime. Harvard University, Safra Center for Ethics, 5 Dec 2013.
241. IS Deadly medicines and organised crime. McGill University, Montreal, 6 Dec 2013.
242. IS Deadly medicines and organised crime. Quebec University, Quebec, 9 Dec 2013.
241. IS Deadly medicines and organised crime. Ottawa Hospital, 10 Dec 2013.
243. IS Deadly medicines and organised crime. Women's College Hospital, Toronto, 11 Dec 2013.
244. IS Deadly medicines and organised crime. Toronto University, 12 Dec 2013.
245. IS Dødelig medicin og organiseret kriminalitet. Patientforeningen Danmark, Rigshospitalet, 14 Jan 2014.
246. IS Myter og fakta om antidepressiva. Plastikkirurgisk afd., 16 Jan 2014.
247. IS Lægers samarbejde med industrien, Overlægeföreningen, Hvidovre Hospital, 23 Jan 2014.
248. IS Receptpligtig medicin – den tredjehyppigste dødsårsag. FoF København, 25 Feb 2014.
249. IS Dødelig medicin og organiseret kriminalitet. Ølstykke Bibliotek, 27 Feb 2014.
250. IS Dødelig medicin og organiseret kriminalitet. JP Læserarrangement, 4 Mar 2014.
251. IS Psykofarmaka. Psykologisk Studenterforum, Århus Universitet, 4 Mar 2014.
252. IS Dødelig medicin og organiseret kriminalitet. Enhedslisten, Region Hovedstaden, 6 Mar 2014.
253. IS Psykofarmaka og andre lægemidler. Plan & Handling, Socialt-Lægeligt Seminar, Valby, 10 Mar 2014.
254. IS General health checks in adults. Deutsche EBM Netzwerk, Halle, 14 Mar 2014.
255. IS Why mammography screening should be stopped. Deutsche EBM Netzwerk, Halle, 14 Mar 2014.
256. IS Dødelig medicin og organiseret kriminalitet. Gentofte Bibliotek, 18 Mar 2014.
257. IS Why are prescription drugs the third leading cause of death? Panama City, 2 Apr 2014.
258. Health checks, what were the reactions? Nordic Cochrane Centre, 8 Apr 2014.
259. IS Set all data free. Young Investigators Network, Faculty Club, Panum, 10 Apr 2014.
260. IS Receptpligtig medicin – den tredjehyppigste dødsårsag. FoF København, 22 Apr 2014.
261. IS Why the use of psychiatric drugs may be doing more harm than good. House of Lords, UK, 30 Apr 2014.
262. IS This is not a symptom. South London Gallery, 30 Apr 2014.
263. IS Hvorfor er lægemidler den 3. hyppigste dødsårsag? Studenterforeningen, København, 2 May 2014.
264. IS Good scientific practice. Institute for Public Health, Copenhagen, 7 May 2014.
265. IS Dødelig medicin og organiseret kriminalitet. Praktiserende læger, Hotel Hesselet, 9 May 2014.
266. IS Psykiatri. Sundhedspolitisk Netværk, Ingeniørforeningen, 12 May 2014.
267. IS Psykiatri på afveje. Psykovision, Bethesda, København, 14 May 2014.
268. IS Interessekonflikter i lægeverdenen. Panum Institut, 19 May 2014.
269. IS Lægers relation til medicinalindustrien. Roskilde Sygehus, 21 May 2014.
270. IS Psychiatric drugs: does the way we use them cause more harm than good? Distinguished seminars in neuroscience and pharmacology. Panum Institute, 28 May 2014.

- 271 IS Håndtering af kommercielle interesser. Københavns Universitet, 10 June 2014.
- 272 IS Psychiatric drugs: does the way we use them cause more harm than good? Amsterdam, 13 June 2014.
- 273 IS Psykiatri på afveje. Stemmehørernetværket, Christiansborg, 17 June 2014.
- 274 IS Academia and industry. Annual Nobel Laureate meeting, Lindau, 3 July 2014.
- 275 IS Overdiagnosis and overtreatment in psychiatry. Finnish Psychological Association, Helsinki, 1 Sept 2014.
- 276 IS Deadly medicines and organised crime. Helsinki University, 2 Sept 2014.
- 277 IS Medicamentos que matan y crimen organizado. Barcelona, Institut d'Estudis Catalans, 8 Sept 2014.
- 278 IS Medicamentos que matan y crimen organizado. Madrid, Organización de Consumidores y Usuarios (OCU), 9 Sept 2014.
- 279 IS Psykofarmaka-debat. Århus Universitet, 11 Sept 2014.
- 280 IS What are the true benefits and harms of our drugs? Jagiellonian University, Krakow, 7 Oct 2014.
- 281 IS Cochrane reviews and their importance for evidence-based medicine. Jagiellonian University, Krakow, 7 Oct 2014.
- 282 IS Deadly medicines and organised crime. Maynooth University, Dublin, 8 Oct 2014.
- 283 IS Deadly medicines and organised crime. Stillorgan Park Hotel, Dublin, 8 Oct 2014.
- 284 IS Danmark på lykkepiller. Herstedøster Forsamlingshus, 21 Oct 2014.
- 285 IS Kan kræft forsvinde af sig selv? Mølholm Forsikring, Carlsberg, 23 Oct 2014.
- 286 IS Danskernes mentale sundhed. Folkeuniversitetet, Panum, 3 Nov 2014.
- 287 IS Kliniske forsøg. Pharmaschool, Copenhagen, 5 Nov 2014.
- 288 IS Dødelig medicin og organiseret kriminalitet. Lægeforeningen Syddanmark, Kolding, 5 Nov 2014.
- 289 IS Kan kræft forsvinde af sig selv? Mølholm Forsikring, Århus, 5 Nov 2014.
- 290 IS Mammography screening: why it hasn't lived up to expectations. Santa Rosa, California, 8 Nov 2014.
- 291 IS Why very few patients benefit from the drugs they take and why many are killed by them. Santa Rosa, California, 9 Nov 2014.
- 292 IS Why very few patients benefit from the drugs they take and why many are killed by them. Stanford Medical School, 11 Nov 2014.
- 293 IS Why very few patients benefit from the drugs they take and why many are killed by them. University of British Columbia, Vancouver, 11 Nov 2014.
- 294 IS Mammography screening: why it hasn't lived up to expectations. University of British Columbia, Vancouver, 12 Nov 2014.
- 295 IS How to reduce big pharma's influence on guidelines. Kaiser Permanente, Los Angeles, 13 Nov 2014.
- 296 IS Transforming mad science, reimagining mental health care. International Society of Ethical Psychology and Psychiatry, Los Angeles, 15 Nov 2014.
- 297 IS Medisinering av psyken – mer skade enn gagn? Cinemateket, Oslo, 25 Nov 2014.
- 298 IS Global Health. Univ. of Copenhagen, 6 Jan 2015.
- 299 IS Depression. Young Psychiatrists, Rigshospitalet, 19 Jan 2015.
- 300 IS Psychiatry. Nurses, Silkeborg 20 Jan 2015.
- 301 IS Selective publication. Joanna Briggs Institute, Adelaide, 9 Feb 2015.
- 302 IS Drugs. Grand round. Royal Adelaide Hospital, Adelaide, 10 Feb 2015.
- 303 IS Psychiatry. Univ. of Adelaide, Adelaide, 10 Feb 2015.
- 304 IS Drug crimes. Alfred Hospital, Melbourne, 11 Feb 2015.
- 305 IS Psychiatry. State Library of Victoria, Melbourne, 11 Feb 2015.
- 306 IS Mammography screening. Alfred Hospital, Melbourne, 12 Feb 2015.
- 307 IS Drug crimes. Grand round. Royal Melbourne Hospital, Melbourne, 12 Feb 2015.
- 308 IS Antidepressants. Garvan Institute, Sydney, 12 Feb 2015.
- 309 IS Drug crimes. Concord Hospital Clinical School, Sydney, 13 Feb 2015.
- 310 IS Mammography screening. Dougherty Community Centre, Sydney, 13 Feb 2015.
- 311 IS Psychiatric drugs. University of Sydney Law School, Sydney, 14 Feb 2015.
- 312 IS Drug crimes. Grand round. Princess Alexandra Hospital, Brisbane, 16 Feb 2015.

- 313 IS Drug crimes. RACGP College House, Brisbane, 16 Feb 2015.
- 314 IS Drug crimes. Univ. of Queensland Medical School, Brisbane, 17 Feb 2015.
- 315 IS Psychiatry. Lady Cilento Children's Hospital, Brisbane, 18 Feb 2015.
- 316 IS Psychiatry. Adina Apartment Hotel, Brisbane, 18 Feb 2015.
- 317 IS Drug crimes. Grand round. Gold Coast University Hospital, 19 Feb 2015.
- 318 IS Lægemedler. Medicinsk Studenterforskning, Nyborg, 12 Mar 2015.
- 319 IS Depression. Rigshospitalet, 16 Apr 2015.
- 320 IS Psychiatric drugs. Lansing, Michigan, 17 Apr 2015.
- 321 IS Antidepressiva. Ålborg Sygehus, 21 Apr 2015.
- 322 IS Drugs. Danish National Board of Health, 27 Apr 2015.
- 323 IS The Maudsley Debate. London, 13 May 2015.
- 324 IS Drugs. Robert-Bosch-Stiftung, Berlin 22 May 2015.
- 325 IS Psychiatry. General Practitioners Annual Meeting, Bergen 27 May 2015.
- 326 IS Lægemedler. Læger fra Lolland, 29 May 2015.
- 327 IS Regulatory data. Int Soc Drug Bull, Pamplona, 29 June 2015.
- 328 IS Overdiagnosis and overtreatment. Int Soc Drug Bull, Pamplona, 30 June 2015.
- 329 IS Psykofarmaka. Dansk Psykologforening, København, 12 Sep 2015.
- 330 IS Antidepressants. Int Meeting, Copenhagen, 16 Sep 2015.
- 331 IS Forced treatment. Int Meeting, Copenhagen, 16 Sep 2015.
- 332 IS Antidepressants. Univ. of Roehampton, London, 18 Sept 2015.
- 333 IS Drugs. Katowice, 19 Sept 2015.
- 334 IS Mammography screening. Cochrane Colloquium, Wien, 3 Oct 2015.
- 335 IS Drugs. Oslo 20 years Anniversary Seminar, 19 Oct 2015.
- 336 IS Tvangsmedicinering. Litteraturhuset, Oslo, 19 Oct 2015.
- 337 IS Lægemedler. Guldborgsund Bibliotekerne, Nykøbing F, 21 Oct 2015.
- 338 IS Psykofarmaka. Benzorådgivningen, Middelfart, 23 Oct 2015.
- 339 IS Psykofarmaka. Enhedslisten, København, 23 Oct 2015.
- 340 IS Lægemedler. Norsk Studenterforening, Tromsø, 30 Oct 2015.
- 341 IS Psykofarmaka. Dansk Psykologforening, København, 7 Nov 2015.
- 342 IS Drugs. Medical Centre in Leiden, 11 Nov 2015.
- 342 IS Drugs. Arminius, Rotterdam, 12 Nov 2015.
- 343 IS Lægemedler. FOF Hvalsø, 23 Nov 2015.
- 344 IS Cancer screening. Gemeinschaftskrankenhaus Havehöhe, Berlin, 25 Nov 2015.
- 345 IS Psykofarmaka. Dansk Socialrådgiverforening, Fredericia, 30 Nov 2015.
- 346 IS Deadly medicines. Roma, Italy, 1 Dec 2015.
- 347 IS Deadly medicines. Univ. of Verona, 2 Dec 2015.
- 348 IS Deadly medicines. Gruppo Abele, Torino, 3 Dec 2015.
- 349 IS Deadly medicines. Alba, 3 Dec 2015.
- 350 IS Psykofarmaka. LAP, København, 18 Dec 2015.
- 351 IS Global Health. Univ. of Copenhagen, 6 Jan 2016.
- 352 IS Psykofarmaka. Hvidovre og Glostrup Psykiatri, 7 Jan 2016.
- 353 IS Psykofarmaka. Bedre Psykiatri, Odense, 14 Jan 2016.
- 354 IS Läkemedel. Stockholm läns landstings läkemedelskomité, 20 Jan 2016.
- 355 IS Psykofarmaka. Socialmedicinsk Enhed, Frederiksberg Hospital, 22 Jan 2016.
- 356 IS Vore overmedicinerede ældre. Assens Ældreråd, 26 Jan 2016.
- 357 IS Vore overmedicinerede ældre. School of Culture and Society, Karup, 11 Feb 2016.
- 358 IS Dødelig medicin og organiseret kriminalitet, LOF Slagelse, 29 Feb 2016.
- 359 IS Receptpligtig medicin – den tredjehyppigste dødsårsag, Tåstrup Bibliotek, 29 Feb 2016.

- 360 IS Antidepressants Do More Harm Than Good, Tampa, Florida, Adlerian Society, 4 March 2016.
- 361 IS Mammography screening, European Breast Cancer Meeting, Amsterdam, 9 March 2016.
- 362 IS Hvorfor gør psykofarmaka større skade end gavn? FOF Gladsaxe, 15 March 2016.
- 363 IS Drugs: the Dutch Medicines vision. Dutch Parliament, 29 March 2016.
- 364 IS Medicinsk behandling af psykiske sygdomme. Danske Regioner, Aarhus, 6 April 2016.
- 365 IS Psykofarmaka gør langt større skade end gavn. Aarhus Universitet, Aarhus, 6 April 2016.
- 366 IS Fup og fakta om antidepressiv medicin. Folkeuniversitetet i Aalborg, 7 April 2016.
- 367 IS Dødelig psykiatri. Sind på Frederiksberg, 10 May 2016.
- 368 IS Hvorfor gør psykofarmaka større skade end gavn? FOF Gladsaxe, 17 May 2016.
- 369 IS Without data sharing, there is no science, only marketing. Krakow University, 20 May 2016.
- 370 IS Den psykiatriske epidemi. National Neurokonference, Middelfart, 26 May 2016.
- 371 IS Dødelig biologisk psykiatri. Dansk Retspsykologisk Selskab, 30 May 2016.
- 372 IS Forced Psychiatric Treatment Must Be Abolished. Anchorage, 2 June 2016.
- 373 IS Prescription drugs are the third leading cause of death. Evidence Live, Oxford, 21 June 2016.
- 374 IS Mortality and drugs (top-3). 50th Anniversary of the Geneesmiddelenbulletin, Leiden, 30 June 2016.
- 375 IS What is wrong with research and treatment in psychiatry? 50th Anniversary, Leiden, 30 June 2016.
- 376 IS Hvorfor så få har gavn af psykofarmaka? Social- og Sundhedsskolen. Middelfart, 30 Aug 2016.
- 377 IS Varning för psykofarmaka! Stockholm, ABF-huset, 5 Sept 2016.
- 378 IS Deadly psychiatry. Spanish Association for Mental Health, Madrid, 19 Sept 2016.
- 379 IS Deadly psychiatry. Alibri Llibreria, Barcelona, 20 Sept 2016.
- 380 IS Varning för psykofarmaka! Bokmässan, Göteborg, 23 Sept 2016.
- 381 IS Why is it controversial to tell the truth about health care? HealthWatch Award, London, 20 Oct 2016.
- 382 IS Mammography screening. Cochrane Colloquium, Seoul, 25 Oct 2016.
- 383 IS Why so few patients benefit from the drugs they take. 21th WONCA, Rio de Janeiro, 3 Nov 2016.
- 384 IS Varning för psykofarmaka! Stockholm, ABF-huset, 22 Nov 2016.
- 385 IS Hvorfor er udtrapning af psykofarmaka så vigtigt? Høring i Folketinget, 13 Dec 2016.
- 386 IS Deadly psychiatry. De Balie, Amsterdam, 19 Dec 2016.
- 387 IS Myter, misforståelser og skader i psykiatrien. Pædagogisk Psykiatrisk Vejledning, Greve, 4 Jan 2017.
- 388 IS Psychiatric drugs. Sherbrooke, education for doctors, 20 Jan 2017.
- 389 IS Myten om den biologiske psykiatri. Christiansborg, 3 March 2017.
- 390 IS Prescription drugs are the third leading cause of death. University of Helsinki, 9 March 2017.
- 391 IS Forskning; med eller uden industri. Medicinsk Studenterforskning, Nyborg, 17 March 2017.
- 392 IS Psykofarmaka. Diplomuddannelsen for socialarbejdere, Faxe Ladeplads, 23 March 2017.
- 392 IS Dödlig psykiatri och organiserad förnekelse. ISPS, Stockholm, 31 March 2017.
- 393 IS Vi kan leve uden antipsykotika. Stemmehørernetværket, Odense Rådhus, 27 April 2017.
- 394 IS Psykofarmaka slår mange ihjel og forkrobler langt flere. Slagelse Kommune, 3 May 2017.
- 395 IS Psykofarmaka, psykoterapi og udtrapning. Psykoterapeuter, København, 22 Aug 2017.
- 396 IS Psykofarmaka, psykoterapi og udtrapning. Psykoterapeuter, Vejle, 28 Aug 2017.
- 397 IS Overdiagnostik og overbehandling i psykiatrien. Bedre Psykiatri, Odense, 31 Aug 2017.
- 398 IS Myter om psykofarmaka? København, 26 Sept 2017.
- 399 IS Myter, misforståelser og skader i psykiatrien. Socialpædagoger, Kolding, 2 Oct 2017.
- 400 IS Den biologiske psykiatri bygger på en række misforståelser og myter. SIND, Aalborg, 10 Oct 2017.
- 401 IS International Institute for Psychiatric Drug Withdrawal. World Congress in Psychiatry, Berlin, 11 Oct.
- 402 IS Psychiatric drugs are the third leading cause of death. World Congress in Psychiatry, Berlin, 11 Oct.
- 403 IS Psykofarmaka. Neurologisk afd., Herlev Sygehus, 1 Oct.
- 404 IS How to survive in an over-medicated world. Columbus, Ohio, 11 Nov.
- 405 IS Harmful drugs you should know about. Columbus, Ohio, 12 Nov.
- 406 IS Afhængighed af og udtrapning af psykofarmaka. BBH, Klinisk Farmakologisk afd., 1 Dec.

- 407 IS Mental health in crisis. Sydney, 24 Feb 2018.
- 408 IS Mental health in crisis. Christchurch, 26 Feb 2018.
- 409 IS Mental health in crisis. Wellington, 27 Feb 2018.
- 410 IS Mental health in crisis. Hamilton, 28 Feb 2018.
- 411 IS Mental health in crisis. Auckland, 2 March 2018.
- 412 IS Psykofarmaka bør undgås, især til børn og unge. FADD, Slangerup, 7 March.
- 413 IS How to survive in an overtreated world. Public health course, Madrid, 10 March.
- 414 IS Why you should usually avoid cancer screening. Cambridge University, 5 April.
- 415 IS Depressionspiller gør mer skada än nytta. Stockholm, 13 April.
- 416 IS Complaint to the European Ombudsman and maladministration at EMA. Dublin 21 April via Skype.
- 417 IS Benefits and harms of depression pills. Copenhagen, 14 June.
- 418 IS Heroes of Science: Survival of a Whistleblower. Berlin, Max Planck Institute, 27 June.
- 419 IS Why the current usage of psychiatric drugs does far more harm than good. Berlin, Charité, 28 June.
- 420 IS Why systematic reviews of published drug trials lead to too much medicine. Helsinki, 17 Aug.
- 421 IS Overlevelse i en overmedicineret verden. Hillerød, 27 Sept.
- 422 IS Hvordan overlever man i en overmedicineret verden? Odense, Seniorhøjskolen, 3 Oct.
- 423 IS Why did we get a Cochrane Collaboration and what is it like today? Rigshospitalet, 12 Oct.
- 424 IS Chemical and physical interventions for house dust mites: why not? Rigshospitalet, 12 Oct.
- 425 IS Survival in an overtreated world: Look up the evidence yourself. Univ. of Groningen, 22 Oct.
- 426 IS Survival in an overtreated world: Look up the evidence yourself. Patiëntenfederatie, Utrecht, 23 Oct.
- 427 IS Survival in an overtreated world: Look up the evidence yourself. De Balie, Amsterdam, 23 Oct.
- 428 IS Survival in an overtreated world: Look up the evidence yourself. Ministry of Health, den Haag, 24 Oct.
- 429 IS Psykofarmaka gør større skade end gavn. Thisted, 31 Oct.
- 430 IS We need a revolution in psychiatry, the only medical specialty that does more harm than good. Berlin, Charité Hospital, 27 Nov.
- 431 IS Open science for better health-care for all. Bruxelles, EU Parliament, 29 Nov.
- 432 Death of a whistleblower: scientific censorship in action. Copenhagen, 9 Mar 2019.
- 433 IS Evidensbasert medisin. Trondheim, 20 Mar.
- 434 IS Myter, misforståelser og skader i psykiatrien. København, 13 May.
- 435 IS Death of a whistleblower and Cochrane's moral collapse. Santa Cruz, California, 9 June.
- 436 IS Mammography screening should be stopped. Barcelona, 15 June.
- 437 IS Death of a whistleblower and Cochrane's moral collapse. Madison, Wisconsin, 30 July.
- 438 IS Critical thinking about psychiatric drugs. Tromsø, 5 Sept.
- 439 IS Myter, misforståelser og skader i psykiatrien. Århus, 3 Oct.
- 440 IS The Cochrane affair and conflicts of interest. Paris, 11 Oct.
- 441 IS Hvordan overlever man i en overmedicineret verden? Esbjerg, 30 Oct.
- 442 IS Breast cancer screening: state of the art. Porto, 4 Nov.
- 443 IS General health checks: state of the art. Porto, 5 Nov.
- 444 IS Forskning og interessekonflikter. Udvalget til Beskyttelse af Videnskabeligt Arbejde. København, 7 Nov.
- 445 IS Sundhedsvæsen og politik. Helsingør, 21 Nov.
- 446 IS Does long term use of psychiatric drugs cause more harm than good? Newcastle University, 22 Jan 2020.
- 447 IS Vacciner, sandhed, løgn og kontroverser. Patientforeningen Danmark, 6 Feb.
- 448 IS Why prescription drugs are the third leading cause of death. Teleseminar, Madrid, 7 June.
- 449 IS Hvordan overlever man i en overmedicineret verden? Egmonthøjskolen, Odder, 14 July.
- 450 IS Uddeling af diagnoser og overmedicinering. Mariehjemmene, København, 4 Sept.
- 451 IS Science and Society in the Pandemia war. Teleconference, Athens Medical Association, 19 Sept.
- 452 IS Mental health survival kit. Stanford, METRICS, telelecture, 1 Oct.

453 IS Hvordan overlever man i en overmedicineret verden? Favrskov aftenskole, 26 okt.

Research mentorships

PhD and other degrees

1992 - 1994	Pia Therkildsen. Clinical research behaviour in Denmark. Main tutor. PhD not finished.
1993 - 1994	Flemming Ørnkov. Drug treatment. Main tutor. PhD not finished (emigration).
1996 - 2001	Asbjørn Hróbjartsson. The placebo concept. Main tutor. PhD defended 8 June 2001 at the University of Copenhagen.
2001 - 2004	Jan Peter Kösters (German doctor). Breast cancer screening. Main tutor. Doktors der Medizin defended 17 Sept 2004 at the University of Hamburg.
2000 - 2004	Lise Lotte Kjærgaard. The randomised clinical trial. PhD, changed to DrMedSci, defended 19 Aug 2005 at the University of Copenhagen.
2001 - 2005	Bodil Als-Nielsen. Hepatic encephalopathy. PhD defended 13 May 2005 at the University of Copenhagen.
2001 - 2005	Julie Pildal. Bias in systematic reviews. Main tutor. PhD defended 6 Sept 2005 at the University of Copenhagen.
2004 - 2013	Karsten Juhl Jørgensen. Screening for breast cancer. Main tutor. PhD changed to DrMedSci, defended 11 Jan 2013 at the University of Copenhagen.
2008 - 2009	Marija Barbateskovic. Impact factors and sponsorship. Main tutor. Candidate in science. Marks 12 (top on new scale)
2007 - 2010	Britta Tendal. Standardised mean difference in meta-analysis. Main tutor. PhD defended 26 Aug 2010 at the University of Copenhagen.
2007 - 2011	Anders W. Jørgensen. Robustness of results and conclusions in systematic reviews, trials and abstracts. Main tutor. PhD defended 16 Nov 2011 at the University of Copenhagen.
2007 - 2013	Margrethe Nielsen. Selective serotonin reuptake inhibitors. Main tutor. PhD defended 19 April 2013 at the University of Copenhagen.
2008 - 2013	Andreas Lundh. Conflicts of interest in biomedical publishing. Main tutor. PhD defended 25 April 2013 at the University of Copenhagen.
2010 - 2015	Lasse Teis Krogsbøll. Health checks. Main tutor. PhD defended.
2011 - 2015	Jeppe Schroll. Coding of harms in randomised trials. Main tutor. PhD defended.
2011 - 2016	Emma Maund. Harms of Selective serotonin reuptake inhibitors. Main tutor. PhD defended.
2012 - 2016	Michelle Ogden. Are randomised trials ethical? Main tutor. Stopped 2016.
2012 - 2018	Tarang Sharma. Suicidality and violence on SSRIs. Main tutor. PhD defended.
2016 - 2018	Kristine Rasmussen. Conflicts of interest. Main tutor. PhD defended.
2014 - 2018	Pia Danborg. Psychiatric animal studies. Main tutor.
2016 - 2018	Camilla Hansen. Conflicts of interest. Tutor.
2016 - 2019	Lars Jørgensen. HPV vaccines. Main tutor. PhD defended.
2016 -	Anders Sørensen. Psychiatry. Main tutor.
2016 -	Marie Bohlbro. Psychiatry. Main tutor.
2017-	Kim Boesen. ADHD drugs. Main tutor.

Training students in research

2003	Troels Wienecke. OSVAL II, marks 9, ref. 153 in reference list above.
2003	Karsten Juhl Jørgensen. OSVAL II, marks 10, ref. 154 in reference list above.
2003	Mette Haahr, scholar student, ref. 157 in reference list above.
2003	Lasse Schmidt. OSVAL II, marks 10, ref. 169 in reference list above.
2003	Katrine Karmisholt, scholar student, ref. 172 og 173 in reference list above.
2004	Anne Due, OSVAL II, marks 10, ref. 189 in reference list above.
2004	Anders Jørgensen, OSVAL II, marks 10, ref. 190 in reference list above.
2005	Anders Klahn, OSVAL II, marks 10, ref. 198 in reference list above.
2006	Britta Tendal, scholar student, ref. 196 in reference list above.
2006	Katja Maric, scholar student, ref. 196 in reference list above.
2007	Matias Vested Madsen, OSVAL II, marks 9, ref. 215 in reference list above.
2007	Lasse Krogsbøll, OSVAL II, marks 10, ref. 221 in reference list above.
2007	Jørgen Jacob Eschen, OSVAL II, marks 11. No journal manuscript.
2009	Marija Barbateskovic, manuscript under preparation.

- 2009 Jeppe Lerche Hansen, manuscript under revision.
 2009 Jeppe Schroll, manuscript under revision.
 2010 Ann-Sofia Skou Thomsen, OSVAL II, marks 12
 2010 Frida Samuelsson, OSVAL II, marks 12
 2010 Christian Grønhøj Larsen, OSVAL II, marks 12
 2010 Nino Ortner, OSVAL II, marks 12 (Hróbjartsson tutor)
 2011 Kristine Rasmussen, special subject, marks 12
 2011 Anine Skibsted, special subject, marks 12
 2011 Jon Egelund Jensen, special subject, marks 10
 2012 Julie Bindslev, special subject, marks 12
 2012 Marie Damkjær Hansen, special subject, marks 10 (Hróbjartsson tutor)
 2014 Mikkel Marquardsen, special subject, marks 12
 2014 Andreas Bielefeldt, special subject, marks 12
 2014 Jakob Jensen, special subject, marks 7
 2014 Louise Jensen
 2014 Nana Freund, no special subject
 2014 Asmus Mortensen, special subject, marks 10
 2015 Asger Paludan-Müller, bachelor subject, marks 12
 2015 Kim Boesen, special subject, marks 12
 2015 Anders Simonsen, special subject, marks 12

Expert, Medical Research Council's Statistical Aid Service

- 1991 Nick Rasmussen. Randomised trial, steroids in periarthrosis.
 1991 Holger Sørensen. Randomised trial, haloperidol vs. oxazepam.
 1991 Arne Gam. Meta-analysis, soft laser treatment.
 1992 Søren Eiskjær. Meta-analysis, osteosynthesis methods in collum fracture.
 1993 Arne Gam. Meta-analysis, ultrasound in musculoskeletal disorders.
 1993 Hanne Olesen. Meta-analysis, oxygen deficit by anaerobic training.
 1993 Kim Brøsen. Meta-analysis, genetic polymorphism and disease risk.
 1993 Anita Rønn. Randomised trial, Maloprim vs. placebo in malaria.
 1993 Mette Bitsch-Christensen. Immune therapy of children with allergy.
 1993 Anne-Lise Christensen. Comparison of methods to diagnose pneumonia.
 1993 Anne-Cathrine Halvorsen. Diagnostic methods in bleeding disorders.
 1993 Michael Hansen. Biochemical markers for bone formation and resorption.
 1994 Robin Bohlen. Treatment of fibromyalgia based on psychomotoric theory.
 1994 Helle Rask. Randomised trial, volume expansion in surgery.
 1995 Allan Ibsen Sørensen. Meta-analysis of endoscopic carpal tunnel dissection.
 1996 Hanne Sørensen. Randomised trial, physiotherapy in back pain.
 1997 Judith Kongsted. Healing in breast cancer.
 1998 Poul Sindberg Eriksen. Risks after laser conisation of cervix uteri.
 1998 Niels Petri. Orthodontic treatment of sleep apnoea.
 2000 Hanne Sørensen. Training for back pain.
 2002 Lars Højgaard-Rasmussen. Asthma and osteopathy.
 2002 Mette Pedersen. Vocal cord nodules: non-surgery vs. surgery.
 2004 Thorkil Christensen. Randomised trial, herbal cream for pain.

Scientific assignments

General

- 1988 - 1990 Secretary, Danish Society for Theory in Medicine.
 1990 Examiner, prize report in medicine, University of Copenhagen.
 1990 Member of WHO's expert group in Bukarest, evaluation of AIDS trial in children.
 1991 Member of drug committee's quality group, Rigshospitalet.
 1992 Member of Ministry of Education's group in Latvia, research evaluation.
 1991 - 1998 Expert, Medical Research Council's Statistical Aid Service.
 1992 - 1996 Chairman, Danish Society for Theory in Medicine.

- 1993 - 2005 Examiner, PhD applications, Rigshospitalet.
 1993 - 2005 Member of Research Council, Rigshospitalet.
 1993 - 2010 Member of Drug Committee, Rigshospitalet.
 1995 Member of HS's working group on clinical databases.
 1998 Examiner, PhD thesis (Rasmus Licht).
 1998 Chairman and examiner, PhD thesis (Palle Valentiner-Brandt).
 1998 Member of ad hoc committee, Office for Scientific Integrity.
 1998 - 2005 Expert, Medical Research Council's Statistical Aid Service for East Denmark.
 1999 Member of ad hoc committee, Office for Scientific Integrity.
 2001 Member of ad hoc committee, Office for Scientific Integrity.
 2008 Examiner of case of suspected scientific misconduct in Iran for The Oxford Health Alliance.
 2008 Examiner of case of suspected scientific misconduct in Norway.
 2011 Examiner, PhD thesis (Bendt Johansen), University of Southern Denmark
 2013 Chairman, assessment of candidates for a professorship, University of Copenhagen
 2014 Chairman and examiner, PhD thesis (Robert Eriksson), University of Copenhagen
 2015 Chairman and examiner, PhD thesis (Bruno Heleno), University of Copenhagen
 1993 - Member CONSORT (Consolidated Standards of Reporting Trials), see www.consort-statement.org.
 2004 - Member of STROBE (Developing Standards of Reporting for Observational Studies in Epidemiology), see www.strobe-statement.org.
 2005 - Member of PRISMA (Quality of reporting of meta-analyses), see <http://www.prisma-statement.org/>.
 2005 - Member of SPIRIT (Standard Protocol Items for Randomised Trials), see www.spirit-statement.org/.

Editorial work

- 1992 - 1998 Editor, Bibliotek for Læger.
 1995 - 2002 Member of Editorial Board, British Medical Journal.
 1995 - Member of Editorial Advisory Board, Scandinavian Journal of Rheumatology.
 1995 - Member of Editorial Advisory Board, The Cochrane Collaboration.
 1997 - 2014 Editor, Cochrane Methodology Review Group
 1997 - Member of Advisory Board, Clinical Evidence, BMJ Publishing.
 2000 - Editorial advisor, BioMedCentral (supports PubMedCentral, USA).
 2000 - 2010 Member of Scientific Board, Ugeskrift for Læger
 2004 - Member of Editorial Board, BioMedCentral Medical Research Methodology
 2004 - Member of BMJ Knowledge Advisory Board
 2007 - Academic editor, PLoS Medicine

Performed peer reviews for:

Acta Neuropsychiatrica
 Annals of Internal Medicine
 BioMed Central Medical Research Methodology
 BioMed Central Family Practice
 BioMed Central Infectious Diseases
 Bibliotek for Læger
 BMJ
 BMJ Open
 Breast Cancer Research and Treatment
 Canadian Medical Association Journal
 Cancers
 Clinical Evidence
 Clinical Trials
 Clinical Trials and Meta-analysis
 Cochrane Airways Group
 Cochrane Anaesthesia Group
 Cochrane Gynaecological Cancer Group
 Cochrane Hepato-Biliary Group
 Cochrane Infectious Diseases Group

Cochrane Musculoskeletal Group
 Cochrane Musculoskeletal Injuries Group
 Cochrane Oral Health Group
 Controlled Clinical Trials
 Danish Medical Bulletin
 European Journal of Neurology
 Hong Kong Government Research Council
 International Journal of Cancer
 International Journal of Epidemiology
 International Journal of Risk and Safety in Medicine
 International Journal of Technology Assessment in Health Care
 JAMA
 Journal of Clinical Epidemiology
 Journal of Medical Ethics
 Lancet
 La revue Prescrire
 Medical Journal of Australia
 Medical Research Council, UK
 Medicine, Philosophy and Health Care
 Nature Reviews Nephrology
 New England Journal of Medicine
 PLoS Medicine
 Politik
 Pharmacogenetics
 PharmacoEconomics
 Radiotherapy and Oncology
 Scandinavian Journal of Gastroenterology
 Scandinavian Journal of Medicine and Science in Sports
 Scandinavian Journal of Rheumatology
 Scandinavian Journal of Social Medicine
 Science
 Statens beredning för medicinsk utvärdering
 Statistics in Medicine
 Tobacco Control
 Ugeskrift for Læger
 Vetenskapsrådet, Sverige
 Women's Health

Chairman at congresses and meetings

1. Seminar on Bias and Controversies in Clinical Research. Rigshospitalet, 28 Feb 1992.
2. Pharmacotherapy I - methodological aspects. 25th Scand Congr Rheumatol, Lillehammer, 2 June 1994.
3. Reviews of data on continuous scales. Workshop, 2nd Cochrane Colloq, Hamilton, Canada, 1 Oct 1994.
4. Reviews and Syntheses. 11th Meeting, International Society of Technology Assessment in Health Care, Stockholm, 6 June 1995.
5. Cochrane Hepato-biliary Review Group Meeting. European Association for the Study of the Liver, København, 19 Aug 1995.
6. Cochrane Tuberculosis Review Group Meeting. International Union against Tuberculosis and Lung Disease, Paris, 9 Sept 1995.
7. Scientific presentations. 3rd Annual Cochrane Colloquium, Oslo, 4-8 Oct 1995.
8. Cochrane Depression/Neurosis Review Group Meeting. 3rd Annual Cochrane Colloq, Oslo, 8 Oct 1995.
9. Cochrane Placebo Methods Working Group Meeting. 4th Annual Cochrane Colloq, Adelaide, 21 Oct 1996.
10. Cochrane Colorectal Cancer Group Pre-exploratory Meeting. Cochrane Cancer Network Meeting, Bruxelles, 1 Feb 1997.
11. Cochrane Colorectal Cancer Group Exploratory Meeting. København, 12-13 Sept 1997.
12. 50 years of clinical trials: past, present and future. BMA/BMJ, London, 29-30 Oct 1998. Conference chair and chair of session: Quality and relevance of randomised controlled trials.
13. Evidence based medicine: How do we implement research results effectively? Annual meeting for the Nordic Cochrane Centre and Network, Rigshospitalet, 28 Jan 1999.

14. Exploratory meeting for the Cochrane Anaesthesia Group. 7th Annual Meeting of the European Society of Anaesthesiologists, Amsterdam, 29-30 May 1999.
15. Medical Editors. Second Asian-Pacific Conference on Evidence Based Medicine, Chengdu, China, 8-10 Apr 2002.
16. Scientific presentations. 15th Annual Cochrane Colloquium, São Paulo, 23-27 Oct 2007.
17. Influenza symposium. Rigshospitalet, 23 Sept 2008.
18. Scientific presentations. 16th Annual Cochrane Colloquium, Freiburg, 3-7 Oct 2008.
19. International Cochrane Symposium: EBM and Cochrane reviews. Rigshospitalet, 22 April 2009.
20. Investigating bias. 19th Cochrane Colloquium, Madrid, 21 Oct 2011.
21. Nordic Cochrane Centre's 25th Anniversary Research Symposium. Rigshospitalet, 12 Oct 2018.
22. Institute for Scientific Freedom, inaugural symposium. Copenhagen, 9 March 2019.

Advisory Board member at international congresses

- 2nd Cochrane Colloquium, Hamilton, Ontario, 1-4 Oct 1994.
- 3rd Cochrane Colloquium, Oslo, 4-8 Oct 1995.
- 4th Cochrane Colloquium, Adelaide, Australia, 20-24 Oct 1996.
- 7th Cochrane Colloquium, Rome, Italien, 5-9 Oct 1999.
- 8th Cochrane Colloquium, Cape Town, Sydafrika, 25-29 Oct 2000.
- 9th Cochrane Colloquium, Lyon, 9-13 Oct 2001.
- 11th Cochrane Colloquium, Barcelona, 26-31 Oct 2003.
- 12th Cochrane Colloquium, Ottawa, 2-6 Oct 2004.
- 5th Congress on Peer Review and Biomedical Publication, Chicago, 15-17 Sept 2005.
- 15th Cochrane Colloquium, São Paulo, 23-27 Oct, 2007, Scientific Program Committee.
- 6th Congress on Peer Review and Biomedical Publication, Vancouver, 10-12 Sept 2009.
- 7th Congress on Peer Review and Biomedical Publication, Chicago, 8-10 Sept 2013.
- Psychiatric drugs do more harm than good. Copenhagen, 16 Sept 2015.
- 8th Congress on Peer Review and Biomedical Publication, Chicago, 10-12 Sept 2017.

Expert witness in court cases

- 2014 Danish High Court, double homicide attempt on methylphenidate.
- 2014 Norwegian High Court, forced treatment with olanzapine.
- 2015 Norwegian High Court, Patient Harms Council, oseltamivir for influenza.
- 2016 Dutch High Court, double homicide case on paroxetine.
- 2016 Alaska High Court, forced retention and medication of a psychiatric patient.
- 2019 New York, effects of the DTP vaccine on mortality.
- 2019 Canada, harms caused by psychiatric drugs.
- 2019 California, harms of an HPV vaccine.
- 2020 Australia, harms after psychiatric drugs.
- 2020 California, forced influenza vaccination
- 2020 California, harms of an HPV vaccine

Management experience

- 1967 Co-founder, local fraction of a political party, cashier 1967-68.
- 1975 - 1977 Cashier, Frederiksberg Athletics Association.
- 1977 - 1983 Founder and head, medical department, Astra-Syntex.
- 1987 - 1995 Founder and head, Nordic coordination office for AIDS trials, Rigshospitalet.
- 1993 Co-founder of the Cochrane Collaboration
- 1993 - 2019 Founder and head, The Nordic Cochrane Centre (39 people employed in 2014, incl. those in Copenhagen Trial Unit).
- 1993 - 1996 Member of the Steering Group, the Cochrane Collaboration.
- 1996 - 2001 Founder and head, Cochrane Placebo Methods Group.
- 2002 SHL leadership course.
- 2008 - 2009 Cashier and board member, Hørsholm Swimming Club.
- 2018 - 2019 Member of the Cochrane Governing Board.

EXHIBIT D

CURRICULUM VITAE

Carl J Heneghan

Title: Professor
Surname: Heneghan
Forename(s): Carl James

Dob: 23/01/1968

Email: carl.heneghan@phc.ox.ac.uk
Tel: +44 (0)1865 289299
GMC: 4731643

Current Positions:

- Professor of Evidence-Based Medicine, Nuffield Dept. of Primary Care University of Oxford
- Director, Centre for Evidence-Based Medicine
- Honorary Senior Academic General Practitioner, NHS England
- General Practitioner (MRCGP)
- NHS Urgent Care GP Oxford NHS Foundation Trust
- Director Evidence Based Healthcare Programs, University of Oxford (Masters and DPhil)
- NIHR Senior Investigator

Education and Qualifications:

- DPhil, New College, University of Oxford 2009: Incidence, prevention and treatment of acute coronary events in a population study: The Oxford Vascular Study (OXVASC)
- MA (Hons), New College, University of Oxford 2007
- MRCGP (Merit) Royal College of General Practice 2004
- BM, BCH, Medicine and Surgery, New College, University of Oxford 2000
- BA (Hons) 2:1 Physiological Sciences, New College, University of Oxford 1997

Research Fellowships

- NCCRD Research Development Fellowship: NIHR Department of Health 2005-2008
- Clinical Research Fellow, University of Oxford 2003–2005

Past posts:

- Clinical Reader, Clinical Lecturer, Department of Primary Care University of Oxford 2008-2013
 - Senior Clinical Research Fellow, Department of Primary Care University of Oxford 2005-2008
 - Deputy Director Clinical Fellow CEBM, University of Oxford 2005-10
 - General Practice Registrar Thames Valley Primary Care Agency 2003 – 2005
 - Senior House Officer 2001– 2003, House Officer Oxford Radcliffe NHS Trust, 2000- 2001
-

Further positions:

- Director WHO Collaboration Centre
- Chair of Examiner MSc in Evidence-Based healthcare, University of Oxford, External examiner MSc in Primary Care University of Birmingham
- Advisor to WHO International Clinical Trials Registry Platform
- Editor in Chief BMJ Evidence-Based Medicine

Professional memberships

- British Medical Association (BMA)
 - Member of the Royal College of General Practice (MRCGP) Specialist register 2005
 - Medical Defence Union of Scotland (MDDUS)
 - General Medical Council (GMC 4731463) registered 2000
-

Awards

- University of Oxford, Medical Sciences Division, Lifetime Achievement Award 2019
- NIHR Senior Investigator Award 2017
- ACCEA consultant clinical excellence awards – SILVER Award, April 2017
- HSJ- top 100 NHS clinical leaders 2013 and 2015
- Brisbane Initiative Fellowship July 2007.

CV: Carl Heneghan BM, BCH, BA, MA (Hons) Oxon, MRCP, DPhil

- Department of Health Research Development Award 2005-8
- Royal College of General Practitioners: Scientific Foundation Board Award 2004
- Goldsmiths Scholarship Award 2000

20 impact Publications (full list of over 400 publications available on request H index 70, I 10 index 232; 23415 citations)

1. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T. *BMJ*. 2014 Apr 9;348:g2547.
2. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. *BMJ*. 2014 Apr 9;348:g2545.
3. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Onakpoya I, Mahtani KR, Nunan D, Howick J, **Heneghan CJ**. *Cochrane Database Syst Rev*. 2014 Apr 10;4:CD008965.
4. Evidence for non-communicable diseases: analysis of Cochrane reviews and randomised trials by World Bank classification. Heneghan C, Blacklock C, Perera R et al. *BMJ Open*. 2013 Jul 6;3(7). pii: e003298. doi: 10.1136/bmjopen-2013-003298. Print 2013.
5. Hayward G, Thompson MJ, Perera R, Glasziou PP, Del Mar CB, **Heneghan CJ**. Corticosteroids as standalone or add-on treatment for sore throat. *Cochrane Database Syst Rev*. 2012 Oct 17;10:CD008268. doi: 10.1002/14651858.CD008268.pub2. PMID: 23076943
6. Friedemann C, **Heneghan C**, Mahtani K, et al. Cardiovascular disease risk in healthy children and its association with body mass index: systematic review and meta-analysis. *BMJ*. 2012 Sep 25;345:e4759. doi: 10.1136/bmj.e4759. PMID: 23015032
7. Blacklock C, **Heneghan C**, Mant D, Ward AM. Effect of UK policy on medical migration: a time series analysis of physician registration data. *Hum Resour Health*. 2012 Sep 25;10(1):35. PMID: 23009665
8. Balla J, **Heneghan C**, Goyder C, Thompson M. Identifying early warning signs for diagnostic errors in primary care: a qualitative study. *BMJ Open*. 2012 Sep 13;2(5). Print 2012. PMID: 22983786
9. Heneghan C, Jefferson T, Doshi P. Antivirals for treatment of influenza. *Ann Intern Med*. 2012 Sep 4;157(5):385-6. PMID: 22944882
10. Hayward G, Thompson MJ, Perera R, Del Mar CB, Glasziou PP, **Heneghan CJ**. Corticosteroids for the common cold. *Cochrane Database Syst Rev*. 2012 Aug 15;8:CD008116. PMID: 22895973
11. **Heneghan C**, Thompson M, Perera-Salazar R, Gill P, O'Neill B, Nunan D, Howick J, Lasserson D, Mahtani K. Authors' reply to Betts, Stokes, and Kleiner. *BMJ*. 2012 Aug 14;345:e5431. PMID: 22893647
12. **Heneghan C**, Howick J, O'Neill B, Gill PJ, Lasserson DS, Cohen D, Davis R, Ward A, Smith A, Jones G, Thompson M. The evidence underpinning sports performance products: a systematic assessment. *BMJ Open*. 2012 Jul 18;2(4). pii: e001702. doi: 10.1136/bmjopen-2012-001702. PMID: 22815461
13. **Heneghan C**, Gill P, O'Neill B, Lasserson D, Thake M, Thompson M. Mythbusting sports and exercise products. *BMJ*. 2012 Jul 18;345:e4848. doi: 10.1136/bmj.e4848. PMID: 22810389
14. **Heneghan C**, Perera R, Nunan D, Mahtani K, Gill P. Forty years of sports performance research and little insight gained. *BMJ*. 2012 Jul 18;345:e4797. doi: 10.1136/bmj.e4797. PMID: 22810388
15. Thompson M, **Heneghan C**, Cohen D. How valid is the European Food Safety Authority's assessment of sports drinks? *BMJ*. 2012 Jul 18;345:e4753. doi: 10.1136/bmj.e4753. PMID: 22810387
16. Nunan D, Wassertheurer S, Lasserson D, Hametner B, Fleming S, Ward A, **Heneghan C**. Assessment of central haemodynamics from a brachial cuff in a community setting. *BMC Cardiovasc Disord*. 2012 Jun 26;12(1):48.
17. **Heneghan C**, Thompson M. Rethinking medical device regulation. *J R Soc Med*. 2012 May;105(5):186-8.
18. Bettiol S, Wang K, Thompson MJ, Roberts NW, Perera R, **Heneghan CJ**, Harnden A. Symptomatic treatment of the cough in whooping cough. *Cochrane Database Syst Rev*. 2012 May 16;5:CD003257.
19. Hayward G, **Heneghan C**, Perera R, Thompson M. *Ann Fam Med*. Intranasal corticosteroids in management of acute sinusitis: a systematic review and meta-analysis. 2012 May;10(3):241-9.
20. Banerjee A, Newman DR, Van den Bruel A, **Heneghan C**. Diagnostic accuracy of exercise stress testing for coronary artery disease: a systematic review and meta-analysis of prospective studies. *Int J Clin Pract*. 2012 May;66(5):477-92.